{
    "Wafer Ash": {
        "sections": {
            "Overview": "Wafer ash is a tree that is native to eastern North America. It has traditionally been used for gastrointestinal disorders, as a tonic, and for its purported antimicrobial and appetite stimulant effects (18).",
            "Safety": "There is insufficient reliable information available about the safety of wafer ash.\nPREGNANCY AND LACTATION: Insufficient reliable information is available; avoid using.",
            "Adverse Effects": "General\nThere is limited reliable information available about the adverse effects of wafer ash when used orally or topically.\nDermatologic\nTopically, skin contact with the wafer ash plant has been reported to cause phototoxic reactions (18).\nless",
            "Effectiveness": "There is insufficient reliable information available about the effectiveness or wafer ash.",
            "Dosing & Administration": "Adult\nResearch is limited; typical dosing unavailable.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of wafer ash.",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "None known.",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with wafer ash.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of wafer ash.",
            "Mechanism of Action": "General\nThe applicable part of wafer ash is the root bark. Wafer ash contains furoquinoline alkaloids including kokusaginin, skimmianine, ptelein, and dictamnine. It also contains furocoumarins (18).\nAntimicrobial effects\nPteleatinium chloride, a constituent of wafer ash, shows evidence of antimicrobial activity (3854), particularly against mycobacterium tuberculosis and yeast fungus (18)."
        }
    },
    "Wahoo": {
        "sections": {
            "Overview": "Avoid confusion with Euonymus europaeus (18).",
            "Safety": "LIKELY UNSAFE when the bark, seeds or berries are used orally. Ingesting 36 berries can be fatal (18). The poisonous principle has not been identified (17).\nPREGNANCY AND LACTATION: LIKELY UNSAFE when used orally (18).",
            "Adverse Effects": "General\nWahoo is considered poisonous (17). Several hours after ingesting wahoo seeds, people experience severe upset stomach, sometimes with bloody diarrhea, fever, shortness of breath, circulatory problems, signs of collapse, stupor increasing to unconsciousness, alternating with motor restlessness, severe tonic-clonic spasms with locked jaw muscles and coma.",
            "Effectiveness": "There is insufficient reliable information available about the effectiveness of wahoo.",
            "Dosing & Administration": "Adult\nNo typical dosage.",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nDIGOXIN (Lanoxin)\nInteraction Rating\nMAJOR Do not take this combination.\nSeverity\nHIGH\nOccurrence\nLIKELY\nLevel of Evidence\nD (Theoretical based on pharmacology)\nContraindicated; using wahoo with digoxin increases risk of cardiac glycoside toxicity due to therapeutic duplication (2).\nDIURETIC DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, concomitant use of potassium-depleting diuretics with wahoo can increase the risk of cardiac glycoside toxicity due to potassium depletion (506). Some diuretics that can deplete potassium include chlorothiazide (Diuril), chlorthalidone (Thalitone), furosemide (Lasix), hydrochlorothiazide (HCTZ, Hydrodiuril, Microzide), and others.\nMACROLIDE ANTIBIOTICS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, concomitant use may increase risk of cardiac glycoside toxicity (17).\nQUININE\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, concomitant use of quinine and wahoo might increase risk of cardiac toxicity (506).\nSTIMULANT LAXATIVES\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, use of stimulant laxatives with wahoo might have additive laxative effects, and can increase the risk of cardiac glycoside toxicity due to potassium depletion (2).\nTETRACYCLINE ANTIBIOTICS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, concomitant use may increase risk of cardiac glycoside toxicity (17).",
            "Interactions with Supplements": "EXPAND ALL\n|\nCOLLAPSE ALL\nCAFFEINE-CONTAINING HERBS AND SUPPLEMENTS\nConcomitant use can have additive effects with the caffeine in wahoo, and can increase the risk of adverse effects. Some natural products that contain caffeine include coffee, black tea, green tea, mate, cola, and others.\nCARDIAC GLYCOSIDE-CONTAINING HERBS\nContraindicated; concomitant use increases the risk of cardiac glycoside toxicity. Cardiac glycoside-containing herbs include black hellebore, Canadian hemp roots, digitalis leaf, hedge mustard, figwort, lily of the valley roots, motherwort, oleander leaf, pheasant's eye plant, pleurisy root, squill bulb leaf scales, and strophanthus seeds (19).\nHORSETAIL\nTheoretically, overuse or misuse of horsetail with cardiac glycoside-containing herbs increases the risk of cardiac toxicity due to potassium depletion (19).\nLICORICE\nTheoretically, overuse or misuse of licorice with cardiac glycoside-containing herbs increases the risk of cardiac toxicity due to potassium depletion (19).\nSTIMULANT LAXATIVE HERBS\nTheoretically, use of stimulant laxatives can have additive effects and adverse effects. Use also increases the risk of cardiac toxicity due to potassium depletion. Stimulant laxative herbs include aloe, alder buckthorn, black root, blue flag, butternut bark, colocynth, European buckthorn, fo ti, gamboge, gossypol, greater bindweed, jalap, manna, Mexican scammony root, rhubarb, senna, and yellow dock (19).",
            "Interactions with Conditions": "GASTROINTESTINAL (GI) CONDITIONS\nTheoretically, wahoo can increase gastric secretions and stimulate peristalsis. These effects might exacerbate GI irritation or inflammation (18).\nless",
            "Interactions with Lab Tests": "None known.",
            "Mechanism of Action": "The applicable parts of wahoo are the trunk, root bark, and fruit. The seeds contain cardioactive steroids known as cardenolides. The trunk, root bark, and fruit also contain varied alkaloids, caffeine, and theobromine (18). Wahoo is thought to stimulate bile flow and have laxative effects. In larger amounts, it can affect the heart (18)."
        }
    },
    "Wallflower": {
        "sections": {
            "Overview": "Wallflower is an herb that contains cardiac glycosides. Although it has some historical use as a medicine, it is now considered obsolete as a medicinal herb (18).",
            "Safety": "POSSIBLY UNSAFE when used orally. Wallflower contains cardiac glycosides, which might cause toxic effects (18).\nPREGNANCY AND LACTATION: POSSIBLY UNSAFE when used orally due to its cardiac glycoside content and possible toxic effects (18); avoid using.",
            "Adverse Effects": "General\nWallflower contains cardiac glycosides, which can cause serious adverse effects. However, the extent of absorption after oral administration is unclear (18).",
            "Effectiveness": "There is insufficient reliable information available about the effectiveness of wallflower.",
            "Dosing & Administration": "Adult\nNo typical dosage.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of wallflower.",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nCORTICOSTEROIDS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nUse of corticosteroids may cause electrolyte depletion and increase risk of cardiac glycoside toxicity (19).\nDIGOXIN (Lanoxin)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nContraindicated; therapeutic duplication increases risk of cardiac glycoside toxicity (2).\nDIURETIC DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, concomitant use of potassium-depleting diuretics and wallflower can increase the risk of cardiac glycoside toxicity due to potassium depletion (506). Some diuretics that can deplete potassium include chlorothiazide (Diuril), chlorthalidone (Thalitone), furosemide (Lasix), hydrochlorothiazide (HCTZ, Hydrodiuril, Microzide), and others.\nQUINIDINE\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nCardiac medications, including quinidine may increase the risk of cardiac glycoside toxicity; contraindicated (18).\nQUININE\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTaking quinine with wallflower may increase the risk of cardiac glycoside toxicity (18).\nSTIMULANT LAXATIVES\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nOveruse or misuse of stimulant laxatives may cause electrolyte depletion and increase the risk of cardiac glycoside toxicity (19).",
            "Interactions with Supplements": "EXPAND ALL\n|\nCOLLAPSE ALL\nCALCIUM SUPPLEMENTS\nCalcium supplements might increase the adverse effects of wallflower (18).\nCARDIAC GLYCOSIDE-CONTAINING HERBS\nContraindicated, concomitant use may increase the risk of cardiac glycoside toxicity. Cardiac glycoside-containing herbs include black hellebore, Canadian hemp roots, digitalis leaf, hedge mustard, figwort, lily-of-the-valley roots, motherwort, oleander leaf, pheasant's eye plant, pleurisy root, squill bulb leaf scales, and strophanthus seeds (19).\nCINCHONA\nUse with wallflower seed may increase risk of toxicity (19).\nEPHEDRA (Ma huang)\nUse with wallflower seed may increase risk of toxicity (19).\nHORSETAIL\nTheoretically, overuse or misuse of horsetail with cardiac glycoside-containing herbs increases the risk of cardiac toxicity due to potassium depletion (19).\nLICORICE\nTheoretically, overuse or misuse of licorice with cardiac glycoside-containing herbs increases the risk of cardiac toxicity due to potassium depletion (19).\nSTIMULANT LAXATIVE HERBS\nTheoretically, overuse or misuse of stimulant laxatives with cardiac glycoside-containing herbs increases the risk of cardiac toxicity due to potassium depletion. Stimulant laxative herbs include aloe, alder buckthorn, black root, blue flag, butternut bark, colocynth, European buckthorn, fo ti, gamboge, gossypol, greater bindweed, jalap, manna, Mexican scammony root, rhubarb, senna, and yellow dock (19).",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the toxicology of wallflower.",
            "Pharmacokinetics": "Absorption\nWhen wallflower is taken orally, its cardiac glycosides may be poorly absorbed (18).",
            "Mechanism of Action": "General\nAll parts of wallflower have been used medicinally (108937). They contain cardiac glycosides, which are also known as cardenolides or cardioactive steroids, and flavonoids, including isorhamnetin, kaempferol, and quercetin (18, 108937). The seeds contain cardiac glycosides such as cheiroside A, cheirotoxin, and neouzarin, and several glucosinolates and isothiocyanates such as cheirolin and iberin (108937).\nAnti-inflammatory effects\nIn vitro, extracts of all parts of wallflower plants have anti-inflammatory activity when compared with diclofenac, with the strongest activity being in the root and flower (108937)."
        }
    },
    "Wasabi": {
        "sections": {
            "Overview": "Wasabi is a perennial plant that grows up to 30 cm in height and is native to Japan. It is now cultivated in other countries including Taiwan and New Zealand. Wasabi is primarily grown for its roots, which are powdered to produce a pungent spice (29994).",
            "Safety": "LIKELY SAFE when used orally in food amounts (29994). When used orally and appropriately in medicinal amounts, short-term, wasabi extract 600 mg once daily has been safely used for up to 4 weeks (112846).\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, wasabi seems to be well tolerated in medicinal amounts.\nEndocrine\nA small clinical study in adults taking oral wasabi extract 2000 mg once daily for 4 weeks has found 1 case of ketone bodies in the urine (112846).\nless\nHepatic\nA small clinical study in adults taking oral wasabi extract 1000 mg once daily for 4 weeks has found 1 case of mildly elevated alanine transaminase and aspartate transaminase levels (112846).\nless\nMusculoskeletal\nA small clinical study in adults taking oral wasabi extract 2000 mg once daily for 4 weeks has found 1 case of elevated creatine phosphokinase (112846).\nless\nRenal\nA small clinical study in adults taking oral wasabi extract 1000 mg once daily for 4 weeks has found 2 cases of proteinuria (112846).\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nCardiovascular disease (CVD). Although there has been interest in using oral wasabi to prevent CVD, there is insufficient reliable information about the clinical effects of wasabi for this purpose.\nChronic fatigue syndrome (CFS). It is unclear if oral wasabi is beneficial for myalgic encephalomyelitis/chronic fatigue syndrome.\nA very small open-label clinical study in adults with myalgic encephalomyelitis/chronic fatigue syndrome shows that taking a wasabi extract containing 3.2 mg of the 6-(methylsulfinyl) hexyl isothiocyanate constituent 3 times a day for 12 weeks modestly improves some scores related to fatigue and the frequency of myalgia and headache when compared to baseline (112845). However, the validity of this study is limited by the lack of a comparator group.\nless\nDyspepsia. Although there has been interest in using oral wasabi for dyspepsia, there is insufficient reliable information about the clinical effects of wasabi for this purpose.\nFatigue. It is unclear if oral wasabi is beneficial for fatigue.\nA small open-label clinical study in healthy adults experiencing fatigue shows that taking wasabi extract 600 mg (containing 4.8 mg of 6-(methylsulfinyl) hexyl isothiocyanate, a constituent of wasabi) daily for 4 weeks improves self-reported scores of fatigue and some factors related to mood when compared to baseline. Oral wasabi extract also improves self-reported scores regarding sleep (e.g., quality of sleep, sleepiness after rising) (112846). However, the validity of these findings is limited by the lack of a comparator group.\nless\nIrritable bowel syndrome (IBS). Although there has been interest in using oral wasabi for IBS, there is insufficient reliable information about the clinical effects of wasabi for this purpose.\nOsteoporosis. Although there has been interest in using oral wasabi for osteoporosis, there is insufficient reliable information about the clinical effects of wasabi for this purpose.\nMore evidence is needed to rate wasabi for these uses.",
            "Dosing & Administration": "Adult\nResearch is limited; typical dosing is unavailable.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of wasabi.",
            "Interactions with Drugs": "ANTICOAGULANT/ANTIPLATELET DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, wasabi might increase the risk of bleeding with anticoagulant or antiplatelet drugs.\nIn vitro research shows that 6-(methylsulfinyl) hexyl isothiocyanate, a constituent of wasabi, inhibits platelet aggregation (29143).\nless",
            "Interactions with Supplements": "ANTICOAGULANT/ANTIPLATELET HERBS AND SUPPLEMENTS\nTheoretically, wasabi may increase bleeding risk.\nIn vitro research shows that 6-(methylsulfinyl) hexyl isothiocyanate (MS-ITC), a constituent of wasabi, inhibits platelet aggregation (29143). Theoretically, concomitant use of wasabi with other herbs that affect coagulation might increase the risk of bleeding. See other products with antiplatelet activity here. See products with anticoagulant activity here.\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with wasabi.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of wasabi.",
            "Mechanism of Action": "General\nThe applicable parts of wasabi are the roots, stems, and leaves. Allyl isothiocyanate, found in the highest concentrations in the roots, is the major flavor component of wasabi (29145, 101228). Wasabi also contains 6-(methylsulfinyl) hexyl isothiocyanate, 5-(methylsulfinyl) pentyl isothiocyanate, 7-(methylsulfinyl) heptyl isothiocyanate desulfosinigrin, linolenoyloleoyl-3-beta-galactosylglycerol, 1,2-dipalmitoyl-3-beta-galactosylglycerol, alpha-tocopherol, and ubiquinone-10 (29139, 55558, 55559, 101229).\nAnti-inflammatory effects\nIn vitro, the wasabi constituents linolenoyloleoyl-3-beta-galactosylglycerol and 1,2-dipalmitoyl-3-beta-galactosylglycerol inhibit cyclooxygenase (COX)-1 (55559). The wasabi constituent 6-(methylsulfinyl) hexyl isothiocyanate also has anti-inflammatory activity (101229).\nAntibacterial effects\nIn vitro, wasabi root, stem, and leaf extracts have antibacterial effects against Helicobacter pylori strains (29145).\nAnticancer effects\nIn vitro, an aqueous extract of wasabi root inhibits growth of human colon cancer cells by inducing apoptosis and autophagy (101229). A constituent of wasabi, 6-(methylsulfinyl) hexyl isothiocyanate, inhibits growth of various cancer cell lines including breast, melanoma, leukemia, and stomach cancers (29137, 29138, 29139). This activity may be due to reaction of 6-(methylsulfinyl) hexyl isothiocyanate with sulfhydryl (-SH) groups in biomolecules (29142, 29143). Another wasabi constituent, linolenoyloleoyl-3-beta-galactosylglycerol, inhibits colon, lung, and stomach cancer cell growth (55559). However, desulfosinigrin, a constituent of wasabi, can promote the growth of human colon and lung cancer cells in a concentration-dependent manner (55558).\nAntidiabetic effects\nAnimal research in mice fed a high-fat diet for 12 weeks shows that giving oral wasabi leaf 200, 100, or 50 mg/kg daily prevents several adverse metabolic changes in a dose-dependent manner when compared with the high-fat diet alone. The effects of wasabi leaf 50 mg/kg daily are similar to those of metformin 250 mg/kg daily. Wasabi reduces serum glucose, glycated hemoglobin, and insulin levels, and pancreatic islet cell hyperplasia. It also reduces obesity, adipocyte hypertrophy, and abdominal fat density. Suggested mechanisms are upregulation of AMPK-related hepatic glucose enzyme activities and increased activity of the antioxidant defense systems (106757).\nAntiplatelet effects\nIn animal research, 6-(methylsulfinyl) hexyl isothiocyanate, a constituent of wasabi, inhibits platelet aggregation, possibly by reacting with sulfhydryl (-SH) groups in biomolecules (29142, 29143).\nBone metabolism effects\nIn vitro and in animal research, extracts from wasabi leafstalk have an anabolic effect on bone metabolism (29144).\nCardiovascular effects\nAnimal research in a rat model of obesity and metabolic syndrome induced by 8 weeks of a high-fat and high-carbohydrate diet shows that adding wasabi powder 5% to the diet daily for a further 8 weeks attenuates the development of hypertension when compared with the diet alone. There is also an increase in levels of beneficial bacteria in the gut. Disruption of the gut microbial flora is thought to contribute to the development of hypertension (106758).\nGastrointestinal effects\nAn extract of wasabi root has activity in a mouse model of diarrhea-predominant irritable bowel syndrome (IBS). It reduces diarrhea and weight loss, lowers serum tumor necrosis factor (TNF)-alpha levels, and reduces infiltration of mast cells into the colon (101227). An ethanol extract of wasabi root prevents development of colitis in a mouse model of ulcerative colitis by inhibiting NF-kappa-B, reducing pro-inflammatory cytokines, and maintaining epithelial tight junctions (101228).\nHepatic effects\nAnimal research in mice fed a high-fat diet for 12 weeks shows that giving oral wasabi leaf 200, 100, or 50 mg/kg daily reduces liver weight, liver function test values, hepatocyte size, steatosis, and non-alcoholic fatty liver disease in a dose-dependent manner when compared with the high-fat diet alone (106757).\nHypocholesterolemic effects\nAnimal research in mice fed a high-fat diet for 12 weeks shows that giving oral wasabi leaf 200, 100, or 50 mg/kg daily is associated with reductions in serum triglyceride, total cholesterol, and low-density lipoprotein cholesterol levels, and an increase in high-density lipoprotein cholesterol levels, when compared with the high-fat diet alone. Suggested mechanisms are upregulation of lipid metabolism-related gene expression and modulation of pancreatic lipid digestion enzyme activity (106757).\nMetabolic effects\nIn animal research, wasabi and its constituent 6-(methylsulfinyl) hexyl isothiocyanate (6-MSITC) are a focus of study for metabolic effects. A study in rats fed high-carbohydrate and high-fat diets suggests that wasabi containing 6-MSITC alters fat composition and reduces body weight, fat mass, triglycerides, total cholesterol, and blood glucose when compared with control (112719).\nMuscle effects\nIn animal research, 6-(methylsulfinyl) hexyl isothiocyanate (6-MSITC), a constituent of wasabi, reduces activation of calpain-1, a protease enzyme that causes gradual loss in strength during prolonged eccentric exercise (106759). However, in young, healthy, untrained males, taking 6-MSITC 9 mg daily for 5 days does not change calpain-1 plasma levels after eccentric exercise of the elbow flexor muscles or levels of muscle damage markers or inflammatory markers when compared with placebo (106759).\nNervous system effects\nAllyl isothiocyanate, the pungent constituent of wasabi, activates TRPA1, a type of excitatory ion channel on sensory neurons of the pain pathway (29147)."
        }
    },
    "Water Avens": {
        "sections": {
            "Overview": "Water avens is a perennial herb that grows in temperate regions of North America, Europe, and Central Asia (102880, 103184).\n\nKEY HIGHLIGHTS\nTraditionally used in diarrhea, irritable bowel syndrome (IBS), and ulcerative colitis, but there is no strong evidence to support any use.\nInsufficient reliable information available about the safety and side effects of water avens.\nNo known major interactions.",
            "Safety": "There is insufficient reliable information available about the safety of water avens.\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "General\nOrally, no adverse effects have been reported. However, a thorough evaluation of safety outcomes has not been conducted.",
            "Effectiveness": "There is insufficient reliable information available about the effectiveness of water avens.",
            "Dosing & Administration": "Adult\nOral:\nGeneral: Tannins, which are found in water avens, can alter the absorption of foods and nutrients by binding with digestive enzymes, alkaloid substances, minerals, and nitrogen-rich compounds. However, tannins are neutralized during processing and dietary consumption, making it difficult to determine the extent, if any, to which water avens might alter absorption (102880, 103184, 103714, 103715). Until more is known, separate the oral use of water avens from other products by at least 1 hour.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of water avens.",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the toxicology of water avens.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of water avens.",
            "Mechanism of Action": "General\nThe applicable parts of water avens are the underground parts, fresh flowering plant, and root. Water avens underground parts contain tannins, phenolic acids, and flavonoids (103184). Monoterpenes are abundant in the essential oil of water avens root, with cis-myrtanal being the most predominant (102880). Water avens aerial parts contain tannins, phenolic acids, aliphatic alcohols, flavonoids, triterpenes, and sterols, with 1-octen-3-ol being the major constituent in the essential oil of the aerial parts (102880). Ellagic acid is the predominant phenolic acid found in water avens underground and aerial parts (103184). Both the underground and aerial parts of water avens contain trace amounts of the volatile oil eugenol (18, 102880).\nAstringent effects\nWater avens is traditionally used for its astringent effects. The high tannin content of water avens is thought to be responsible for these effects (18)."
        }
    },
    "Water Dock": {
        "sections": {
            "Overview": "Water dock is a perennial plant that is native to Europe and temperate regions of Asia. The leaves of the plant have been used in salads (98211). Water dock has traditionally been used for various purposes, including gastrointestinal disorders, oral ulcers, blood purification, and as a diuretic and antipyretic.",
            "Safety": "There is insufficient reliable information available about the safety of water dock.\nPREGNANCY AND LACTATION: Insufficient reliable information is available; avoid using.",
            "Adverse Effects": "General\nNo adverse effects have been reported. However, a thorough evaluation of safety outcomes has not been conducted.",
            "Effectiveness": "There is insufficient reliable information available about the effectiveness of water dock.",
            "Dosing & Administration": "Adult\nResearch is limited; typical dosing unavailable.\n\nWater dock contains oxalate, which might bind to multivalent metal ions, such as iron, calcium, and zinc, in the gastrointestinal tract and decrease absorption (7, 12).\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of water dock.",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "EXPAND ALL\n|\nCOLLAPSE ALL\nCALCIUM\nWater dock might decrease the absorption of calcium.\nWater dock contains oxalate (7, 12), which can bind multivalent metal ions in the gastrointestinal tract and decrease mineral absorption.\nless\nIRON\nWater dock might decrease the absorption of iron.\nWater dock contains oxalate (7, 12), which can bind multivalent metal ions in the gastrointestinal tract and decrease mineral absorption.\nless\nZINC\nWater dock might decrease the absorption of zinc.\nWater dock contains oxalate (7, 12), which can bind multivalent metal ions in the gastrointestinal tract and decrease mineral absorption.\nless",
            "Interactions with Conditions": "NEPHROLITHIASIS (KIDNEY STONES)\nUse with caution in individuals with a history of kidney stones. Insoluble oxalate crystals may form in the kidneys, causing further damage (12).\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with water dock.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of water dock.",
            "Mechanism of Action": "General\nThe applicable parts of water dock are the leaves and dried root. Water dock contains anthracene derivatives, oxalic acid, calcium oxalate, tannins, fat, protein, quercitrin, and starch (18).\nGastrointestinal effects\nIn vitro, an ethanol extract of water dock leaf has demonstrated a protective effect against hydrogen peroxide-induced oxidative stress and the resulting cell damage in a culture of human gastric epithelial cells. The active constituent is thought to be quercetin glucopyranoside, which upregulates production of antioxidant enzymes, including glutathione peroxidase (98211). The ethanol extract containing quercetin glucopyranoside also inhibits the production of pro-inflammatory cytokines that occurs in Helicobacter pylori-infected gastric cells (98212)."
        }
    },
    "Water Hemlock": {
        "sections": {
            "Overview": "Water hemlock grows in temperate wet, marshy areas in mainly North America. According to the United States Department of Agriculture (USDA), \"water hemlock is the most violently toxic plant that grows in North America.\"",
            "Safety": "UNSAFE when used orally. Water hemlock is considered to be the most poisonous plant growing in North America (6349). Intoxication can result from chewing or ingestion any part of the plant (6348, 6352, 85540, 85543, 85546, 85548). The usual lethal adult dose is one rhizome (6347) or a 2-3 cm portion of root (6349). ...when used topically (6348). Death can result when hemlock is applied topically (6348, 6349).\nCHILDREN: UNSAFE when used orally or topically (6347, 6351, 6355, 85531, 85538, 85542, 85544, 85545). Fatalities have resulted when hollow stems of water hemlock are used as whistles (6347), when hemlock is ingested (6355), or when hemlock has been applied topically (6351).\nPREGNANCY AND LACTATION: UNSAFE when used orally or topically. Water hemlock is toxic (6348, 6349); avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nWater hemlock is a known highly toxic plant and causes a variety of symptoms including vomiting (6350), acute renal failure (54716, 6351), marked metabolic acidosis (6348, 6346), seizures and convulsions (54716, 85535, 6348, 6346), or unconsciousness (6348, 6350) that may lead to death (85531, 85535, 6350, 6346).\nCardiovascular\nAccording to case reports, oral ingestion may cause an explosive illness with orthostatic hypotension (6350) or tachycardia (6350).\nless\nDermatologic\nAccording to case reports, oral ingestion causes an explosive illness with reddish tinted cyanosis (6348).\nless\nGastrointestinal\nAccording to case reports, oral ingestion causes an explosive illness with nausea (6350), vomiting (6350), or abdominal cramps (6350).\nless\nMusculoskeletal\nAccording to case reports, oral ingestion may cause an explosive illness with rhabdomyolysis (54716, 6351).\nless\nNeurologic/CNS\nAccording to case reports, oral ingestion may cause an explosive illness with seizures and convulsions (54716, 85535, 6348, 6346), neurologic lethargy (6350), or unconsciousness (6348, 6350) that may lead to death (85531, 85535, 6350, 6346).\nless\nOcular/Otic\nAccording to case reports, oral ingestion may cause an explosive illness with dilated pupils (6348).\nless\nPsychiatric\nAccording to case reports, oral ingestion may cause an explosive illness with neurologic lethargy (6350).\nless\nRenal\nAccording to case reports, oral ingestion may cause an explosive illness with rhabdomyolysis (54716, 6351), marked metabolic acidosis (6348, 6346), or acute renal failure (54716, 6351).\nless",
            "Effectiveness": "There is insufficient reliable information available about the effectiveness of water hemlock.",
            "Dosing & Administration": "Adult\nInsufficient available evidence.\nChildren\nInsufficient available evidence.\nStandardization & Formulation\nThere is no well-known standardization for water hemlock.",
            "Interactions with Drugs": "LITHIUM\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPROBABLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nWater hemlock is thought to have diuretic properties. Theoretically, due to these potential diuretic effects, water hemlock might reduce excretion and increase levels of lithium. The dose of lithium might need to be decreased.",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "None known.",
            "Interactions with Lab Tests": "EXPAND ALL\n|\nCOLLAPSE ALL\nSERUM LIVER ENZYMES\nIngestion of water hemlock can cause elevations in serum liver enzymes such as lactic dehydrogenase (LDH), aspartate aminotransferase (AST), and alkaline phosphatase (6346, 6347).\nless\nSERUM MUSCLE ENZYMES\nIngestion of water hemlock can cause elevations in serum muscle enzymes such as creatine phosphokinase (CPK) and lactic dehydrogenase (LDH isoenzyme fraction 5) levels (6346, 6347).\nless",
            "Overdose": "Water hemlock is a known highly toxic plant, and there are many reported cases of poisoning due to its ingestion (85532, 85533, 85548, 54716, 85535, 85534, 6348, 85543, 85545, 85544, 85546, 6350, 6351, 85549, 6346, 85530, 85537, 85539, 85542, 85541, 85540, 85536). Several have been accidental poisonings due to confusion of water hemlock roots with turnip, parsnip, or wild carrot (85531, 6350), and other poisonings have occurred in children (85531, 85545, 85544, 85538, 85542). Although water hemlock species are found primarily in marshy, temperate areas in North America, poisonings have been reported from Maine to New Mexico (85548, 85547, 54716).\n\n\nDiagnosis may be difficult as cicutoxin, the main water hemlock toxin, may not be positively identified in sera or gastric lavage contents (85531). According to case reports, oral ingestion causes an explosive illness with orthostatic hypotension (6350), tachycardia (6350), nausea (6350), vomiting (6350), abdominal cramps (6350), rhabdomyolysis (54716, 6351), acute renal failure (54716, 6351), reddish tinted cyanosis (6348), dilated pupils (6348), marked metabolic acidosis (6348, 6346), seizures and convulsions (54716, 85535, 6348, 6346), neurologic lethargy (6350), or unconsciousness (6348, 6350) that may lead to death (85531, 85535, 6350, 6346).\n\n\nTreatments have addressed the symptoms presented, including protecting the patient's airway from gastric aspiration (6350), hemodialysis (6348), restoring the intravascular and extracellular volume deficit through Ringer's lactate (6350) or hemoperfusion (6348), forced diuresis (6348), controlling cerebral edema (6350), controlling the gross and irregular body movements (6346), managing the metabolic acidosis (6346), and artificial ventilation (6348). According to one case report, the cicutoxin molecule size was calculated and it was found to be dialyzable (6348). According to one case report, cicutoxin toxicity may have both acute and chronic symptoms (85537).",
            "Pharmacokinetics": "Insufficient available evidence.",
            "Mechanism of Action": "Constituents\nThe toxin found in water hemlock is cicutoxin (85531, 6348, 85537)."
        }
    },
    "Watercress": {
        "sections": {
            "Overview": "Watercress originates from the eastern Mediterranean and adjoining areas of Asia. It is cultivated commercially for its small, pungent leaves, which are used as a salad green and as medicine (99815).",
            "Safety": "LIKELY SAFE when consumed in amounts commonly found in foods.\nPOSSIBLY SAFE when used orally in medicinal amounts, short-term. Watercress extract 750 mg/kg daily has been used with apparent safety for up to 5 weeks (103891).\nPOSSIBLY UNSAFE when used orally in excessive amounts or long-term (8, 12, 19). Watercress can cause gastric mucosal irritation (8, 12, 85599) or damage (19).\nCHILDREN: LIKELY UNSAFE when used orally in medicinal amounts; avoid using in children younger than 4 years old (12, 19).\nPREGNANCY: LIKELY UNSAFE when used in medicinal amounts. Watercress might stimulate menstruation or have abortifacient effects (19).\nLACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, watercress is well-tolerated when consumed in food amounts. There is limited reliable information available about the adverse effects of watercress when used in medicinal amounts. When excessive doses are used, watercress can cause gastrointestinal irritation (85599). Consuming raw watercress has been associated with the development of fascioliasis, a parasitic fluke disease of the liver (85575, 85574, 85573, 85567, 85564, 85582, 85563, 85562, 85580, 85561, 85560)(85554, 85558, 85596, 85579, 85571, 85569, 85583, 85586, 85584, 85588)(85585, 85590, 85592, 85591).\n\nTopically, watercress can cause contact dermatitis (85594, 85587).\nDermatologic\nTopically, watercress can cause contact dermatitis, resulting in hives, rash, itching, or swollen skin (85594, 85587).\nless\nGastrointestinal\nOrally, large quantities of watercress may cause gastrointestinal irritation (85599).\nless\nHepatic\nRaw, wild watercress can be contaminated with parasitic flukes which, when ingested, cause the liver disease fascioliasis. Symptoms include abdominal pain, fever, vomiting, diarrhea, urticaria, eosinophilia, and hepatomegaly (85575, 85574, 85573, 85567, 85564, 85582, 85563, 85562, 85580, 85561)(85560, 85554, 85558, 85596, 85579, 85571, 85569, 85583, 85586, 85584)(85588, 85585, 85590, 85592, 85591). Clinical research shows that taking a standardized extract of watercress orally 750 mg/kg daily for 5 weeks is not associated with increases in liver function enzymes (109666).\nless\nRenal\nOrally, excessive or prolonged use of watercress may theoretically cause kidney damage (85598). However, in overweight adults with physical disabilities, taking a watercress extract 750 mg/kg daily for 5 weeks does not cause any change in levels of creatinine or urea (109666).\nless",
            "Effectiveness": "There is insufficient reliable information available about the effectiveness of watercress.",
            "Dosing & Administration": "Adult\nOral:\nResearch is limited; typical dosing is unavailable.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of watercress.",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nCHLORZOXAZONE (Parafon Forte, Paraflex)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPROBABLE\nLevel of Evidence\nB (Nonrandomized clinical trial)\nWatercress might reduce the metabolism of chlorzoxazone and increase its effects and side effects. Clinical research in healthy volunteers shows that a single ingestion of watercress 50 grams increases the chlorzoxazone plasma concentration-time curve by about 56% and increases its half-life by about 53% (4018).\nLITHIUM\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPROBABLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nWatercress is thought to have diuretic properties (18). Theoretically, due to these potential diuretic effects, watercress might reduce excretion and increase levels of lithium.\nWARFARIN (Coumadin)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nB (Epidemiologic study)\nWatercress contains vitamin K. Consuming large amounts of watercress might antagonize the anticoagulant effects of warfarin (11285).",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "EXPAND ALL\n|\nCOLLAPSE ALL\nGASTRIC OR DUODENAL ULCERS\nWatercress is contraindicated in people with gastric or duodenal ulcers due to its potential to irritate the gastrointestinal mucosa (12, 19).\nless\nINFLAMMATORY KIDNEY DISEASES\nWatercress is contraindicated in people with inflammatory kidney disease (12, 19).\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with watercress.",
            "Pharmacokinetics": "Metabolism\nGlucosinolates present in watercress are converted to 2-phenylethyl isothiocyanate by microbial myrosinase in the intestine (109663, 109666).\nExcretion\nAfter consumption of watercress, one study found that the urine of study subjects contained the N-acetylcysteine conjugates of 7-methylsulfinylheptyl and 8-methylsulfinyloctyl isothiocyanates and phenethyl isothiocyanate (PEITC) (85555).",
            "Mechanism of Action": "General\nThe applicable parts of watercress are the above ground parts. Watercress contains mustard glycosides, mustard oil, glucosinolates such as gluconasturtiin, and nitriles such as 3-phenylpropionitrile and 8-methylthiooctanone nitrile (85568, 85600). It also contains protein, minerals, including manganese, iron, phosphorus, iodine, copper, and calcium, and vitamins A, B6, C, E, and K, thiamine, riboflavin, and niacin (19, 85598, 85599, 109663, 109664). Watercress also contains chlorophylls, carotenoids, flavonoids, polyphenols, terpenes, and coumarins (85550, 109663). Watercress also contains 16:3 omega-3, a polyunsaturated fatty acid (68114).\n\nMicrobial contamination of watercress is common. In one evaluation of raw watercress obtained from supermarkets, grocery stores, and self-service restaurants, 96% of samples were found to contain acarids, acarid eggs, insects, nematode larvae, and ciliated protozoa (85552).\nAnti-inflammatory effects\nAnimal research shows that applying a gel containing watercress extract to the skin of mice reduces edema and leukocyte infiltration caused by croton oil (99815). In adults with physical disabilities, watercress extract 750 mg/kg daily for 5 weeks reduces levels of the inflammatory marker C-reactive protein but does not lower cytokine levels (103891). Clinical research in healthy young males shows that consuming 100 grams of watercress does not affect plasma levels of interleukin (IL)-6 or tumor necrosis factor (TNF)-alpha when compared with consuming lettuce or neither vegetable (109665). Other clinical research in healthy, untrained adults undergoing 30-minute high-intensity workouts shows that eating fresh watercress 85 grams 2 hours before the workout up-regulates the post-exercise immune response, with increases in levels of both pro-inflammatory markers (IL-1-beta, IL-6, tumor necrosis factor (TNF)-alpha), and anti-inflammatory markers (IL-10), when compared with consuming 85 grams of lettuce (109663).\nAnticarcinogenic effects\nThe organic isothiocyanates (ITCs), or mustard oils, that are present in watercress have chemo-preventive properties due to their inhibition of carcinogen metabolic activation. Watercress contains phenethyl isothiocyanate (PEITC), a naturally occurring ITC, which has been shown to block chemical carcinogenesis in laboratory research (85572, 85566, 55547, 85556, 85555, 85551, 85553, 85593, 85597, 85595, 4019, 85568). PEITC is released by chewing watercress (4019). Additionally, the microflora in the intestine can hydrolyze glucosinolates in watercress to ITCs (85551).\nAntidiabetic effects\nClinical research in healthy young males shows that after consuming a meal containing 100 grams of watercress, lettuce, or neither, the area under the plasma glucose or insulin concentration time curves and the peak plasma insulin levels are lower with lettuce than with watercress or control. There is no difference in these values between watercress and the control (109665).\nAntioxidant effects\nSome clinical research shows that watercress extract has antioxidant effects. In adults with physical disabilities, watercress extract 750 mg/kg orally daily for 5 weeks reduces lipid peroxidation, as well as superoxide dismutase and catalase levels (103891). However, in another study using the same dosage regimen in the same patient population, only lipid peroxidation was reduced (109666). Clinical research in adults on maintenance hemodialysis for at least 3 months shows that taking an ethanol extract of watercress 500 mg daily for 4 weeks has mixed effects on biomarkers of oxidative stress, reducing serum malondialdehyde (MDA) while increasing superoxide dismutase (SOD) when compared with placebo. It is also associated with stable total antioxidant capacity (TAC), compared with a decline seen with placebo (109664).\nDiuretic effects\nWatercress is thought to have diuretic activity. The mustard oil constituent of watercress is believed to be responsible for this effect (18).\nLipid effects\nClinical research in overweight adults with physical disabilities shows that taking watercress extract 750 mg/kg daily for 5 weeks reduces low-density lipoprotein (LDL) cholesterol levels when compared with placebo, but does not affect total cholesterol or high-density lipoprotein (HDL) cholesterol levels (109666). Clinical research in healthy young males shows that consuming 100 grams of watercress does not affect plasma total cholesterol, LDL cholesterol, or triglycerides when compared with consuming lettuce or neither vegetable (109665). Clinical research in adults on maintenance hemodialysis for at least 3 months shows that taking an ethanol extract of watercress 500 mg daily for 4 weeks is associated with small decreases in total and LDL cholesterol and triglycerides and an increase in HDL cholesterol (109664)."
        }
    },
    "Wheat Bran": {
        "sections": {
            "Overview": "Wheat bran is the outer layers of the wheat grain kernel that are separated from the starchy endosperm (wheat germ) during milling. It contains both soluble and insoluble fiber (94068, 100638, 100641).",
            "Warnings": "The Food Allergen Labeling and Consumer Protection Act (FALCPA) of 2004 recognizes wheat as a major food allergen in the United States and requires that wheat contents, including wheatgrass, be labeled on packaged food and supplement products (105410).",
            "Safety": "LIKELY SAFE when used orally and appropriately. Wheat bran in doses up to 30 grams daily has been used for 3 months with no reports of serious adverse effects (10326, 10328, 113128).\nCHILDREN: LIKELY SAFE when used orally and appropriately. Wheat bran in doses up to 10 grams daily has been used safely for up to 2 years (94068).\nPREGNANCY AND LACTATION: LIKELY SAFE when used orally (5).",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, wheat bran seems to be well tolerated.\nMost Common Adverse Effects\nOrally: Flatulence and gastrointestinal discomfort.\nSerious Adverse Effects (Rare)\nAll routes of administration: Wheat products can cause allergic reactions, including anaphylaxis.\nGastrointestinal\nOrally, wheat bran may cause flatulence and gastrointestinal discomfort, especially with initial use. However, 2 clinical studies designed to look at side effects noted no increase in GI symptoms in subjects taking 20 to 40 grams of wheat bran per day (6265, 113128).\nless\nImmunologic\nWheat can cause allergic reactions in sensitive individuals. Due to the prevalence of this allergy in the general population, wheat and wheat products, such as wheat bran, are classified as major food allergens in the United States (105410).\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nPOSSIBLY EFFECTIVE\nConstipation. Oral wheat bran seems to be beneficial for restoring normal bowel function in people with mild constipation.\nTaking wheat bran orally seems to be effective for treating mild constipation and restoring normal bowel function in adults and children. Wheat bran seems to increase stool output and improve colonic transit, but it does not soften normal-viscosity stool. In adults, doses of 20-25 grams daily are used. In children, an age-based dose of 5-10 grams daily for those under 1 year of age, 10-20 grams daily for 1-2 years of age, and 20 grams daily for those over 2 years of age has been used (6265, 11004, 11116, 11117, 94068). Additionally, a large clinical study in Chinese adults with constipation shows that taking wheat bran 5 grams daily in combination with blond psyllium for 4 weeks relieves hard stools when compared with placebo (112994). However, it is unclear if this effect is due to wheat bran, blond psyllium, or the combination.\nless\nHemorrhoids. Oral wheat bran may reduce the risk for hemorrhoids in some people.\nClinical research in adults with hemorrhoids shows that taking wheat bran 10 grams twice daily reduces the risk of hemorrhoid recurrence at 10 weeks when compared with a control group (11118, 11119).\nless\nIrritable bowel syndrome (IBS). Oral wheat bran seems to improve bowel function in some people with IBS.\nClinical research in adults with mild to moderate IBS shows that taking wheat bran 30 grams daily for 4 weeks may reduce abdominal pain and improve bowel function when compared to baseline. However, it does not appear to be as effective as taking partially hydrolyzed guar gum 5 grams daily (10326).\nless\nPOSSIBLY INEFFECTIVE\nColorectal cancer. Most research shows that oral wheat bran does not reduce the risk for colorectal cancer.\nSeveral large well-designed studies show that consuming fiber, including wheat bran, does not prevent the recurrence of colorectal adenomas, despite earlier evidence that suggested a beneficial effect (160, 4819, 4820, 4821). Additionally, a large clinical study in Japanese patients with previous removal of colorectal tumors shows that taking wheat bran 7.5 grams daily for 4 years does not reduce the risk of new colorectal tumors when compared with not taking wheat bran. Additionally, this study suggests that taking wheat bran increases the occurrence of large colorectal tumors after 4 years. Half of the patients included in this research were also taking Lacticaseibacillus paracasei (111959). It is unclear if the results from this study can be extrapolated to patients in geographic locations other than Japan.\nless\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nCancer. Although there is interest in using oral wheat bran to prevent various types of cancer, there is insufficient reliable information about the clinical effects of wheat bran for this purpose.\nDiabetes. It is unclear whether consuming wheat bran can improve glycemic control in people with type 2 diabetes.\nSmall crossover studies in adults with type 2 diabetes have yielded conflicting outcomes. One small study shows that consuming 25 grams of fiber, including wheat bran, daily as part of the diet for 6 weeks can improve glycemic control and reduce insulin and plasma lipid levels when compared with a high-fiber diet providing 50 grams of fiber daily. However, another small crossover study shows that consuming bread or cereal providing wheat bran 18 grams daily for 3 months does not improve glycemic control or lipid levels when compared with a low-fiber diet providing 4 grams of fiber daily (6266, 10328). The reasons for these discrepant findings are unclear, but may relate to the type of fiber added to the diet. More recent research in adults with type 2 diabetes shows that consuming wheat bran 40 grams daily for 1 month reduces fasting blood glucose, serum triglycerides, total cholesterol, very-low-density lipoprotein, and body weight when compared to baseline (113126). The validity of this study is limited by the lack of a comparator group.\nless\nHyperlipidemia. It is unclear if oral wheat bran is beneficial for hyperlipidemia.\nA small clinical study in adults with normal weight or obesity shows that taking wheat bran 20 grams daily for 1 month does not reduce serum total cholesterol or triglycerides when compared with placebo (113127). However, most participants had normal serum lipid levels, and it is unclear if any of the participants had hyperlipidemia at baseline.\nless\nHypertension. Although there is interest in using oral wheat bran for hypertension, there is insufficient reliable information about the clinical effects of wheat bran for this purpose.\nMelasma. Topical wheat bran extract has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nA small clinical study in patients with melasma shows that applying a cream containing wheat bran extract 3.45% and lycopene 0.05% twice daily for 12 weeks seems to modestly reduce the severity of melasma, but not the area of affected skin, when compared with a placebo cream. Both groups were also provided with sunscreen and advised to use throughout the study (105569). It is unclear if this effect is due to wheat bran, lycopene, or the combination.\nless\nStress. It is unclear if oral wheat bran can reduce stress.\nA small clinical study in healthy male adults shows that taking wheat bran 25 grams daily for 28 days does not improve self-reported stress and mood or modify physiological measures of stress responses (113128). However, the study may have been of too short duration and inadequately powered to detect a difference.\nless\nMore evidence is needed to rate wheat bran for these uses.",
            "Dosing & Administration": "Adult\nOral:\nGeneral: Wheat bran is a source of dietary fiber. Daily adequate intakes (AI) of dietary fiber for healthy individuals are as follows: males 19-50 years, 38 grams; males 51 years and older, 30 grams; females 19-50 years, 25 grams; females 51 years and older, 21 grams; during pregnancy, 28 grams; during lactation, 29 grams (11120).\n\nWheat bran is most often used in doses of 20-30 grams daily. See Effectiveness section for condition-specific information.\n\nWheat bran may contain high levels of phytate, which can alter the absorption of nutrients by binding to cations such as iron, zinc, and calcium. Phytate content varies depending on growing methods and seasons. Phytate is also neutralized during food processing and within the small intestine. This makes it difficult to determine the extent, if any, to which the phytate in wheat bran might alter nutrient absorption (1858, 103788, 103789, 103790, 103923).\nChildren\nOral:\nGeneral: Wheat bran is a source of dietary fiber. The daily adequate intakes (AI) of dietary fiber in children are based on age as follows: 1-3 years, 19 grams; 4-8 years, 25 grams; males 9-13 years, 31 grams; males 14-18 years, 38 grams; females 9-18 years, 26 grams. There is no set AI for children under one year of age (11120).\nStandardization & Formulation\nWheat bran is primarily composed of fiber. In one clinical study, wheat bran was standardized to contain 39% dietary fiber (94068).",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "None known.",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the treatment or presentation of overdose with wheat bran.",
            "Pharmacokinetics": "Absorption\nThe fiber present in wheat bran is not absorbed (100638). However, it is fermented by bacteria in the colon to short chain fatty acids (SCFAs), hydrogen, and methane which are absorbed into the bloodstream (113124). Clinical research shows that after ingestion of wheat bran 25-40 grams in a single dose, the SCFAs acetate, butyrate, and propionate increase in the blood as early as 1-2.5 hours after ingestion, with levels still slightly above baseline 24 hours after ingestion (113124, 113128).\nMetabolism\nDietary insoluble fiber is not digested by enzymes in the upper gastrointestinal tract and reaches the colon largely intact (100640).\nExcretion\nInsoluble fiber in wheat bran is fermented in the colon by the gut bacteria and some of the products, such as SCFAs, are excreted in the feces (100638, 113124). Some products from this fermentation, such as hydrogen and methane, are also exhaled (113124).",
            "Mechanism of Action": "General\nWheat bran is the outer layers of wheat grain, separated during milling. It constitutes about one-fifth of the total grain by weight. The major component of wheat bran is fiber, both insoluble and soluble, but it also contains proteins, fats, carbohydrates, minerals, vitamins, antioxidants, and phenolic compounds (100641). The main insoluble fibers present in the bran are arabinoxylans, accounting for 17% to 33% of the total bran (100638, 100639).The effects of wheat bran are dependent on particle size. In addition to changes in surface area, ultra-fine grinding breaks down the fiber matrix and releases the contents of cells. It also disrupts chemical bonds in insoluble fiber, making smaller, more soluble molecular fragments (100641, 113127).\n\nWheat bran oil is prepared by soaking the bran in diethyl ether for 24-48 hours, then filtering and evaporating the liquid filtrate (100642). The oil contains lower levels of saturated fats and higher levels of unsaturated fats than lard. It also contains phytosterols including campesterol, campestanol, stigmasterol, beta-sitosterol, and stigmastenol (100642).\n\nInsoluble fiber in wheat bran reaches the colon intact and is an important carbon and energy source for colonic bacteria, resulting in fermentation of the fiber (100638, 100640, 113124, 113125, 113127). Changes in the type of bran, particle size, processing methods, or digestion in the upper gastrointestinal tract can alter the types and activity of the colonic bacteria, and the products of the fermentation process (100638, 100640). The products of the fermentation process may also vary as a function of individual differences in gut microbiome and fermentation-related hydrogen and methane gas excretion profiles (113124).\nAnticancer effects\nIt has been proposed that high dietary fiber intake can prevent certain cancers, particularly colorectal cancer via mechanisms such as insoluble fiber binding and removing carcinogens from the intestine (111959). Additionally, the fiber in wheat bran reaches the colon virtually unchanged and is then fermented by the colonic bacterial flora (100640). The products of fermentation include short chain fatty acids such as butyrate which may have anticancer effects (100639). In the distal colon, butyrate reduces ammonia produced by fermentation of foods high in fat and sugar, possibly preventing cell damage and reducing the risk of colon cancer (375). In healthy individuals who add wheat bran to their diet in the form of cereal bars eaten twice daily for 4 weeks, fecal concentrations of butyrate and butyrate-producing bacteria are increased (100639).\nAntidiabetic effects\nIncreases in serum glucose seen in rats fed a high-fat diet are lower, and glucose tolerance is improved, when wheat bran is added to the diet (100641, 113123, 113125). Another animal study in obese rats shows that adding red wheat bran to the diet reduces insulin resistance and postprandial glucose levels (103787). However, clinical research in adults with type 2 diabetes is conflicting as to whether regular intake of wheat bran improves glycemic control (6266, 10328, 113126).\nAntihypercholesterolemic effects\nWheat bran or wheat bran oil added to a high-fat diet in animals moderates increases in total and low-density lipoprotein (LDL) cholesterol, triglycerides, and liver cholesterol content (100641, 100642). Wheat bran constituents decrease plasma total cholesterol levels by inhibiting cholesterol synthesis in the liver. Wheat bran also increases fecal excretion of sterols, which are products of the breakdown of cholesterol in the gut, including unabsorbed cholesterol and cholesterol secreted in the bile (100642). However, clinical research is conflicting on whether taking wheat bran daily, at least in the short term, reduces serum cholesterol levels (113126, 113127).\nDermatological effects\nThere has been interest in using wheat bran extracts in topical skin lightening products possibly due to hydroquinone, found in wheat bran extract, inhibiting tyrosinase activity (105569).\nEndocrine effects\nSoluble fiber in wheat bran slows the release of glucose from food and can bind free fat molecules in the gut, preventing their absorption (100641).\nGastrointestinal effects\nWheat bran has laxative effects. The insoluble fiber present increases fecal bulk, promotes peristalsis, decreases intestinal transit time, and increases frequency of bowel movements (6265, 11463, 100639, 100641). Wheat bran has negligible water-holding capacity and no stool softening effect in people with normal stools (6265, 113127). The laxative effect of wheat bran is dependent on particle size. Larger particles have a greater laxative effect than smaller particles (6265).\nPsychological effects\nIt is theorized that the short chain fatty acids (SCFAs) produced from the fermentation of wheat bran by intestinal bacteria may improve psychological outcomes via a microbiota-gut-brain axis. Specifically, it is hypothesized that the SCFAs may alter gene expression, bind receptors, interact with vagal afferents, cross the blood brain barrier, affect the hypothalamic-pituitary-adrenal axis, and modify cortisol release (113128). However, in clinical research, wheat bran 25 grams daily for 28 days did not modify serum brain derived neurotrophic factor, the cortisol response to acute stress, cortisol awakening response, or subjective ratings stress and mood (113128).\nWeight loss effects\nSoluble fiber in wheat bran enhances feelings of fullness and stimulates release of appetite-suppressing hormones which can aid in weight loss. Rats fed a high-fat diet have less weight and adipose tissue gain, lower food consumption, and reduced lipogenic enzyme expression in liver and adipose tissue when they also receive wheat bran (100641, 113125). Specifically, gene expression for fatty acid synthase, acetyl-CoA carboxylase, and peroxisome proliferator-activated receptor-gamma was reduced when wheat bran was added to the diet (113125). However, in humans with abdominal obesity, consuming wheat bran with or without whey protein for 12 weeks does not seem to affect adipose tissue gene expression or inflammatory markers (103786)."
        }
    },
    "Wheatgrass": {
        "sections": {
            "Overview": "Wheatgrass is the freshly sprouted shoot of the common wheat plant, Triticum aestivum (11165). This species is considered to be native to southwest Asia and Mediterranean regions, although it is cultivated all over the world (91572).",
            "Warnings": "The Food Allergen Labeling and Consumer Protection Act (FALCPA) of 2004 recognizes wheat as a major food allergen in the United States and requires that wheat contents, including wheatgrass, be labeled on packaged food and supplement products (105410).",
            "Safety": "LIKELY SAFE when consumed in amounts commonly found in foods (5286).\nPOSSIBLY SAFE when wheatgrass juice is taken orally and appropriately in medicinal amounts. Wheatgrass juice 60-100 mL daily has been used safely for up to 18 months (11165, 85601, 104878, 104879). ...when wheatgrass cream is used topically. Wheatgrass 10% cream has been used safely for up to 6 weeks (85602).\nThere is insufficient reliable information available about the long-term safety of wheatgrass when used medicinally.\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, wheatgrass is generally well tolerated.\nMost Common Adverse Effects\nOrally: Allergic reactions, anorexia, constipation, nausea.\nGastrointestinal\nOrally, wheatgrass may cause nausea, anorexia, and constipation (11165).\nless\nImmunologic\nWheat can cause allergic reactions in sensitive individuals. Due to the prevalence of this allergy in the general population, wheat and wheat products, such as wheatgrass, are classified as major food allergens in the United States (105410).\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nBenign prostatic hyperplasia (BPH). Although there has been interest in using oral wheatgrass for BPH, there is insufficient reliable information about the clinical effects of wheatgrass for this purpose.\nBeta-thalassemia. It is unclear if oral wheatgrass is beneficial in patients with beta-thalassemia.\nA small clinical study in children with beta-thalassemia major shows that taking wheatgrass tablets orally in doses of 1-1.5 grams daily for children aged 1-3 years, 3 grams daily for children 4-8 years, and 4 grams daily for children aged 9 years and older for 12 months decreases the mean blood transfused as packed cells by about 18%, increases mean hemoglobin by about 7%, and increases the mean interval between consecutive blood transfusions by about 5 days when compared to baseline (93021). The validity of this study is limited by the lack of a comparator group and high patient dropout rate. However, another small clinical study shows that taking wheatgrass tablets 100 mg/kg orally daily for 6 months followed by 200 mg/kg daily for an additional 6 months does not reduce the transfusion requirement when compared to baseline in children or adults with beta-thalassemia major (93020). The validity of this study is limited by the lack of a comparator group.\n\nAnother small, low-quality study shows that drinking wheatgrass juice 100 mL daily for 18 months reduces blood transfusion requirements in children with beta-thalassemia major when compared to baseline (85601). The validity of this study is limited by the lack of a comparator group and high patient dropout rate.\nless\nBronchitis. Although there has been interest in using oral wheatgrass for bronchitis, there is insufficient reliable information about the clinical effects of wheatgrass for this purpose.\nCancer. Although there has been interest in using oral wheatgrass for cancer, there is insufficient reliable information about the clinical effects of wheatgrass for this purpose.\nCommon cold. Although there has been interest in using oral wheatgrass for common cold, there is insufficient reliable information about the clinical effects of wheatgrass for this purpose.\nCough. Although there has been interest in using oral wheatgrass for cough, there is insufficient reliable information about the clinical effects of wheatgrass for this purpose.\nDiabetes. Although there has been interest in using oral wheatgrass for diabetes, there is insufficient reliable information about the clinical effects of wheatgrass for this purpose.\nGout. Although there has been interest in using oral wheatgrass for gout, there is insufficient reliable information about the clinical effects of wheatgrass for this purpose.\nHypercholesterolemia. It is unclear if oral wheatgrass is beneficial in patients with hypercholesterolemia.\nPreliminary clinical research shows that taking freeze-dried wheatgrass powder 3.5 grams orally daily for 10 weeks reduces total cholesterol by 5% and triglycerides by 10% when compared to baseline in females aged 30-60 years with elevated cholesterol levels. However, taking wheatgrass powder does not reduce low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, or fasting blood glucose levels in these patients (95906).\nless\nHypertension. Although there has been interest in using oral wheatgrass for hypertension, there is insufficient reliable information about the clinical effects of wheatgrass for this purpose.\nKidney stones (nephrolithiasis). Although there has been interest in using oral wheatgrass for nephrolithiasis, there is insufficient reliable information about the clinical effects of wheatgrass for this purpose.\nPharyngitis. Although there has been interest in using oral wheatgrass for pharyngitis, there is insufficient reliable information about the clinical effects of wheatgrass for this purpose.\nPlantar heel pain. It is unclear if topical wheatgrass is beneficial in patients with plantar heel pain.\nPreliminary clinical research in adults with chronic plantar fasciitis shows that applying a wheatgrass 10% cream topically to the bottom of the feet twice daily for 6 weeks is no more effective than placebo for reducing pain or improving measures of injury resolution (85602).\nless\nProstatitis. Although there has been interest in using oral wheatgrass for prostatitis, there is insufficient reliable information about the clinical effects of wheatgrass for this purpose.\nUlcerative colitis. It is unclear if oral wheatgrass is beneficial in patients with ulcerative colitis.\nA small clinical study in adults with active distal ulcerative colitis shows that drinking 100 mL of freshly extracted wheatgrass juice daily for 1 month modestly reduces overall disease activity and the severity of rectal bleeding when compared with placebo (11165).\nless\nUrinary tract infections (UTIs). Although there has been interest in using oral wheatgrass for UTIs, there is insufficient reliable information about the clinical effects of wheatgrass for this purpose.\nWound healing. Although there has been interest in using oral wheatgrass for wound healing, there is insufficient reliable information about the clinical effects of wheatgrass for this purpose.\nMore evidence is needed to rate the effectiveness of wheatgrass for these uses.",
            "Dosing & Administration": "Adult\nOral:\nResearch is limited; typical dosing is unavailable.\nChildren\nOral\nResearch is limited; typical dosing is unavailable.\nStandardization & Formulation\nWheatgrass supplements are typically sold as fresh or frozen juice, tablets, or powder concentrate (93017). Wheatgrass juice is prepared by squeezing extract from mature wheat sprouts. Wheatgrass juice is thought to possess therapeutic qualities only when fresh and consumed on an empty stomach immediately after extraction (11165). Powdered wheatgrass is produced by freeze-drying or oven-drying, with the former containing higher free radical scavenging and antioxidant activity (95906).",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nANTIDIABETES DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, taking wheatgrass with antidiabetes drugs might lower blood glucose levels and increase the risk of hypoglycemia.\nAnimal research shows that taking wheatgrass stimulates the release of insulin from beta-cells and lowers blood glucose (93018, 93019).\nless\nCYTOCHROME P450 1A2 (CYP1A2) SUBSTRATES\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, wheatgrass might decrease the levels and clinical effects of CYP1A2 substrates.\nIn vitro research shows that wheatgrass induces CYP1A2 enzymes (111404).\nless",
            "Interactions with Supplements": "HERBS AND SUPPLEMENTS WITH HYPOGLYCEMIC POTENTIAL\nTheoretically, taking wheatgrass with herbs and supplements with hypoglycemic potential might lower blood glucose levels and increase the risk of hypoglycemia.\nAnimal research shows that taking wheatgrass stimulates the release of insulin from beta-cells and lowers blood glucose (93018, 93019). See other products with hypoglycemic potential here.\nless",
            "Interactions with Conditions": "PERIOPERATIVE\nTheoretically, taking wheatgrass might interfere with blood glucose control during and after surgical procedures. Animal research shows that taking wheatgrass stimulates the release of insulin from beta-cells and lowers blood glucose (93018, 93019). Tell patients to discontinue wheatgrass products at least 2 weeks before elective surgical procedures.\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with wheatgrass.",
            "Pharmacokinetics": "Absorption\nAlthough wheatgrass juice is thought to possess therapeutic qualities only when fresh and consumed on an empty stomach immediately after extraction, there is no research to determine the effect of freshness on bioavailability of its constituents (11165).",
            "Mechanism of Action": "General\nThe applicable parts of wheatgrass are the above ground parts, root, and rhizome. Wheatgrass contains large amounts of chlorophyll. High-chlorophyll beverages are sometimes included in diets purported to treat diseases such as cancer and rheumatoid arthritis (5286, 6982). It also contains vitamin A, vitamin C, and vitamin E, iron, calcium, magnesium and amino acids (93017).\nAnti-arthritic effects\nHigh-chlorophyll beverages such as wheatgrass juice are sometimes included in diets purported to treat diseases such as rheumatoid arthritis (5286, 6982).\nAnti-inflammatory effects\nThe wheatgrass constituent, apigenin, may have anti-inflammatory activity, which might explain its use for ulcerative colitis (11165). Clinical research in adult patients undergoing adjuvant chemotherapy for colon cancer shows that taking 60 mL of wheat grass juice daily throughout chemotherapy treatment increases levels of interleukin-10, an anti-inflammatory cytokine, and attenuates the decline in white blood cell count when compared with control (104878).\nAntibacterial effects\nA constituent of wheatgrass, agropyrene, seems to have antibiotic activity (7162).\nAnticancer effects\nHigh-chlorophyll beverages such as wheatgrass juice are sometimes included in diets purported to treat diseases such as cancer (5286, 6982). In vitro evidence suggests that apigenin, a constituent of wheatgrass, inhibits the proliferation and induces apoptosis of cancer cells (93017). Clinical research in adult patients undergoing adjuvant chemotherapy for colon cancer shows that taking 60 mL of wheat grass juice daily throughout chemotherapy treatment decreases levels of vascular growth factors, procoagulants, and markers of vascular damage when compared with control. Theoretically, these effects may slow tumor progression and reduce the adverse effects of some chemotherapies, but further research is needed to confirm (104879).\nAntidiabetic effects\nSome animal research shows that administering ethanol extract of wheatgrass 100 mg/kg daily for 30 days can decrease levels of fasting blood glucose and glycosylated hemoglobin (HbA1c) in rats with streptozotocin-induced diabetes. This effect is attributed to the ability of wheatgrass to simulate insulin release from beta-cells (93018). Other animal research shows that wheatgrass cam improve glucose and insulin levels in male rats with diabetes, possibly by increasing the activity of glucose oxidative enzymes (93019).\nAntioxidant effects\nThe wheatgrass constituent, apigenin, may have antioxidant activity, which might explain its use for ulcerative colitis (11165). Also, chlorophyll is thought to protect mitochondrial membranes from gamma-radiation. This may help lessen side effects of cancer treatment (93017).\nChelation effect\nPreliminary clinical evidence suggests that wheatgrass juice can reduce iron levels in patients needing to undergo repeated blood transfusions, including those with myelodysplastic syndrome and intermediate thalassemia (93022).\nCholesterol-lowering effects\nEvidence from animal research suggests that fresh wheatgrass juice induces a dose-dependent reduction in levels of total cholesterol, triglycerides, low-density lipoprotein (LDL) cholesterol, and very low-density lipoprotein (VLDL) cholesterol in hypercholesterolemic rats. The effect is similar to that of atorvastatin (93017)."
        }
    },
    "Whey Protein": {
        "sections": {
            "Overview": "Whey protein is the protein derived from whey. Whey is a by-product of cheese manufacturing (2640, 85857, 85978).",
            "Safety": "LIKELY SAFE when used orally and appropriately. Whey protein up to 30 grams has been safely used in clinical trials for up to 6 months (4930, 16728, 16729, 105587).\nCHILDREN: LIKELY SAFE when used orally and appropriately as a dietary protein in food or infant formula. Hydrolyzed whey protein-based formula has been safely used in infants for up to 6 months in clinical trials (4927, 105585, 105594).\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, whey protein is generally well tolerated.\nMost Common Adverse Effects\nOrally: Acne, bloating, cramps, diarrhea, fatigue, headache, nausea, reflux, reduced appetite, and thirst. Most adverse effects are dose-related.\nCardiovascular\nIn one case report, use of an unclear quantity of whey protein over one month was thought to be probably responsible for the development of coronary embolism in three coronary arteries in a 33-year-old male with no history of atherosclerosis risk factors. The patient required treatment with intravenous glycoprotein IIb/IIIa inhibitor and heparin (96023).\nless\nDermatologic\nOrally, whey protein has been reported to trigger the onset or worsening of acne. Multiple case reports in teenagers and young adults have associated intake of whey protein with the development of acne or the worsening of existing acneiform lesions. In these reports, the discontinuation of whey protein was typically associated with the clearance of acne lesions. In some cases, patients who were unresponsive to acne treatments while using whey protein became responsive after whey protein discontinuation (103965, 103970, 103971). Cow's milk, which is comprised of 20% whey protein, is also thought to exacerbate acne. It is theorized that this effect may be due to the growth factor and alpha-lactalbumin content of whey protein (103971, 103982).\nless\nGastrointestinal\nOrally, whey protein, especially in higher doses of 2.3-6.5 grams/kg daily, may cause increased bowel movements, nausea, thirst, bloating, esophageal reflux, cramps, and reduced appetite (2640, 85961, 85702, 86043, 86074, 86075, 86084, 86089, 86095).\nless\nHepatic\nIn two case reports, acute cholestatic liver injury occurred after consumption of the combination of whey protein and creatine supplements (46701, 90319).\nless\nMusculoskeletal\nIn one case report, a 26-year-old male experienced fasciitis, or swelling of the forearms, hands, and legs, after consuming the supplement Pure Whey (85895).\nless\nNeurologic/CNS\nOrally, high doses of whey protein may cause tiredness or fatigue and headache (2640). Mild drowsiness has also been reported (86089, 86092, 86124).\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nPOSSIBLY EFFECTIVE\nAthletic performance. Regular consumption of whey protein in conjunction with exercise may improve muscle strength and performance. However, inconsistent consumption of whey protein, as well as intake of whey protein without concomitant exercise, may not be beneficial.\nMost clinical research shows that taking whey protein 1.2-1.5 grams/kg or 30-33 grams daily in combination with strength training for 6-21 weeks can increase lean body mass, strength, and muscle hypertrophy in healthy young adults (16728, 16729, 16748, 46552, 85765, 85910, 91806, 96025, 102173). Higher doses of whey protein, such as 46-77 grams daily, have also been shown to increase strength when combined with athletic training (98886, 98888). Some clinical research shows that whey protein hydrolysate (Lacprodan HYDRO.365, Arla Food Ingridiens Group P/S) twice daily for 1 week may slightly improve running speed (91793).\n\nHowever, less frequent intake or lower doses of whey protein do not seem to be beneficial for muscle strength. Some clinical research in middle-aged males shows that taking whey protein 35 grams three times weekly with resistance training for 14 weeks does not improve strength or muscle mass when compared with placebo (46736, 85893). A small clinical study in trained males shows that taking whey protein 25 grams daily has no effect on body mass or strength after 2 weeks of detraining and 4 weeks of retraining when compared with maltodextrin (96021). Also, consuming whey protein without concomitant exercise does not seem to improve body composition or strength. Some clinical research shows that whey protein does not improve muscle mass or strength in obese postmenopausal patients who are losing weight through diet without exercise (98889).\n\nSome research has compared whey protein to other types of protein. A meta-analysis of preliminary clinical research, as well as individual clinical studies, show that whey protein is similarly beneficial to soy, beef, chicken, and dairy (casein with whey) protein for improving muscle strength (85941, 98871, 98888, 105591). However, the validity of these findings is limited by the small size and high heterogeneity of the studies.\nless\nPOSSIBLY INEFFECTIVE\nChronic obstructive pulmonary disease (COPD). Oral whey protein does not seem to improve COPD symptoms.\nClinical research in adults with COPD shows that taking a specific whey protein supplement (ImuPower) 12 grams twice daily for 6 weeks can improve shortness of breath, but not lung function, exercise tolerance, or quality of life, when compared with placebo (86302). Other clinical research shows that taking a pressurized whey protein supplement 20 grams daily for 16 weeks, in combination with strength training for weeks 8-16, does not improve exercise tolerance, lung function, or muscle function when compared with placebo (86025).\nless\nOsteoporosis. Oral whey protein does not seem to improve bone mineral density in older adults.\nClinical research shows that taking whey protein 30-45 grams daily for up to 2 years does not improve bone density when compared with a low-protein placebo in postmenopausal patients and males over 70 years of age (86074, 91796). Taking whey protein 20-60 grams daily for 36 weeks also does not improve bone density when compared with an isoenergetic placebo in overweight or obese adults undergoing an exercise program (96027). The effect of whey protein in patients with osteoporosis has not been evaluated.\nless\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nAge-related cognitive decline. It is unclear if oral whey protein is beneficial for age-related cognitive impairment.\nPreliminary clinical research in older adults with subjective cognitive decline shows that taking whey peptide 1 gram for 12 weeks does not improve memory, executive functioning, or attention when compared with placebo. However, in a subgroup of patients with high levels of fatigue, whey peptide modestly improved memory (98885).\nless\nAsthma. It is unclear if oral whey protein is beneficial in children with asthma.\nA very small clinical study in children with asthma shows that taking a specific type of whey protein (HMS 90, Immunotec Inc.) 20 grams daily for 30 days does not improve lung function when compared to baseline (85833). The validity of this finding is limited by the lack of a comparator group.\nless\nAtopic dermatitis (eczema). It is unclear if consuming infant formula containing whey protein reduces the risk of developing eczema.\nA high-quality meta-analysis of small clinical studies shows that use of infant formula containing hydrolyzed whey protein for 4-6 months is no better than standard milk formula for reducing the risk of eczema (105585). This is in contrast to older meta-analyses that found benefit after consumption of fully or partially hydrolyzed whey protein (85987, 86007, 86048). However, these older publications had notable conflicts of interest and did not include small negative studies (105585).\n\nIn 2011, the US Food and Drug Administration (FDA) allowed a qualified health claim in healthy infants with a family history of allergy who are not solely breastfed. It stated that feeding a formula of 100% partially hydrolyzed whey protein instead of formula containing intact cow's milk proteins from birth up to 4 months of age may reduce the risk of atopic dermatitis throughout 1-3 years of age. However, the FDA has concluded that there is very little scientific evidence to support this claim (102311).\nless\nAtopic disease. It is unclear if consuming infant formula containing whey protein reduces the risk of developing atopic disease.\nA high-quality meta-analysis of small clinical studies shows that use of infant formula containing hydrolyzed whey protein for 4-6 months is no different than standard milk formula for reducing the risk of atopic disease. However, there was a non-significant trend to reduced risk in the hydrolyzed whey protein group (105585). This finding conflicts with older meta-analyses which found benefit with hydrolyzed whey protein formula (85987, 86007). However, these older publications had notable conflicts of interest and did not include small negative studies (105585).\nless\nCystic fibrosis. It is unclear if oral whey protein is beneficial for children or adults with cystic fibrosis.\nA small clinical study in patients with cystic fibrosis shows that taking pressurized whey protein, 20 grams in children and 40 grams in adults, daily for 28 days, improves lung function in children, but not adults, when compared with baseline (85995). The validity of this finding is limited by the lack of a comparator group.\nless\nDiabetes. It is unclear if oral whey protein is beneficial for improving glycemic control in people with type 2 diabetes.\nA small clinical study in patients with well-controlled diabetes shows that consuming a 220 kcal drink containing whey protein concentrate 50 grams (Beit Haemek Advanced Technologies, Beit Haemek) before a meal lowers blood glucose levels by 28% and increases insulin levels in the first 3 hours after a meal when compared with drinking water (91795). However, whey protein does not seem to have long-term benefit on glycemic control when added to an exercise regimen. Another small clinical study in middle-aged males with type 2 diabetes shows that adding 20 grams of whey protein daily for 10 weeks to high-intensity mixed-mode interval training (MMIT) does not further improve glycemic control or body composition when compared to MMIT with placebo (98883).\nless\nExercise-induced asthma. It is unclear if oral whey protein is beneficial for exercise-induced asthma.\nA small clinical study in patients with exercise-induced asthma shows that taking whey protein 30 grams daily for 10 days improves lung function when compared to baseline (85791). The validity of this finding is limited by the lack of a comparator group.\nless\nExercise-induced muscle damage. It is unclear if oral whey protein is beneficial for attenuating exercise-induced muscle damage; evidence is conflicting.\nA meta-analysis of small heterogeneous clinical studies in trained and untrained adults shows that supplementation with a median dose of whey protein 25 grams (range 20-120 grams) given after and/or before exercise modestly improves muscle recovery measured over 3 days when compared with control (98881). Individual studies included in the analysis used whey protein 1.5 grams/kg daily for up to 2 weeks (86044), and whey protein isolate or whey protein hydrolysate (NatraPro or NatraBoost XR, MG Nutritionals) 25 grams three times in 24 hours (85915).\n\nOther small studies have not found benefit, but it is unclear if they were adequately powered. One small clinical study in healthy untrained males shows that taking whey protein 36.6 grams daily, starting 7 days before and continuing until 4 days after arm exercise, does not prevent muscle soreness over 5 days or attenuate reductions in strength (96024). Another small study in untrained healthy males shows that taking whey protein isolate (biPro, Eden Prairie) 0.3 grams/kg three times daily for 5 days does not reduce self-reported delayed onset muscle soreness, but may reduce creatine kinase, a biomarker of muscle damage, when compared with water (104758).\n\nWhey protein may not be beneficial for recovery from exercise in trained athletes. Small clinical studies show that consuming a whey protein beverage before or after exercise does not improve muscle recovery for trained adult and adolescent athletes when compared with a carbohydrate or non-caloric control (86303, 91799, 105592).\nless\nHepatitis. It is unclear if oral whey protein is beneficial for hepatitis.\nA small clinical study in patients with chronic hepatitis B shows that taking a specific type of whey protein (Immunocal) 12 grams twice daily for 12 weeks can reduce liver transaminase levels and can increase glutathione (GSH) levels when compared with baseline. However, whey protein supplementation does not seem to improve liver function in patients with chronic hepatitis C (85687). The validity of these findings is limited by the lack of a comparator group.\nless\nHIV/AIDS. It is unclear if oral whey protein is beneficial for improving immune function in children with HIV/AIDS.\nOne small clinical study in children with rapidly progressive HIV infection shows that taking whey protein at levels corresponding to 20% to 50% of total required protein for 4 months does not affect CD4 or CD8 cell count or the ratio of CD4+/CD8+ when compared with baseline. However, the occurrence of acute co-infections might be reduced with whey protein supplementation when compared with control (85781).\nless\nHIV/AIDS-related wasting. Although oral whey is an adequate source of protein, it is unclear if it is better than other protein sources for reducing HIV/AIDs-related wasting.\nA small open-label clinical study in malnourished patients with HIV shows that taking whey protein (dose unspecified) daily for 14 weeks increases muscle and fat mass when compared with baseline (85693). The validity of these findings is limited by the lack of a comparator group. Another small study in patients with HIV, stable weight, and a history of unintentional weight loss shows that taking whey protein 40 grams daily for 12 weeks does not affect weight or muscle mass when compared with taking an isocaloric control (85921). These study findings are limited because they cannot be generalized to patients with active weight loss or wasting. Another limitation is the higher dropout rate in the whey protein group due to gastrointestinal adverse events.\nless\nHyperlipidemia. It is unclear if oral whey protein is beneficial for lowering cholesterol levels.\nA very small clinical study in overweight males with hyperlipidemia shows that taking whey protein 26.6 grams daily while participating in a resistance training program for 12 weeks reduces total cholesterol levels when compared with baseline but not when compared with placebo (85941). A meta-analysis of small heterogeneous clinical studies in healthy adults, as well as those with obesity and/or mild hypertension, shows that consuming whey protein alone or with other interventions seems to reduce lipid levels when compared with control (105586). However, most included studies were in patients without hyperlipidemia; it is unclear if whey protein is beneficial in patients with hyperlipidemia. Furthermore, these findings are limited by the variability in whey protein dosing, study duration, and patient population.\nless\nHypertension. It is unclear if oral whey protein reduces blood pressure.\nPreliminary clinical research shows that drinking a beverage containing whey protein 2.6 grams daily for 12 weeks does not lower blood pressure in patients with mild hypertension when compared with placebo (85835). Also, taking whey protein 28 grams twice daily in water for 8 weeks reduces 24-hour systolic and diastolic blood pressure by 2.9 mm Hg and 2 mmHg, respectively, when compared with maltodextrin or casein in adults with mild hypertension and prehypertension. There were also improvements in endothelial function (96019).\nless\nMitochondrial myopathies. It is unclear if oral whey protein improves symptoms in patients with mitochondrial myopathies.\nA small clinical study in individuals with mitochondrial diseases shows that taking a whey protein supplement 10 grams daily for one month does not improve muscle strength or quality of life when compared with placebo (85984).\nless\nNonalcoholic steatohepatitis (NASH). It is unclear if oral whey protein improves NASH.\nA small clinical study in patients with untreated NASH shows that taking whey protein 20 grams daily for 12 weeks can reduce liver function tests, including alanine aminotransferase (ALT) and aspartate aminotransferase (AST), and reduce hepatic macrovesicular steatosis when compared with baseline (85961). The validity of these findings is limited by the lack of a comparator group.\nless\nObesity. It is unclear if oral whey protein is beneficial for weight loss when used without dietary modifications. Adding whey protein to a calorie-restricted diet or an exercise regimen does not seem to improve weight loss.\nMost research in overweight and obese individuals shows that taking whey protein along with a low-calorie diet and/or in addition to an exercise program does not further increase weight loss when compared with the low-calorie diet or exercise alone (85897, 86069, 86130, 91794, 91798, 91802, 96027, 102172). However, a small clinical study in patients who have regained weight after bariatric surgery shows that following a low-calorie diet and taking whey protein 0.5 grams/kg daily for 16 weeks reduces body weight by about 2 kg and fat mass by about 3 kg when compared with following a low-calorie diet alone (96022).\n\nWhen whey protein is taken without diet modifications, studies have yielded conflicting results. One small clinical study in overweight and obese adults shows that taking whey protein isolate 27 grams twice daily for 12 weeks does not reduce body weight when compared with a glucose control (86011). However, another small clinical study in overweight and obese adults shows that taking whey protein concentrate 52 grams daily for 23 weeks reduces weight by 1.8 kg and fat by 2.4 kg when compared with a carbohydrate control, but is no better than taking soy protein isolate 52 grams (86077). In contrast, a small clinical study in overweight males shows that taking whey protein concentrate 65 grams before lunch daily for 12 weeks decreases calorie intake and reduces weight by about 1 kg when compared with taking soy protein isolate 60 grams (91801).\n\nIn contrast to adults, supplementation with whey protein might increase weight in adolescents. A clinical study in overweight adolescents shows that consuming 1 liter of a milk-based whey protein drink daily for 12 weeks increases weight and body mass index when compared with a water control (86144).\nless\nParkinson disease. It is unclear if oral whey protein improves symptoms of Parkinson disease.\nClinical research in a small group of patients shows that taking a specific type of whey protein isolate (HMS 90/Immunocal) 10 grams twice daily for 6 months does not improve symptoms of Parkinson disease when compared with placebo (96026). However, this study may have been inadequately powered to detect a difference between groups.\nless\nPolycystic ovary syndrome (PCOS). It is unclear if oral whey protein improves symptoms and metabolic effects of PCOS.\nOne small clinical study in patients with PCOS shows that taking 240 kcal as a nutritional supplement containing pure whey protein 96% daily, in addition to a calorie-restricted diet for 2 months, reduces body weight, fat mass, and cholesterol and apolipoprotein B levels when compared with a simple sugar control supplement. However, the whey protein supplement does not improve glucose or insulin levels, and seems to decrease high-density lipoprotein (HDL) cholesterol levels (85912). The validity of this study is limited by its small size and a significant dropout rate.\nless\nPolymyalgia rheumatica. It is unclear if oral whey protein improves muscle function in patients with polymyalgia rheumatica.\nA small clinical study in patients with polymyalgia rheumatica shows that taking a whey protein-enriched dairy product twice daily for 8 weeks does not improve lower limb muscle function, walking speed, chair stand test performance, peak jump power, or peak jump force when compared with a regular dairy product (Play, Valio Ltd.) (86075).\nless\nPsoriasis. It is unclear if oral whey protein improves psoriasis.\nA small clinical study in patients with stable psoriasis shows that taking a specific whey protein extract product (Dermylex, Advitech, Inc.) 5 grams daily for 8 weeks modestly decreases symptom severity when compared with placebo (85885).\nless\nSarcopenia. Research on the use of oral whey protein in older adults with sarcopenia is conflicting.\nSmall clinical studies in trained older females show that consuming whey protein 35 grams three times weekly for 12 weeks, either before or after resistance training, modestly increases skeletal muscle mass, strength, and functional capacity when compared with resistance training and insufficient protein intake (98887, 98890). Research on the use of whey supplementation without exercise is conflicting. A small clinical study in older adults with low muscle mass living in China shows that taking whey, or a whey-soy protein blend, 16 grams daily for 6 months slightly attenuates muscle loss when compared with no intervention (105603). However, a clinical study in healthy, active older adults living in Denmark shows that taking whey protein hydrolysate 20 grams twice daily does not increase muscle size or strength when compared with a carbohydrate control (105593). This finding may not be generalizable to frail adults or those with existing sarcopenia.\n\nWhey protein with or without exercise has shown benefit when used in combination with other nutrients. Specifically, whey protein 60 grams has been used with creatine 5 grams, calcium 800 mg, vitamin D 1000 IU, and omega-3 fatty acids 3 grams (Infinit Nutrition) for 6 weeks (96016). A beverage with leucine-enriched whey protein 20 grams has been used in combination with vitamin D 800 IU (Nutricia Advanced Medical Nutrition) daily for 6 weeks (96017). Another beverage containing whey protein 20 grams and vitamin D 800 IU has been used daily for 6 months (98882).\nless\nSepsis. It is unclear if oral whey protein is beneficial in children with sepsis.\nA very small clinical study in long-term intensive care pediatric patients shows that taking a specific whey protein supplement (Beneprotein) 0.3 grams/kg daily for up to 28 days has a similar effect on the time to onset and the rate of hospital-acquired infection or sepsis when compared with taking a combination of zinc, selenium, glutamine, and metoclopramide. It is not clear how these results compare to patients receiving no supplementation (86095).\nless\nMore evidence is needed to rate whey protein for these uses.",
            "Dosing & Administration": "Adult\nOral:\nWhey protein, as whey protein concentrate, hydrolysate, or isolate, has most often been used in doses of up to 30 grams daily for up to 6 months. Higher doses of up to 65 grams daily have been used for up to 3 months. See Effectiveness section for condition-specific information.\nChildren\nOral:\nResearch is limited; typical dosing is unavailable.\nStandardization & Formulation\nIn clinical trials, whey protein has been supplied as pressurized whey protein, whey protein concentrate, whey protein isolate, and whey protein hydrolysate (85915, 85995, 91793, 91795, 96026).",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nBISPHOSPHONATES\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPROBABLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, whey protein might reduce the absorption of bisphosphonates.\nWhey protein contains minerals such as calcium that bind bisphosphonates in the gut (9, 12937). Advise patients to take bisphosphonates at least 30 minutes before whey protein, but preferably at a different time of day.\nless\nLEVODOPA\nInteraction Rating\nMAJOR Do not take this combination.\nSeverity\nHIGH\nOccurrence\nPROBABLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, whey protein might decrease levodopa absorption.\nSmall clinical studies show that concomitant ingestion of protein or high doses of leucine or isoleucine (100 mg/kg) and levodopa can exacerbate tremor, rigidity, and the \"on-off\" syndrome in patients with Parkinson disease (3291, 3292, 3293, 3294, 4944).\nless\nQUINOLONE ANTIBIOTICS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPROBABLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, whey protein might decrease quinolone absorption.\nWhey protein contains minerals, such as calcium, that can bind to quinolones in the gut (9, 10339). To avoid this interaction, advise patients to take oral quinolones at least 2 hours before or 4-6 hours after whey protein.\nless\nTETRACYCLINE ANTIBIOTICS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPROBABLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, whey protein might decrease tetracycline absorption.\nWhey protein contains minerals, such as calcium, that bind to tetracyclines in the gut (9, 1843). To avoid this interaction, advise patients to take oral tetracyclines at least 2 hours before or 4-6 hours after whey protein.\nless",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "MILK ALLERGY\nWhey protein, a milk product, might trigger an allergic response in patients allergic to milk. Individuals allergic to bovine milk products should avoid using whey protein (4942).\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with whey protein.",
            "Pharmacokinetics": "Absorption\nConsuming whole whey protein results in a more rapid absorption of leucine and branched-chain amino acids in the blood compared to hydrolyzed whey protein (85908).\nMetabolism\nWhey protein appears to be extensively broken down by digestive enzymes (86008).\nExcretion\nWhey supplementation increases nitrogen, creatinine, and calcium excretion in the urine (86150). Gastric emptying rates appear to be the same with whole whey protein and hydrolysates and with casein protein and hydrolysates (85751).",
            "Mechanism of Action": "General\nWhey protein is a milk protein. It primarily consists of beta-lactoglobulin, alpha-lactalbumin, bovine serum albumin (BSA), and immunoglobulin. It generally contains a higher concentration of essential amino acids than other protein sources (16728, 86053, 86213). The composition of whey protein may vary slightly depending on the animal species from which it was obtained (85605, 85622, 85688, 86209, 86260).\nAnti-allergy effects\nWhey protein has been studied for atopic disease such as asthma and dermatitis possibly because it may attenuate immune response (4927, 85987, 86007). Animal research suggests that consuming whey protein may degrease the immune response to the food antigen ovalbumin and other antigens (85700, 85717). Furthermore, animal research suggests that whey protein may have anti-inflammatory effects (85850, 85935).\nAntibacterial effects\nWhey protein has been used to prevent hospital infections and sepsis (86095). Whey protein may help prevent infection due to its antimicrobial and bacteriostatic effects that have been shown in laboratory and animal studies (85894, 85939, 85988, 86004).\nAntiburn effects\nIn animal models, whey protein appears to supply the optimal nutrition to promote healing of cutaneous burns (85803, 86166).\nAntidiabetic effects\nThe benefits of whey supplementation have been studied in diabetic patients (91795). Whey protein appears to reduce postprandial increase in blood glucose after a meal possibly by slowing glucose absorption into the blood (86058, 86139, 86141, 91795). The amino acids in whey protein appear to increase insulin responses which would further help manage hyperglycemia (16731, 85872, 85888, 86030, 86058, 86100, 86119, 86129). Another theory of how whey protein may help reduce blood glucose in diabetics is the increase of incretin response after supplementation (86088, 86139, 86141).\nAntilipemic effects\nWhey protein is unlikely to clinically benefit cholesterol levels in hyperlipidemia or healthy patients (85941, 86058, 86081, 86119, 86130, 96019). However, whey protein fermented with Lactobacillus may have a cholesterol lowering effect (86014).\nAntineoplastic effects\nSome researchers are interested in using whey protein to prevent cancer. It's thought that whey protein might prevent cancer by providing glutathione (GSH) substrates and increasing tissue GSH levels (4943). Whey protein might exert antitumor effects by depleting tumor cells of GSH, making them more vulnerable to chemotherapy (2640, 4930, 85714, 86038, 86206, 86228). Animal models of cancer show that whey protein diets might protect against certain cancers (3976, 4928, 4933). However, this does not seem to be the case in clinical research. A small study in cancer patients receiving intravenous chemotherapy shows that consuming 40 grams of whey protein isolate with zinc and selenium daily for 12 weeks does not increase levels of GSH, interferon, CD4+, albumin, or other immune markers when compared with placebo (98880).\nAntioxidant effects\nWhey protein may have positive effects on certain disease states, such as nonalcoholic steatohepatitis (NASH) and hepatitis, due to its antioxidant effects (85687, 85961). Animal and laboratory research support that whey protein has antioxidant, radical-scavenging, and metal-chelating effects (85796, 85804, 85818, 85907, 85913, 85940, 86037, 86281). Clinical research associates whey protein consumption with antioxidant effects such increased glutathione (GSH) levels, total antioxidant capacity (TAC), and reduced thiobarbituric acid reactive substances (TBARS) (86115, 86136). However, whey protein might not have measurable antioxidant effects in all patient populations. Clinical research in healthy females 60 years and older shows that taking whey protein 35 grams before and after daily resistance training for 12 weeks does not improve antioxidant enzyme activity nor oxidative stress markers when compared with placebo (102174).\nBone effects\nWhey protein supplementation does not appear to help improve bone mineral density in osteoporosis (86074, 91796). However, theoretically, the calcium content of whey protein may offer some benefit as shown in animal research (85787, 85914).\nCardiovascular effects\nResearchers are also interested in whey protein for cardiovascular conditions. There is preliminary evidence that a unique combination of hydrolyzed whey protein isolates inhibits angiotensin converting enzyme (ACE) which may result in decrease in blood pressure (6171, 85614, 85637, 85699, 85713, 85726, 85729, 85738, 85749, 85750)(85760).\nGastrointestinal effects\nConsumption of whey protein alters gut hormones. A small clinical study in healthy adults shows that whey ingestion reduces plasma levels of ghrelin and increases levels of insulin, glucagon, cholecystokinin (CCK), gastric inhibitory peptide (GIP), and glucagon-like peptide-1 (GLP-1) in a dose-dependent manner. These effects on CCK, GLP-1, and ghrelin suggest that whey protein might reduce appetite and energy intake. Plasma levels of CCK and GIP were more elevated in older adults compared to younger adults (98884). Aging seems to reduce the degree to which high-calorie drinks decrease hunger, satiety, and energy intake. Thus, protein-rich nutrition supplements, including whey protein supplements, may be an effective strategy to increase energy intake in undernourished older adults (105588). A small clinical study in patients with metabolic syndrome shows that consuming whey protein once prior to a fat-rich meal reduces glucose, increases GLP-1 in response to insulin and glucagon, and delays gastric emptying in a dose-dependent manner (102171).\nImmunomodulating effects\nWhey protein may vary in the amount and activity of immunoglobulins and other proteins present, depending on the production methods used (2640). Whey protein typically contains 24% branched chain amino acids which are readily oxidized as an energy source during stress. Whey protein is also a source of gamma-glutamylcysteine, a precursor of glutathione (GSH), which acts as an intracellular antioxidant (2640). GSH is depleted by oxidative stress, which occurs during infections, trauma, or major surgery (2640). Low levels of GSH in patients with HIV have been associated with impaired T-cell function (2640). A specific whey protein formulation (Immunocal) might enhance the reduced-to-oxidized glutathione ratio (GSH/GSSG) in lymphocytes, a marker of oxidative stress in reactive oxygen species (ROS)-mediated diseases, including AIDS-related wasting (1382). Whey products also have anti-HIV and anti-apoptotic effects in vitro (4937). In patients with HIV infection, whey protein increases body weight (85693) and reduces co-infections, but might not affect CD4 and CD8 counts (85781). Whey protein also has immunomodulating activity (4939, 4940). It's thought that immunoglobulins in whey protein may bind antigens in the gut and prevent their absorption (2640). Whey protein formulations can be produced that are high in specific immunoglobulins. For example, whey proteins derived from the milk of cows infected with Cryptosporidium may be a rich source of antibodies against Cryptosporidium (2640). These types of whey protein formulations can reduce gastrointestinal Cryptosporidium parvum infection in animal models (4934).\nMetabolic effects\nThere is also interest in whey protein as a protein source in high-protein diets used for weight loss and improving athletic performance. In animal models, a whey protein diet seems to reduce weight and improve insulin sensitivity compared to red meat (12111). Whey protein supplementation also results in higher blood amino acid concentrations compared to some other protein sources. This results in greater stimulation of protein synthesis (16728). Research in healthy volunteers shows that consuming whey protein 10-25 grams following exercise can stimulate muscle protein synthesis, which could potentially lead to increased muscle hypertrophy (16730, 68819, 85764, 85931, 86041, 86046, 86052, 86056, 86080). In healthy males performing resistance exercise, whey protein 20 grams improved the optimal muscle protein synthesis by 49%, while 10 grams did not appear to have an effect (91803). Consuming whey protein with a single meal has been shown to increase muscle protein synthesis (96017, 104640). However just supplementing with whey protein 30 grams daily for 2 years without additional exercise does not appear to affect muscle mass or physical function in healthy postmenopausal patients (91804).\n\nConsumption of 20-80 grams of whey protein appears to increase satiety and decrease appetite in a non-dose dependent manner, possibly by increasing gastrointestinal peptides glucagon-like peptide-1 (GLP-1) and peptide YY (86079, 91797, 102175). Whey protein has been associated with lower ghrelin concentration compared to soy protein, which may contribute to the satiety feeling after whey protein consumption (86077). Research also shows that males who ingest 45 grams of whey protein have increased levels of insulin. Whey protein increases insulin secretion to a greater extent than whey protein hydrolysate (16731).\n\nIn older adults, whey protein intake with a single meal does not increase satiety, resulting in increased caloric intake. However, it does slow gastric emptying of the meal. This is possibly due to alterations in various gastric hormone levels (96020)."
        }
    },
    "White Dead Nettle Flower": {
        "sections": {
            "Overview": "White dead nettle is a perennial plant which grows to 15-30 cm in height. It has serrated leaves like stinging nettle, but does not sting when touched (98463, 104876). The flowers are white or cream colored and include many glandular and non-glandular trichomes (104876).",
            "Safety": "There is insufficient reliable information available about the safety of white dead nettle flower.\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "General\nThere is currently a limited amount of information on the adverse effects of white dead nettle flower. No adverse effects have been reported in clinical trials (2, 18, 98462).",
            "Effectiveness": "INSUFFICIENT RELIABLE EVIDENCE TO RATE\nAtopic dermatitis (eczema). A small clinical study shows that taking a mixture of white dead nettle flower, Siberian ginseng, and yarrow extracts orally three times daily for 2 weeks does not improve symptoms of atopic dermatitis when compared with placebo (98462).\nMore evidence is needed to rate white dead nettle flower for this use.",
            "Dosing & Administration": "Adult\nOral:\nTraditionally, the average daily dose of white dead nettle flower is 3 grams (2).\nTopical:\nTraditionally, 5 grams of white dead nettle flower is added to a sitz bath (2).\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of white dead nettle flower.",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Lab Tests": "None known.",
            "Mechanism of Action": "General\nThe applicable parts of white dead nettle are the leaves, young shoots, and flowers (104876). White dead nettle flower extracts contain phenolic acids, tannins, flavonoids, pectins, phenylpropanoids, iridoids, and phenylethanoid glycosides. Constituents of white dead nettle flower extract include lamiuside A, B, and C, lamiridoside, rutoside, tiliroside, quercetin, isoquercetin, quercetin hexorhamnoside, verbascoside, chlorogenic acid, ferulic acid, gallic acid, p-coumaric acid, protocatechuic acid, syringic acid, gentisic acid, and vanillic acid (98463, 104876).\nAnti-inflammatory effects\nWhite dead nettle flower extracts demonstrate anti-inflammatory activity in vitro. Mechanisms include scavenging superoxide and hydroxyl radicals, inhibiting production of reactive oxygen species, and inhibiting secretion of interleukins (98463)."
        }
    },
    "White Hellebore": {
        "sections": {
            "Overview": "White hellebore is a perennial plant with green-yellow flowers and stems up to 5 feet tall (95892). Crude white hellebore is not used therapeutically (13), though it is sometimes used in homeopathic dilutions (18). White hellebore is commonly mistaken for Gentiana lutea, a less toxic plant (95892).",
            "Safety": "LIKELY UNSAFE when used orally. All plant parts are considered toxic (6). Between 10-20 mg of alkaloids (1-2 grams of rhizome/root) are lethal (6, 18). ...when used topically. Toxic alkaloids can be absorbed through intact skin (6, 18).\nPREGNANCY: LIKELY UNSAFE when used orally or topically because it could be teratogenic (6); avoid using.\nLACTATION: LIKELY UNSAFE when used orally or topically (6); avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally and topically, white hellebore is generally regarded as unsafe for any use. Any benefits of therapy do not outweigh the risk of toxicity.\nMost Common Adverse Effects\nOrally: Abdominal pain, blurred vision, bradycardia, confusion, headache, hypotension, nausea, muscle weakness, vomiting.\n\nTopically: Skin irritation.\nSerious Adverse Effects (Rare)\nOrally: Arrythmias, blindness, gastric erosion, loss of consciousness, paralysis, respiratory depression, seizures, severe bradycardia, severe hypotension, shock\nCardiovascular\nOrally, white hellebore can cause bradycardia, and hypotension. Large doses of white hellebore can cause more severe bradycardia and hypotension and even cardiac arrythmias (6, 553, 95892, 95893, 101431, 109467, 115960).\nless\nDermatologic\nTopically, white hellebore can cause skin irritation (18).\nless\nGastrointestinal\nOrally, white hellebore is toxic and usually causes nausea, vomiting, and abdominal pain. Symptoms occur 15-30 minutes after ingestion (553, 95893, 101431, 109467, 115960). White hellebore can also cause a burning sensation in the upper abdomen, hypersalivation, and gastric erosion (6, 553).\nless\nMusculoskeletal\nOrally, white hellebore is toxic and can cause muscle weakness. In large doses it can cause paralysis (101431, 115960).\nless\nNeurologic/CNS\nOrally, white hellebore is toxic and can cause vertigo, confusion, numbness, headache, paresthesia, seizures, loss of consciousness, and shock (553, 101431, 95893).\nless\nOcular/Otic\nOrally, white hellebore is toxic and can cause blurred and dim vision, and transitional blindness in case reports (101431, 95893).\nless\nPulmonary/Respiratory\nOrally, white hellebore is toxic and can cause respiratory depression in large doses (6, 101431).\n\nBy inhalation, the powdered root induces violent sneezing and runny nose (6).\nless",
            "Effectiveness": "There is insufficient reliable information available about the effectiveness of white hellebore.",
            "Dosing & Administration": "Adult\nResearch is limited; typical dosing is unavailable.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of white hellebore.",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "Presentation\nInitial signs and symptoms in patients presenting with white hellebore overdose include abdominal pain, hypersalivation, nausea, and vomiting (101431, 115960). Others that can follow include arrythmia, bradycardia, coordination dysfunction, headache, hypotension, muscle weakness, paralysis, paresthesia, respiratory depression, seizures, sweating, and loss of consciousness (95893, 101431, 109467, 115960).\n\nSymptoms can occur as soon as 15-30 minutes after ingestion (553, 95893, 101431, 109467), or up to 4 hours following ingestion in some cases (109467). Additionally, symptom severity seems to correlate with the concentration of alkaloids in blood and urine samples (115960).\nTreatment\nTreatment of white hellebore overdose typically includes a combination of gastric lavage with activated charcoal, diuresis, atropine, saline infusions for hypotension, correction of electrolytes, antiemetics, and/or other cardioprotective therapy as needed (95892, 101431, 109467, 115960).",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of white hellebore.",
            "Mechanism of Action": "General\nThe applicable parts of white hellebore are the rhizome and root. White hellebore contains the toxic ester-alkaloids protoveratirine A and B (13, 95892). Roots and rhizome of white hellebore contain up to 1.6% alkaloids. Other alkaloids that occur in white hellebore include jervine, pseudojervine, veratramine (95892).\nCardiovascular effects\nWhite hellebore has been reported to cause bradycardia, hypotension, arrhythmia, and other toxic effects. The cardiotoxic constituents of white hellebore include the alkaloids jervine, protoveratrine A, and protoveratrine B. Preliminary data suggest that these alkaloids inhibit cardiac sodium ion channels, reducing conductivity and depolarization similarly to the antiarrhythmic drug quinidine (18, 101431, 95892, 115960).\nNeurologic effects\nWhite hellebore has been reported to cause paralysis, seizures, paresthesia, and other toxic effects. Constituents of white hellebore include the alkaloids jervine, protoveratirine A, and protoveratrine B (13, 18, 95892, 101431). These alkaloids inhibit the inactivation of the sodium ion channels and thus have a paralyzing effect on many excitable cells (18, 95892, 101431)."
        }
    },
    "White Horehound": {
        "sections": {
            "Overview": "White horehound is a plant native to Eurasia and northern Africa. It has a long tradition of use for respiratory infections (98491).",
            "Safety": "LIKELY SAFE when used orally in amounts commonly found in foods. White horehound has Generally Recognized as Safe (GRAS) status in the US (4912).\nPOSSIBLY SAFE when used orally and appropriately (2, 12).\nPOSSIBLY UNSAFE when used orally in excessive amounts; white horehound may have a purgative effects (4, 12).\nThere is insufficient reliable information available about the safety of the topical use of white horehound.\nPREGNANCY: LIKELY UNSAFE when used orally; white horehound might have abortifacient effect (19), or stimulate menstrual flow and the uterus (12). There is insufficient reliable information available about the safety of topical use during pregnancy; avoid using.\nLACTATION: There is insufficient reliable information available about the safety of oral use during lactation; avoid amounts greater than those commonly found in foods. There is insufficient reliable information available about the safety of topical use during lactation; avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, white horehound may cause nausea, dry mouth, excessive salivation, loss of appetite, and dizziness in some patients (86369). Large amounts of white horehound (exact dose is unclear) may cause purgative effects (4, 12).\n\nTopically, skin contact with the plant juice may cause contact dermatitis (4).\nDermatologic\nTopically, skin contact with the plant juice may cause contact dermatitis (4).\nless\nGastrointestinal\nOrally, clinical research shows that drinking one cup of tea prepared with white horehound 1 gram three times daily for 3 weeks may cause nausea, dry mouth, excessive salivation, and loss of appetite in some patients (86369). Intake of large amounts of white horehound (exact dose is unclear) may cause purgative effects (4, 12).\nless\nNeurologic/CNS\nOrally, clinical research shows that drinking one cup of tea prepared with white horehound 1 gram three times daily for 3 weeks may cause dizziness in some patients (86369).\nless",
            "Effectiveness": "INSUFFICIENT RELIABLE EVIDENCE TO RATE\nDiabetes. There is preliminary clinical evidence that taking a tea prepared from white horehound three times daily before meals for 21 days, in addition to conventional medicines for type 2 diabetes, slightly reduces fasting blood glucose by about 0.64% compared with baseline. However, the reduction in blood glucose following treatment with white horehound was significantly less than the blood glucose reduction observed for patients who drank tea prepared from guarumo (Cecropia obtusifolia) (86369). It is not clear whether white horehound has a clinically significant effect when taken alone.\nMore information is needed to rate white horehound for this use.",
            "Dosing & Administration": "Adult\nOral:\nDiabetes: A tea prepared from white horehound powder 1 gram added to one cup of boiling water for 5 minutes and taken three times daily for 3 weeks has been used (86369).\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of white horehound.",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nANTIDIABETES DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nB (Lower quality RCT)\nEvidence from animal research suggests that white horehound might lower blood glucose (23603, 26149). However, preliminary clinical research suggests that white horehound only slightly lowers blood glucose when taken in combination with antidiabetic agents, suggesting that the effect may not be clinically significant (86369). Until more is known, use with caution. Theoretically, white horehound may have additive effects when used by patients taking antidiabetic drugs. The dose of diabetes medications might need to be adjusted. Some antidiabetes drugs include glimepiride (Amaryl), glyburide (DiaBeta, Glynase PresTab, Micronase), insulin, metformin (Glucophage), pioglitazone (Actos), rosiglitazone (Avandia), and others.\nANTIHYPERTENSIVE DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nEvidence from animal research suggests that taking white horehound extract lowers blood pressure (49408, 86367). Theoretically, taking white horehound with antihypertensive drugs might enhance therapeutic effects and increase the risk of hypotension. Some antihypertensive drugs include captopril (Capoten), enalapril (Vasotec), losartan (Cozaar), valsartan (Diovan), diltiazem (Cardizem), Amlodipine (Norvasc), hydrochlorothiazide (HydroDiuril), furosemide (Lasix), and many others.",
            "Interactions with Supplements": "EXPAND ALL\n|\nCOLLAPSE ALL\nHERBS AND SUPPLEMENTS WITH HYPOGLYCEMIC POTENTIAL\nEvidence from animal research suggests that white horehound might lower blood glucose (23603, 26149). However, preliminary clinical research suggests that white horehound only slightly lowers blood glucose, suggesting that the effect may not be clinically significant (86369). Until more is known, use cautiously in combination with other herbs and supplements with hypoglycemic potential. Theoretically, concomitant use might increase the risk of hypoglycemia. Other herbs with hypoglycemic potential include devil's claw, fenugreek, garlic, guar gum, horse chestnut, Panax ginseng, psyllium, Siberian ginseng, and others.\nHERBS AND SUPPLEMENTS WITH HYPOTENSIVE EFFECTS\nEvidence from animal research suggests that taking white horehound extract lowers blood pressure (49408, 86367). Theoretically, taking white horehound along with other herbs and supplements with hypotensive effects might increase the risk of hypotension. Some of these herbs and supplements include andrographis, casein peptides, cat's claw, coenzyme Q-10, fish oil, L-arginine, lycium, stinging nettle, theanine, and others.",
            "Interactions with Conditions": "EXPAND ALL\n|\nCOLLAPSE ALL\nDIABETES\nWhite horehound might lower blood glucose, although the effect might not be clinically significant (23603, 26149, 86369). Until more is known, monitor blood glucose closely.\nless\nHEART CONDITIONS\nTheoretically, large amounts of white horehound might cause arrhythmias (4).\nless\nHYPOTENSION\nWhite horehound might lower blood pressure (49408, 86367). Theoretically, white horehound might increase the risk of hypotension in people who are prone to low blood pressure.\nless\nSURGERY\nWhite horehound might affect blood glucose levels (23603, 26149, 86369). Theoretically, white horehound might interfere with blood glucose control during and after surgical procedures. Tell patients to discontinue taking white horehound at least 2 weeks before elective surgical procedures.\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the toxicology of white horehound.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of white horehound.",
            "Mechanism of Action": "Analgesic effects\nAnalgesic effects of white horehound in animal models have been attributed to the constituent marrubiin (86360, 86387).\nAnti-inflammatory effects\nWhite horehound extract has anti-inflammatory activity (4, 11).\nAntimicrobial effects\nWhite horehound extract and volatile oil have antibacterial effects against various types of bacteria (86375, 86375, 86377). White horehound essential oil also has antifungal effects (86377) and antischistosomal activity (4).\nAntioxidant effects\nWhite horehound has weak antioxidant effects, possibly related to constituent phenylpropanoid glycosides (86370, 86372, 86381, 98491).\nCardiovascular effects\nThe constituent marrubiin may act to normalize extrasystolic arrhythmias (4, 11), but large amounts might cause arrhythmias (4). White horehound lowers blood pressure in animal models, possibly by causing vasodilation or relaxation (49408, 86389).\nCentral nervous system effects\nAn aqueous extract of white horehound has been shown to antagonize serotonin in vitro (11).\nConstituents\nThe applicable parts of white horehound are the above ground parts. White horehound contains marrubiin, other bitter lactones, volatile oil, tannins, phenols, and flavonoids (515, 86366, 86371, 86376, 98491). The constituent, marrubiin does not exist in the fresh plant; it is formed from premarrubiin during processing (86360, 86390).\nExpectorant effects\nMonoterpenes from the volatile oil of Marrubium vulgare have exhibited expectorant activity (86389), which may result from direct stimulation of bronchial mucosal secretions (512).\nGastrointestinal effects\nThe constituent marrubinic acid may stimulate bile secretion (515). Also, an alcoholic extract of white horehound reduces spasms of gastrointestinal (GI) tract (86360, 86391).\nWound healing effects\nIn vitro, white horehound had wound healing effects related to marrubiin and other constituents (98491)."
        }
    },
    "White Lily": {
        "sections": {
            "Overview": "White lily is a perennial herbaceous flowering plant that grows to a height of 60-150 cm (18). It is native to the Mediterranean and Balkan regions, the Middle East, and Asia (18, 106404, 106405).",
            "Safety": "There is insufficient reliable information available about the safety of white lily when used orally or topically.\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "General\nNo adverse effects have been reported. However, a thorough evaluation of safety outcomes has not been conducted.",
            "Effectiveness": "INSUFFICIENT RELIABLE EVIDENCE TO RATE\nBack pain. It is unclear if topical white lily is beneficial in patients with back pain.\nPreliminary clinical research in patients with chronic back pain of more than 3 months duration shows that applying a white lily flower extract in sesame oil for 8 weeks reduces pain scores more than sesame oil alone. By comparison, placebo (petroleum jelly) was associated with increased pain scores over the same period (106403).\nless\nBleeding. Although there has been interest in using oral white lily for bleeding, there is insufficient reliable information about the clinical effects of white lily for this condition.\nBurns. Although there has been interest in using topical white lily for burns, there is insufficient reliable information about the clinical effects of white lily for this condition.\nCough. Although there has been interest in using oral white lily for cough, there is insufficient reliable information about the clinical effects of white lily for this condition.\nPressure ulcers. Although there has been interest in using topical white lily for pressure ulcers, there is insufficient reliable information about the clinical effects of white lily for this condition.\nWound healing. Although there has been interest in using topical white lily for wound healing, there is insufficient reliable information about the clinical effects of white lily for this condition.\nMore evidence is needed to rate white lily for these uses.",
            "Dosing & Administration": "Adult\nOral:\nResearch is limited; typical dosing is unavailable.\nTopical:\nResearch is limited; typical dosing is unavailable.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of white lily.",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with white lily.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of white lily.",
            "Mechanism of Action": "General\nThe applicable parts of white lily are the bulb, flowers, and leaves (18, 106403, 106405). White lily contains flavonoids (quercetin, kaempferol, isorhamnetin, isorhamnetin glycosides), steroids (beta-sitosterol), furostane- and spinostane-type steroid saponins, tannins, polysaccharides, organic acids, amino acids, terpenes (linalool, citonellal, caryophyllene, humulene, neridiol), gamma-methylene glutamic acid, glucomannans, and tuliposide (18, 106404, 106405).\nAnti-diabetic effects\n: In vitro, an ethanolic extract of white lily, and its constituents kaempferol, linalool, citronellal, and humulene, increase glucose uptake by adipocytes, suggesting anti-diabetic activity (106405).\nAnti-inflammatory effects\nIn vitro, an ethanolic extract of white lily, and its constituents kaempferol, citronellal, and humulene, decrease secretion of the pro-inflammatory cytokines interleukin-6 (IL-6) and IL-8 (106405).\nAntioxidant effects\nIn vitro, a white lily extract inhibits free radicals (106403).\nCytotoxic effects\nIn vitro, white lily has cytotoxic effects on the human breast cancer cell line MCF-7, causing apoptosis (106404)."
        }
    },
    "White Mulberry": {
        "sections": {
            "Overview": "White mulberry is a small-to-medium sized shrub or tree. The fruit is like a blackberry, but white or pinkish violet in color, with an unpleasant taste. White mulberry is native to China but was introduced into the US during colonial times. Its wood is valued for its durability, flexibility, and elasticity, and its fibrous stem has been used in paper making (16493).",
            "Safety": "POSSIBLY SAFE when used orally and appropriately. White mulberry powdered leaf or leaf extract has been used with apparent safety at doses of up to 4.6 grams three times daily for up to 12 weeks (16494, 17051, 100627, 103870, 105796, 110480).\n\nThere is insufficient reliable information available about the safety of white mulberry berries.\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "General\nOrally, white mulberry leaf seems to be well tolerated.\nMost Common Adverse Effects\nOrally: Transient bloating, constipation, flatulence, and loose stools.\nGastrointestinal\nOrally, white mulberry leaf powder 4.6 grams three times daily for 4 weeks was associated with bloating and flatulence in 50% of patients, loose stools in 25% of patients, and constipation in 21% of patients in one clinical study. However, reports of these adverse effects decreased over the course of the 12-week study, suggesting that for some patients the adverse effects may be transient in nature (103870).\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nAndrogenic alopecia. Although there has been interest in using oral white mulberry for androgenic alopecia, there is insufficient reliable evidence about the clinical effects of white mulberry for this purpose.\nCommon cold. Although there has been interest in using oral white mulberry for symptoms of the common cold, including cough and sore throat, there is insufficient reliable evidence about the clinical effects of white mulberry for this purpose.\nDiabetes. While research is mixed, most small clinical studies suggest that oral white mulberry does not reduce fasting blood glucose or glycated hemoglobin (HbA1c) in patients with type 2 diabetes; however, it does seem to improve insulin resistance and postprandial blood glucose in these patients.\nA meta-analysis of 4 small, mostly low-quality clinical studies in adults with impaired glucose tolerance or type 2 diabetes shows that taking white mulberry extract for 12 weeks does not reduce HbA1c when compared with placebo, dietary education, or no treatment. White mulberry extract also does not reduce fasting plasma glucose but may improve glucose intolerance (110480). However, studies utilized heterogeneous dosing regimens, with doses ranging from 500 mg twice daily to 4.6 grams three times daily and 1-deoxynojirimycin (DNJ) content in each dose ranging from 5-18 mg. Additionally, a small clinical study in adults with type 2 diabetes not included in the analysis above shows that taking white mulberry extract 300 mg twice daily for 12 weeks improves insulin resistance but does not reduce fasting blood glucose or HbA1c when compared with placebo (110481). Due to its small size, this study may have been inadequately powered to detect a difference between groups. One clinical study in adults with type 2 diabetes shows that taking powdered white mulberry leaf 1 gram three times daily for 4 weeks reduces fasting blood glucose levels by 27% compared with an 8% reduction with glyburide 5 mg daily. However, neither treatment significantly reduced HbA1c levels over the 4-week period (16494). The short study duration may explain the lack of significant HbA1c reduction.\n\nThe effect of white mulberry on postprandial glucose levels has also been assessed. Taking a single 0.8-1.2 gram dose of powdered white mulberry leaf standardized to contain DNJ 1.5% or taking a single 250 mg dose of a specific white mulberry leaf extract (Reducose, Phynova Group) standardized to contain DNJ 4.5% to 5.5% reduces peak blood glucose levels after ingestion of 50-75 grams of sucrose when compared with placebo in adults with or without type 2 diabetes (16495, 17051, 105796).\nless\nHyperlipidemia. It is unclear if oral white mulberry is beneficial in patients with hyperlipidemia; the available research has mixed results.\nA small clinical study in adults with type 2 diabetes shows that taking white mulberry extract 300 mg twice daily for 12 weeks does not decrease serum triglycerides, or levels of total, low-density lipoprotein (LDL), or very-low-density lipoprotein (VLDL) cholesterol when compared with placebo (110481). Due to its small size, this study may have been inadequately powered to detect a difference between groups. However, another small clinical study in adults with type 2 diabetes shows that taking white mulberry leaf 1 gram three times daily for 4 weeks reduces total cholesterol levels by 12%, triglycerides by 16%, LDL by 23%, and VLDL by 17% when compared to baseline. Plasma HDL was increased by 18% (16494). The validity of these findings is limited by the lack of a comparator group.\n\nWhite mulberry has also been studied in combination with other ingredients. In one small clinical study, taking a specific product (LopiGLIK, Akademy Pharma) containing white mulberry leaf extract 200 mg, berberine, and red yeast rice daily for 4 weeks reduced LDL cholesterol to less than 130 mg/dL in 57% of participants, compared with only 22% of those receiving a different combination product (Armolipid Plus, RottapharmSpA) that contains red yeast rice, berberine, and other ingredients, without white mulberry. Both products reduced triglycerides and total cholesterol to a similar extent (100624).\nless\nHypertension. Although there has been interest in using oral white mulberry for hypertension, there is insufficient reliable evidence about the clinical effects of white mulberry for this purpose.\nImpaired glucose tolerance (prediabetes). It is unclear if oral white mulberry is beneficial in patients with impaired glucose tolerance.\nOne small clinical study in obese patients with impaired glucose tolerance shows that taking white mulberry leaf powder 4.6 grams three times daily before meals for 12 weeks decreases fasting blood glucose by around 4 mg/dL and glycated hemoglobin (HbA1c) by 0.12% when compared to baseline. Neither measure was improved in the placebo group (103870). Although a statistically significant improvement in glycemic control was established, the observed reductions in fasting plasma glucose and HbA1c were modest and unlikely to be clinically meaningful.\nless\nJoint pain. Although there has been interest in using oral white mulberry for joint pain, including joint pain associated with osteoarthritis and rheumatoid arthritis (RA), there is insufficient reliable information about the clinical effects of white mulberry for these conditions.\nObesity. It is unclear if oral white mulberry can reduce body weight in patients who are obese or overweight.\nA small clinical study in overweight and obese adults on a calorie-restricted diet shows that taking white mulberry extract 800 mg three times daily with meals for 90 days reduces body weight by about 10%, compared to a loss of about 3% with placebo (100627). However, a small clinical study in overweight and obese adults with type 2 diabetes shows that taking white mulberry extract 300 mg twice daily for 12 weeks does not decrease body weight when compared with placebo (110481).\nless\nOsteoporosis. Although there has been interest in using oral white mulberry for osteoporosis, there is insufficient reliable evidence about the clinical effects of white mulberry for this purpose.\nMore evidence is needed to rate white mulberry for these uses.",
            "Dosing & Administration": "Adult\nOral:\nWhite mulberry leaf powder or extract has most often been used in doses of 0.8-1 gram three times daily for up to 3 months. See Effectiveness section for condition-specific information.\nStandardization & Formulation\nStandardized products used in clinical research include a specific white mulberry leaf powder standardized to contain 1-deoxynojirimycin (DNJ) 1.5% (17051) and a specific white mulberry leaf extract (Reducose, Phynova Group) standardized to contain DNJ 4.5% to 5.5% (105796).",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nANTIDIABETES DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, white mulberry leaf might increase the risk of hypoglycemia when taken with antidiabetes drugs.\nClinical research shows that white mulberry leaf can lower blood glucose levels (16494, 16495, 17051, 103870, 105796). Advise patients to monitor glucose levels closely.\nless\nORGANIC CATION TRANSPORTER 2 (OCT2) SUBSTRATES\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, white mulberry leaf might slow the elimination and increase the adverse effects of drugs which are OCT2 substrates.\nAnimal research shows that coadministration of white mulberry leaf extract with metformin, an OCT2 substrate, slows the renal elimination of metformin via inhibition of OCT2 activity (103869). OCT2 is expressed in the kidneys and is responsible for transporting cationic drugs into tubular epithelial cells in order to be excreted in the urine.\nless",
            "Interactions with Supplements": "HERBS AND SUPPLEMENTS WITH HYPOGLYCEMIC POTENTIAL\nWhite mulberry leaf has hypoglycemic effects.\nTaking white mulberry leaf with other products with hypoglycemic potential might increase the risk of hypoglycemia. Clinical research shows that white mulberry leaf can lower blood glucose levels (16494, 16495, 17051, 103870, 105796). See other products with hypoglycemic potential here.\nless",
            "Interactions with Conditions": "None known.",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with white mulberry.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of white mulberry.",
            "Mechanism of Action": "General\nThe applicable parts of white mulberry are the leaves, stems, fruit, and root bark. Constituents found in white mulberry leaves include flavones, steroids, triterpenes, amino acids, vitamins, trace minerals, and nitrogen-containing iminosugars (16497). The fruit contains anthocyanins, including cyanidin and pelargonidin glycosides, and flavonols, including quercetin and kaempferol (100625).\nAnti-cancer effects\nExtracts from dried white mulberry have anticancer activity. In vitro, extracts inhibit growth of leukemia cells. These extracts also appear to inhibit growth of multi-drug resistant cells (14619).\nAnti-gout effects\nPreliminary research in animal models shows that morin, a constituent of white mulberry twigs, reduces uric acid levels. Morin is thought to inhibit xanthine oxidase and have uricosuric activity (14617).\nAnti-inflammatory effects\nAn extract of white mulberry fruit inhibits inflammatory processes in macrophages in vitro by inhibiting the synthesis and release of nitric oxide. It also reduces the secretion of proinflammatory cytokines such as interleukin (IL)-6 and tumor necrosis factor (TNF)-alpha (100625).\nAntidiabetes effects\nWhite mulberry leaf powder has been traditionally used in the treatment of diabetes. It seems to have both antihyperglycemic effects and hypoglycemic effects (16496, 17051). In one clinical study of adults with type 2 diabetes, white mulberry leaf reduced fasting blood glucose levels (16494). However, in a study of healthy, non-diabetic adults, taking 1.2 grams of the powder before each meal for 38 days reduced postprandial glucose levels, but did not result in hypoglycemia (17051). A constituent of white mulberry leaf, a nitrogen-containing sugar called fagomine, potentiates glucose-induced insulin release (16496, 16497). Additionally, several compounds identified in the leaves and roots of white mulberry have alpha-glucosidase inhibiting activity. Inhibition of this enzyme in the intestinal lumen and brush border interferes with carbohydrate digestion, so that glucose is released more slowly from food. This reduces postprandial peak blood glucose levels and endogenous insulin secretion (16495, 16498, 16500).\n\nWhite mulberry leaf extracts inhibit intestinal alpha-glucosidase enzymes to different degrees. Sucrase, maltase, and isomaltase are inhibited by 95% to 99%, lactase by 38%, and trehalose by 44% (16495, 17052). Compounds identified in the leaves and roots of white mulberry that have alpha-glucosidase inhibiting activity include 1-deoxynojirimycin (moranoline), N-methyl-1-deoxynojirimycin, fagomine (1,2-dideoxynojirimycin), 1,4-dideoxy-1,4-imino-D-arabinitol, calystegin B2 (1-alpha,2-beta,3-alpha,4-beta-tetrahydroxy-nor-tropane), 1,4-dideoxy-1,4-imino-(2-o-beta-D-glucopyranosyl)-D-arabinitol, and 2-o-alpha-D-galactopyranosyl-1-deoxynojirimycin (16498, 16499, 17051, 17052, 103870). The most active alpha-glucosidase inhibitor is 1-deoxynojirimycin, which is present in the highest levels in young leaves taken from the top parts of branches in the summer (17051). The N-hydroxyethyl derivative of 1-dexoynojirimycin is marketed in the United States as the prescription drug miglitol (Glyset) (16498). The 1-deoxynojirimycin content of commercial white mulberry products varies, with some containing less than 0.05% (17051).\n\nAnimal research shows that diabetic rats fed dried white mulberry leaf powder as 25% of their diet for 8 weeks become virtually normoglycemic and stop excreting glucose in their urine (16496, 16497). Abnormal hepatic gluconeogenic activity is reduced, and insulin release in response to glucose is increased (16496). White mulberry leaf extract also reduces development of nephropathy and microalbuminuria in diabetic rats. A high glucose level in the kidneys increases the activity of peroxisome proliferator activated receptor gamma (PPAR-gamma) and the levels of the inflammatory mediator, nuclear factor (NF)-kappa-B. These increases seem to be attenuated by white mulberry leaf extracts (100628).\nAntihyperlipidemic effects\nAnimal research shows that rats with hyperlipidemia fed white mulberry leaf powder gain less weight, have lower blood glucose and lipid levels, and have reduced atherosclerotic lesions compared to rats not consuming the powder (14616, 14618, 16904). The reduction in atherosclerotic lesions is thought to be due to increased resistance of low-density lipoprotein (LDL) to oxidative changes (14616). Animal models also show that diets supplemented with white mulberry root bark extract increase antioxidant activity and improve lipid levels (16903). In studies of mice on a high-fat diet, adding white mulberry fruit powder or leaf polysaccharides to the diet attenuates increases in serum LDL (110482, 110483).\nAntimicrobial effects\nSome constituents of white mulberry have antimicrobial activity. Kuwanon G, a constituent of the root bark, has in vitro bactericidal activity against Streptococcus mutans and other microorganisms found in the mouth (16899). A flavonoid extract from the root bark has in vitro antiviral activity against the herpes simplex type I virus (16898).\nAntioxidant effects\nWhite mulberry leaf extracts have antioxidant activity, including reducing abnormal lipid peroxidation in erythrocyte membranes and improving activity of antioxidant enzymes, such as glutathione peroxidase and superoxide dismutase (16494, 16497). There are also compounds in white mulberry leaves that have free radical scavenging activity, including quercetin, a glucopyranoside of quercetin, moracin C, moracin N, prenylflavane compounds, and chalcomoracin (16497, 16896).\nBone effects\nA small clinical study shows that taking a mixture of white mulberry and Vietnamese coriander extracts for 8 weeks increases plasma levels of osteocalcin and alkaline phosphatase, which are markers of bone formation. This combination also decreases C-telopeptide of type 1 collagen (CTX), a marker of bone resorption (100626). It is not clear if these changes produce clinically significant improvements in bone density. Additionally, it is not clear if these effects are due to white mulberry or Vietnamese coriander.\nDermatologic effects\nThere is interest in using white mulberry for hyperpigmentation disorders. Extracts from white mulberry leaves have been shown to inhibit melanin production (16897).\nMetabolic effects\nThere is interest in using white mulberry to prevent metabolic syndrome. In studies of mice on a high-fat diet, adding white mulberry fruit powder or leaf polysaccharides to the diet improves glucose tolerance, and attenuates weight gain, fat accumulation, and increases in serum LDL (110482, 110483). Feeding mice white mulberry also attenuates changes in gut microbiota and inflammatory cytokines (110483).\nPsychiatric effects\nThere is interest in using white mulberry to improve recovery from stress. A preliminary study in animals suggests that dried white mulberry fruits have some effect on the actions of monoamine oxidase A and B during exercise (14615). However, the significance of this is not known.\nWeight loss effects\nDeoxynojirimycin in white mulberry inhibits alpha-glucosidase enzymes in the brush border of the small intestine. This results in delayed breakdown and absorption of polysaccharides after consumption (100627). In a study in mice, white mulberry leaf polysaccharides inhibit pancreatic lipase, which is necessary for dietary fat absorption (110482). In studies of mice on a high-fat diet, adding white mulberry fruit powder or leaf polysaccharides to the diet attenuates weight gain and fat accumulation (110482, 110483)."
        }
    },
    "White Mustard": {
        "sections": {
            "Overview": "White mustard is an annual plant that has been naturalized in Europe, Siberia, east Asia, and America. The ripe, dried seeds are used in medicine (18, 101056). Both the seed and leaves are used in foods.",
            "Safety": "LIKELY SAFE when used orally in amounts commonly found in foods. White mustard has Generally Recognized as Safe (GRAS) status in the US (4912).\n\nThere is insufficient reliable information available about the safety of white mustard when used orally or topically for medicinal purposes.\nPREGNANCY: LIKELY UNSAFE when used orally in medicinal amounts. White mustard is thought to have abortifacient and menstrual-stimulant properties (19).\nLACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, some people may be allergic to white mustard (101058). When taken as medicine, no adverse effects have been reported. However, a thorough safety evaluation has not been conducted. Isothiocyanates, such as those in white mustard, have been linked with endemic goiters (6, 11).\n\nTopically, white mustard oil or powder can cause blistering and skin ulceration when left on the skin for an extended period (2, 12, 18, 19). Also, some people are allergic to topical application of white mustard (101057).\nDermatologic\nTopically, white mustard oil or powder can cause blistering and skin ulceration when left on the skin for an extended period (2, 12, 18, 19).\nless\nEndocrine\nOrally, isothiocyanates, such as those in white mustard, have been linked with endemic goiters (6, 11).\nless\nImmunologic\nOrally and topically, white mustard can cause allergic responses (101057, 101058). Topically, white mustard can result in allergic contact dermatitis. Symptoms including spreading itching, red, and burning lesions have been observed on the skin of a 48-year-old woman approximately one week after she used a topical Chinese herbal medicine patch consisting of white mustard seed, licorice, ginger, corydalis, and asarabacca. The symptoms continued after discontinuation of the patch. The patient tested positive to white mustard seed in allergen testing. The suspected allergen was 4-(hydroxymethyl) phenol (101057).\nless",
            "Effectiveness": "There is insufficient reliable information available about the effectiveness of white mustard.",
            "Dosing & Administration": "Adult\nTopical:\nGeneral: Traditionally, as a foot bath, 20-30 grams of white mustard flour is typically mixed in 1 liter of water (18). For a mustard bath, 150 grams of white mustard flour in a pouch is commonly placed in the bath (18). For local application, 4 tablespoons (50-70 grams) of the powdered seeds are usually mixed with warm water to form a soft material, which is applied for 10-15 minutes for adults and 5-10 minutes for children older than 6 years of age (2, 18). Decrease the application time in individuals with sensitive skin (2). Treatment should not exceed two weeks (2, 12, 18, 19).\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of white mustard.",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the toxicology of white mustard.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of white mustard.",
            "Mechanism of Action": "General\nThe applicable part of white mustard is the ripe, dried seed. The seed contains mustard oil glycosides. White mustard contains the glucosinolate sinalbin, which on hydrolysis yields p-hydroxybenzyl isothiocyanate, p-hydroxybenzylamine, and other constituents, such as proteins, fatty oil, and sinapine (11, 18, 101056).\nAnticancer effects\nWhite mustard extract, sinalbin, and allyl isothiocyanate may have anticancer effects. The constituents are thought to slow down the growth of cancer cells and cause apoptosis (101056).\nAntimicrobial effects\nWhite mustard extract has antibacterial effects (101056). The compound allyl isothiocyanate has antibacterial properties (18)."
        }
    },
    "White Oak": {
        "sections": {
            "Overview": "White oak is a tree that is found primarily in North America (86394). The bark is used for medicinal purposes.",
            "Safety": "POSSIBLY SAFE when used orally for up to 3-4 days for treating diarrhea (2, 12, 7). ...when used topically up to 2-3 weeks on intact skin (2).\nLIKELY UNSAFE when used topically on extensive areas of damaged skin or for longer than 2-3 weeks (2).\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "General\nWhite oak bark seems to be well tolerated when used orally to topically on unbroken skin, short-term. White oak pollen may cause allergic reactions in some people (86395).\nImmunologic\nWhite oak pollen may cause allergic reactions in some people (86395).\nless",
            "Effectiveness": "There is insufficient reliable information available about the effectiveness of white oak bark.",
            "Dosing & Administration": "Adult\nNo typical dosage.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of white oak.",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "EXPAND ALL\n|\nCOLLAPSE ALL\nIRON\nTheoretically, concomitant administration might precipitate iron salts due to tannin content (19).\nTANNIN-CONTAINING HERBS\nTheoretically, herbs that contain high percentages of tannins such as white oak bark may cause precipitation of alkaloids and other constituents of herbs (19).",
            "Interactions with Conditions": "EXPAND ALL\n|\nCOLLAPSE ALL\nCARDIAC CONDITIONS\nWhite oak bark baths are contraindicated in individuals with cardiac insufficiency (2).\nless\nECZEMA\nWhite oak bark baths are contraindicated in individuals with weeping eczema or large areas of skin damage (2).\nless\nHYPERTONIA\nWhite oak bark baths are contraindicated in individuals with hypertonia (2).\nless\nINFECTION\nWhite oak bark baths are contraindicated in individuals with febrile or infectious diseases (2).\nless\nKIDNEY DYSFUNCTION\nTheoretically, oral use of white oak bark might worsen kidney dysfunction (12).\nless\nLIVER DYSFUNCTION\nTheoretically, oral use of white oak bark might worsen liver dysfunction (12).\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information about the toxic effects of white oak.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of white oak.",
            "Mechanism of Action": "Antioxidant activity\nLaboratory studies have demonstrated the antioxidant activity of white oak (48402). The antioxidant effects of white oak may be at least partially responsible for some of its supposed effects.\nConstituents\nThe primary chemical constituents of white oak bark or wood include the ellagitannins. Examples include the roburins, castalagin, vescalagin, and grandinin (86394, 93293). Other constituents include oak lactones such as beta-methyl-gamma-octalactone (93411). American white oak has slightly lower levels of ellagitannins and higher levels of oak lactones when compared to European species of oak (86394, 93293, 93411, 93412)."
        }
    },
    "White Pepper": {
        "sections": {
            "Overview": "White pepper is native to tropical Asian countries and is also produced in Brazil (94016). The fruit of Piper nigrum are peppercorns. The three types of peppercorns, black, white, and green, all come from the same plant. However, they are harvested at different times of the year and are processed differently (94016). White pepper is prepared by cooking and drying the ripe seeds, whereas black pepper is made by cooking the dried unripe fruit (29995). White pepper has a spicy flavor, although it is milder than black pepper, and is mainly used in fish, meat, and snacks including instant noodles (94016).",
            "Safety": "LIKELY SAFE when used orally in amounts commonly found in foods. White pepper has Generally Recognized as Safe (GRAS) status in the US (4912).\nPOSSIBLY SAFE when used orally and appropriately in medicinal amounts (12).\nCHILDREN: LIKELY SAFE when used orally in amounts commonly found in foods (11).\nCHILDREN: POSSIBLY UNSAFE when used orally in large amounts. Fatal cases of pepper aspiration have been reported in some patients (5619, 5620).\nPREGNANCY: LIKELY SAFE when used orally in amounts commonly found in foods (11). There is insufficient reliable information available about the safety of topical white pepper or white pepper oil when used in medicinal amounts during pregnancy.\nLACTATION: LIKELY SAFE when used orally in amounts commonly found in foods (11). There is insufficient reliable information available about the safety of white pepper when used in medicinal amounts during breast-feeding.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, white pepper can cause dyspepsia and other gastrointestinal discomfort (29263, 29265, 29266, 29267). When given in a nasal spray, white pepper has been reported to cause cardiovascular, gastrointestinal, neurologic, and respiratory effects (29263). Rarely, white pepper has been reported to cause allergic reaction (25599, 46241, 88204, 88206, 88207).\nCardiovascular\nWhen given in a nasal spray, piperine, a constituent of white pepper, induced palpitations in 8 out of 127 study participants (29263).\nless\nDermatologic\nOccupational exposure to white pepper has been reported to cause allergic sensitization. Irritant patch test reactions to white pepper have been documented in factory and office employees in a spice factory, however, positive skin test reactions from scratch tests with powdered white pepper are generally rare (25599, 46241, 88204, 88206, 88207).\nless\nGastrointestinal\nOrally, white pepper can cause a burning aftertaste and irritation to the throat and anterior tongue (29268). Single and repeated application of piperine, a constituent of white pepper, increased irritation of the tongue and oral cavity, resulting in decreased taste (29265, 29266, 29267). When given in a nasal spray, piperine induced nausea in 9 out of 127 study participants and irritation of the nose and throat in up to 82 out of 127 study participants (29263).\nless\nNeurologic/CNS\nWhen given in a nasal spray, piperine, a constituent of white pepper, induced headache, lightheadedness, dizziness, and feeling calm, alert, or \"high\" in up to 82 out of 127 study participants (29263).\nless\nPulmonary/Respiratory\nOrally, white pepper can cause constriction of the larynx, resulting in an increase in airway resistance (2391). Following occupational exposure to white pepper, rhinoconjunctivitis symptoms have been reported (88209). When given in a nasal spray, piperine, a constituent of white pepper, induced irritation of the nose and throat, coughing, sneezing, and runny eyes and nose in up to 98 out of 127 study participants (29263).\nless\nOther\nWhen given in a nasal spray, piperine, a constituent of black pepper, induced sweating in 17 out of 127 study participants and cold hands and feet in 18 out of 127 participants (29263).\nless",
            "Effectiveness": "INSUFFICIENT RELIABLE EVIDENCE TO RATE\nDiarrhea. Preliminary clinical research in children ages 2 months to 2.5 years shows that covering the navel with cooked and ground white pepper is more effective for curing acute or persistent diarrhea, but not chronic diarrhea, when compared with oral montmorillonite (clay) powder. Cure was defined as no diarrhea within three days of initiating treatment (94016).\nMore evidence is needed to rate white pepper for this use.",
            "Dosing & Administration": "Adult\nNo typical dosage.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of white pepper.",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nAMOXICILLIN (Amoxil, Trimox)\nInteraction Rating\nMINOR Be watchful with this combination.\nSeverity\nMILD\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nEvidence from animal research shows that piperine, a constituent of white pepper, increases the plasma levels of amoxicillin when taken concomitantly (29269). Theoretically, piperine from white pepper might increase the effects and side effects of amoxicillin in humans. Be watchful with this combination.\nANTICOAGULANT/ANTIPLATELET DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nIn vitro evidence suggests that piperine, a constituent of white pepper, inhibits platelet aggregation (29206). Theoretically, white pepper might increase the risk of bleeding when used with antiplatelet or anticoagulant drugs.\nSome anticoagulant/antiplatelet drugs include aspirin, clopidogrel (Plavix), dalteparin (Fragmin), enoxaparin (Lovenox), heparin, ticlopidine (Ticlid), warfarin (Coumadin), and others.\nless\nANTIDIABETES DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nEvidence from animal research suggests that piperine, a constituent of white pepper, reduces blood glucose levels (29225). Theoretically, white pepper might have additive effects with antidiabetes drugs and increase the risk of hypoglycemia. Monitor blood glucose levels closely. Dose adjustments might be necessary.\nSome antidiabetes drugs include glimepiride (Amaryl), glyburide (DiaBeta, Glynase PresTab, Micronase), insulin, pioglitazone (Actos), rosiglitazone (Avandia), and others.\nless\nCARBAMAZEPINE (Tegretol)\nInteraction Rating\nMINOR Be watchful with this combination.\nSeverity\nMILD\nOccurrence\nPOSSIBLE\nLevel of Evidence\nB (Nonrandomized clinical trial)\nWhite pepper might increase levels of carbamazepine. Patients taking carbamazepine 300 mg or 500 mg twice daily had increased levels after taking a single dose of 20 mg purified piperine, which is a constituent of white pepper. Piperine may increase absorption by increasing blood flow to the GI tract, increasing the surface area of the small intestine, or by cytochrome P450 3A4 (CYP3A4) inhibition in the gut wall. Absorption was significantly increased by 7-10 mcg/mL/hour. The time to eliminate carbamazepine was also increased by 4-8 hours. Although carbamazepine levels were increased, this did not appear to increase side effects (16833). In vitro research also shows that piperine can increase carbamazepine levels by 11% in a time-dependent manner (103819).\nCEFOTAXIME (Claforan)\nInteraction Rating\nMINOR Be watchful with this combination.\nSeverity\nMILD\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nEvidence from animal research shows that piperine, a constituent of white pepper, increases the plasma levels of cefotaxime when taken concomitantly (29269). Theoretically, piperine from white pepper might increase the effects and side effects of cefotaxime in humans. Be watchful with this combination.\nCYCLOSPORINE (Neoral, Sandimmune)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nIn vitro evidence shows that piperine, a constituent of white pepper, increases the bioavailability of cyclosporine (29282). Theoretically, white pepper might increase levels of cyclosporine.\nCYTOCHROME P450 1A1 (CYP1A1) SUBSTRATES\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nIn vitro evidence suggests that piperine, a constituent of white pepper, inhibits cytochrome P450 1A1 (CYP1A1) (29213). Theoretically, concomitant use with white pepper might increase the effects and side effects of drugs metabolized by CYP1A1.\nSome of these drugs include chlorzoxazone, theophylline, and bufuralol.\nless\nCYTOCHROME P450 2B1 (CYP2B1) SUBSTRATES\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nIn vitro evidence suggests that piperine, a constituent of white pepper, inhibits cytochrome P450 2B1 (CYP2B1) (29332). Theoretically, concomitant use with white pepper might increase the effects and side effects of drugs metabolized by CYP2B1.\nSome drugs metabolized by CYP2B1 include cyclophosphamide, ifosfamide, barbiturates, bromobenzene, and others.\nless\nCYTOCHROME P450 2D6 (CYP2D6) SUBSTRATES\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nIn vitro evidence suggests that some constituents of white pepper inhibit cytochrome P450 2D6 (CYP2D6) (29207). Theoretically, concomitant use may affect drugs metabolized by CYP2D6.\nSome drugs metabolized by CYP2D6 include amitriptyline (Elavil), codeine, desipramine (Norpramin), flecainide (Tambocor), haloperidol (Haldol), imipramine (Tofranil), metoprolol (Lopressor, Toprol XL), ondansetron (Zofran), paroxetine (Paxil), risperidone (Risperdal), tramadol (Ultram), venlafaxine (Effexor), and others.\nless\nCYTOCHROME P450 3A4 (CYP3A4) SUBSTRATES\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nIn vitro evidence suggests that piperine, a constituent of white pepper, inhibits cytochrome P450 3A4 (CYP3A4). Theoretically, concomitant use with white pepper might increase the effects and side effects of drugs metabolized by CYP3A4.\nSome drugs metabolized by CYP3A4 include some calcium channel blockers (diltiazem, nicardipine, verapamil), chemotherapeutic agents (etoposide, paclitaxel, vinblastine, vincristine, vindesine), antifungals (ketoconazole, itraconazole), glucocorticoids, cisapride (Propulsid), alfentanil (Alfenta), fentanyl (Sublimaze), losartan (Cozaar), fluoxetine (Prozac), midazolam (Versed), omeprazole (Prilosec), ondansetron (Zofran), propranolol (Inderal), fexofenadine (Allegra), and numerous others.\nless\nLITHIUM\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPROBABLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nWhite pepper is thought to have diuretic properties. Theoretically, due to these potential diuretic effects, white pepper might reduce excretion and increase levels of lithium. The dose of lithium might need to be decreased.\nNEVIRAPINE (Viramune)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPROBABLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nEvidence from human research shows that piperine, a constituent of white pepper, increases the plasma concentration of nevirapine (29209). While no adverse effects were observed in the study, theoretically, white pepper might increase the effects and side effects of nevirapine. Use with caution.\nP-GLYCOPROTEIN SUBSTRATES\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, white pepper might increase levels of p-glycoprotein substrates. The piperine constituent of white pepper seems to inhibit p-glycoprotein in vitro (14375, 29281, 29283).\nSome drugs metabolized by p-glycoprotein include some chemotherapeutic agents (etoposide, paclitaxel, vinblastine, vincristine, vindesine), antifungals (ketoconazole, itraconazole), protease inhibitors (amprenavir, indinavir, nelfinavir, saquinavir), H2 antagonists (cimetidine, ranitidine), some calcium channel blockers (diltiazem, verapamil), digoxin, corticosteroids, erythromycin, cisapride (Propulsid), fexofenadine (Allegra), cyclosporine, loperamide (Imodium), quinidine, and others.\nless\nPENTOBARBITAL (Nembutal)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nIn an animal model, the piperine constituent of white pepper increased pentobarbitone-induced sleeping time (29214). It is not known if this occurs in humans or if this applies to other barbiturates or sedatives. Theoretically, combining white pepper and pentobarbital might increase the sedative effects of pentobarbital.\nPHENYTOIN (Dilantin)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nWhite pepper might increase levels of phenytoin. In humans, the piperine constituent of white pepper seems to increase absorption, slow elimination, and increase levels of phenytoin (537, 14442).\nPROPRANOLOL (Inderal)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nB (Nonrandomized clinical trial)\nTheoretically, white pepper might increase levels of propranolol. In humans, the piperine constituent of white pepper seems to increase absorption and slow elimination of propranolol (538).\nRIFAMPIN (Rifadin)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nB (Nonrandomized clinical trial)\nTheoretically, white pepper might increase levels of rifampin. The piperine constituent of white pepper seems to increase absorption and serum levels of rifampin (14375, 29284).\nTHEOPHYLLINE\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, white pepper might increase levels of theophylline. In humans, the piperine constituent of white pepper seems to increase absorption and slow elimination of theophylline (538).",
            "Interactions with Supplements": "EXPAND ALL\n|\nCOLLAPSE ALL\nANTICOAGULANT/ANTIPLATELET HERBS AND SUPPLEMENTS\nIn vitro, the piperine constituent of white pepper seems to inhibit platelet aggregation (29206). Theoretically, concomitant use of white pepper with herbs that affect platelet aggregation could theoretically increase the risk of bleeding in some people. These herbs include angelica, danshen, garlic, ginger, ginkgo, red clover, turmeric, willow, Panax ginseng, and others.\nHERBS AND SUPPLEMENTS WITH HYPOGLYCEMIC POTENTIAL\nEvidence from animal research suggests that piperine, a constituent of white pepper, can reduce blood sugar levels (29225). Theoretically, white pepper might have additive effects when used with herbs and supplements with hypoglycemic potential. Monitor blood glucose levels closely. Some herbs and supplements with hypoglycemic potential include devil's claw, fenugreek, guar gum, Panax ginseng, Siberian ginseng, and others.\nRHODIOLA\nEvidence from animal research suggests that concomitant use of rhodiola and piperine, a constituent of white pepper, reduces the activity of the rhodiola extract (71176).\nSPARTEINE\nPiperine, a constituent of white pepper, increases the bioavailability of sparteine, a constituent of scotch broom (19).",
            "Interactions with Conditions": "EXPAND ALL\n|\nCOLLAPSE ALL\nBLEEDING CONDITIONS\nPiperine, a constituent of white pepper, might inhibit platelet aggregation (29206). Theoretically, taking white pepper in medicinal amounts might increase the risk of bleeding in individuals with bleeding disorders.\nless\nDIABETES\nWhite pepper might affect blood glucose levels (29225). Theoretically, medicinal amounts of white pepper might interfere with blood glucose control in patients with diabetes. Dosing adjustments for insulin or oral hypoglycemic agents may be necessary.\nless\nSURGERY\nThe piperine constituent of white pepper has antiplatelet effects (29206) and might affect blood glucose levels (29225). Theoretically, using white pepper in medicinal amounts might cause excessive bleeding or interfere with blood glucose control if used perioperatively. Tell patients to discontinue using white pepper in medicinal amounts at least 2 weeks before elective surgical procedures.\nless",
            "Interactions with Lab Tests": "EXPAND ALL\n|\nCOLLAPSE ALL\nBLOOD GLUCOSE\nTheoretically, piperine, a constituent of white pepper, might decrease blood glucose levels and test results (29225).\nless\nPLATELET FUNCTION\nTheoretically, white pepper might inhibit platelet function and measures of platelet aggregation time test results (29206).\nless\nSERUM DRUG ASSAYS\nWhite pepper can increase phenytoin, propranolol, and theophylline serum concentrations and test results (537, 538).\nless",
            "Overdose": "In vitro evidence suggests that piperine, a constituent of white pepper, is not genotoxic (29233). However, some white pepper constituents may have carcinogenic effects. In vitro evidence suggests that the mutagenic N-nitroso and C-nitroso metabolites of piperine are created in acidic conditions (29259, 29260, 39828).\n\nThe lethal dose (LD50) for piperine, a constituent of white pepper, has been evaluated in mice and rats. In mice, the LD50 values for single intravenous, subcutaneous, intragastric, and intramuscular administration, were 15, 200, 330, and 400 mg/kg of body weight, respectively (29238). The intraperitoneal LD50 of piperine ranged from 43-60 mg/kg of body weight; in weanling male mice, the LD50 was 132 mg/kg of body weight (29238). In rats, the intraperitoneal LD50 for piperine was 33.5 mg/kg of body weight, and the intragastric LD50 was 514 mg/kg (29238). A lethal dose resulted in death due to respiratory paralysis within 3-17 minutes (29238).",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of white pepper.",
            "Mechanism of Action": "General\nWhite pepper contains piperyline, piperlonguminine, piperanine, isochavicine, piperdardine, piperttine isomers, and the piperine isomers, piperine, isopiperine, and chavicine (29293, 29305, 88213, 88214). White pepper essential oils contain alpha-humulene, alpha-pinene, beta-caryophyllene, beta-eudesmol, beta-pinene, caryophyllene oxide, delta-3-carene, eugenol, hedycaryol, limonene, sabinene, alpha-phalandrene, and terpinen-4-ol (29308, 88214).\nAnalgesic effects\nIn animals, the white pepper constituent piperine exhibits analgesic effects (29169).\nAnti-asthma effects\nIn animal research, the white pepper constituent piperine inhibited eosinophil infiltration and airway hyperresponsiveness. Suppression of T-cell activity and inhibition of the production of interleukins 4 and 5 might play a role in this process (29181).\nAntiamebic effects\nIn animals, the white pepper constituent piperine demonstrated antiamebic activity against cecal amoebiasis (29199).\nAnticancer effects\nThe white pepper constituent piperine has demonstrated anti-cancer effects in animal models, including reduced tumor growth (29226, 29309, 29313, 29324). In animal research, piperine also reduced tumor nodule formation, as well as lung collagen hydroxyproline, tissue uronic acid, lung hexosamine, and serum sialic acid and gamma-glutamyl transpeptidase activity (29277). In vitro, piperine inhibited proliferation of cancer cells, induced differentiation, and had additive or protective effects against toxicity of 1-methyl-4-phenylpyridinium, depending on concentration (29319, 29320, 29321, 29322). Potential mechanisms of action for anticancer effects of piperine include decreased protein-bound carbohydrate levels, altered mitochondrial enzyme activity, enhanced detoxification enzymes, reduced DNA damage, protein phosphorylation, modulation of lipid peroxidation, augmentation of antioxidant defense systems, reduced genotoxicity and chromosomal aberrations and aldehyde dehydrogenase, and a suppression of metabolic activation by mutagens (29309, 29310, 29311, 29312, 29313, 29314, 29315, 29316, 29317, 29318)(29323, 29324). In animals with lung cancer, piperine decreased lipid peroxidation, protein carbonyls, nucleic acid content, and polyamine synthesis, and normalized erythrocyte membrane and tissue ATPase enzyme activities (29325, 29326). In combination with 5-fluorouracil, piperine enhanced the inhibition of tumor growth in animals (29274).\nAntidiabetic effects\nIn animals fed a high-fat diet, the white pepper constituent piperine improved plasma levels of insulin (29188). Evidence from animal research suggests that piperine can reduce blood sugar levels (29225).\nAntifungal effects\nIn vitro, the white pepper constituent piperine inhibited aflatoxin B1-induced cytotoxicity and genotoxicity, potentially by inhibiting some cytochrome P450 metabolic effects (29332, 29333). However, in animals, piperine enhanced the bioavailability of aflatoxin B1 (29330).\nAntimicrobial effects\nIn vitro, white pepper has exhibited antimicrobial effects (71743). The white pepper constituent piperine inhibited glucan production by oral bacteria and had efflux inhibitory activity against methicillin-resistant Staphylococcus aureus (29172, 29173). Piperine also inhibited ochratoxin A production by inhibiting the polyketide synthesis step in Aspergilli (29174).\nAntioxidant effects\nIn animal research, the white pepper constituent piperine had antioxidant effects, including the protection of erythrocytes from oxidative stress and reduced oxidative stress associated with a high-fat diet (29179, 29180). In rats, intraperitoneal administration of piperine resulted in enhanced hepatic oxidized glutathione concentration and decreased renal glutathione concentration and renal glutathione reductase activity. In diabetic rats, piperine reversed the effects on oxidized glutathione concentration in the brain, on renal glutathione peroxidase and superoxide dismutase activities, and on cardiac glutathione reductase activity and lipid peroxidation (29338). However, piperine did not reverse all diabetes-associated oxidative effects measured in this model. Also, in vitro, piperine acted as a superoxide scavenger at low concentrations and increased the generation of hydroxyl radicals at high concentrations (29339, 46243). In other in vitro research, piperine exerted cardiac myocyte protective effects due to its antioxidant activity (29344).\nAntiparasitic effects\nIn vitro, the white pepper constituent piperine had antiparasitic effects against Trypanosoma cruzi, which involved ultrastructural alterations (29201, 29202). In animal research, piperine had antiparasitic effects against Leishmania species (29203, 29204).\nCardiovascular effects\nIn animal research, piperine exerted positive chronotropic and inotropic effects in the isolated spontaneously beating right atria and electrically driven left atria; the calcitonin gene-related peptide was involved (29279, 29280). However, in other animal research, intravenous piperine had hypotensive effects, likely through calcium channel blockade (29224).\nChemotherapy protective effects\nIn vitro, the white pepper constituent piperine protected non-cancer cells from cisplatin-induced apoptosis (29273).\nCoagulation effects\nIn vitro, the white pepper constituent piperine inhibits platelet aggregation (29206).\nGastrointestinal effects\nIn animal research, the white pepper constituent piperine inhibits gastric emptying and gastrointestinal transit (29356, 29357). Piperine has had various effects in animals, including protection against castor oil, arachidonic acid, and magnesium sulfate-induced diarrhea, possibly due to an effect on calcium-related contractions as shown in isolated organs, as well as protection from gastric ulceration, possibly due to protective prostaglandins and increased activity of enzymes, such as lipase, amylase, sucrose, maltase, trypsin, and chymotrypsin (29350, 29351, 29352, 29353, 29354, 29355, 29362, 46178, 49538). In one animal study, increased gastric acid secretion following piperine administration was likely due to stimulation of histamine H2 receptors (29358, 39864).\n\nPiperine appears to affect absorption from the gastrointestinal tract. In vitro, piperine inhibited digoxin and cyclosporine A transport in Caco-2 cells (29208). Piperine also produced effects such as stimulated gamma-glutamyl transpeptidase, enhanced uptake of radio-labelled amino acids, enhanced lipid peroxidation in freshly isolated epithelial cells of rat jejunum, and altered kinetic behavior of gamma-glutamyl transpeptidase towards substrate and acceptor, indicating increased permeability of intestinal cells (29363). Potential mechanisms of action explaining the gastrointestinal effects of piperine may involve the vanilloid receptor TRPV1(29158).\nGenitourinary effects\nIn vitro, the white pepper constituent piperine induced bladder contraction, which was partially mediated by transient receptor potential cation channel (TRPV1) (29343, 64149).\nHepatic effects\nIn animal research, the white pepper constituent piperine has had both hepatoprotective and hepatotoxic effects. In various hepatotoxicity models, piperine had hepatoprotective effects, such as increased hepatic glutathione, sulfhydryl, cytochrome B5, and cytochrome P450 levels, and decreased malonaldehyde (3760, 29197, 29198). Also, piperine inhibited enzymatic drug biotransformation reactions in the liver, inhibiting hepatic and intestinal aryl hydrocarbon hydroxylase and UDP-glucuronyl transferase (29364). In animal and in vitro research, piperine has been shown to both stimulate or inhibit aryl hydroxylase, and inhibits N-demethylase, hepatic microsomal glucuronyl transferase, and liver microsomal cytochrome P450 (29365). Other hepatic enzymes have also been shown to be affected by piperine in laboratory research. For example piperine may decrease NADH-dehydrogenase and malate dehydrogenase and increase Mg(++)-ATPase, NADPH-cytochrome c reductase, benzphetamine N-demethylase, aminopyrine N-demethylase, aniline hydroxylase, and microsomal cytochrome P-450 and cytochrome b5 activities (29366, 29367). However, increased activity of NADPH-cytochrome c reductase has also been implicated in the piperine-induced increase in carbon tetrachloride-induced hepatotoxicity as shown in animal research (29227).\nHormonal effects\nThe anti-fertility effects of the white pepper constituent piperine have been investigated in both male and female animal models. In males, piperine resulted in testicular and accessory sex organ apoptosis, perhaps initiated by inhibited testicular superoxide dismutase, catalase, glutathione peroxidase, and glutathione reductase, as well as increased lipid peroxidation and hydrogen peroxide generation, and decreased sialic acid in germ cells (29215, 29216). Other changes included partial degeneration of germ cells and damage to seminiferous tubules and spermatocytes and spermatids (29216). Also, piperine decreased weights of the caput, corpus, and cauda regions of the epididymis, decreased epididymal sperm count and motility and sperm vitality, and decreased sialic acid levels (29217). Fertility effects in the testes were thought to be due to decreased phospholipid concentration and free cholesterol, increased total cholesterol and cholesterol ester, and modifications in the ratio of triacyl to diacyl glycerols (29347). In female animals, piperine increased the period of the diestrous phase, resulting in decreased mating performance and fertility (29218). Other negative effects included anti-implantation period five days post-mating with oral use and total absence of implants following intrauterine injection. However, in super-ovulated female hamsters, intragastric piperine increased the rate of fertilization following artificial insemination, with no difference in stage of embryonic development after 48 hours (29278). In pregnant mice, piperine inhibited implantation, produced abortion, and delayed labor; uterotonic activity and hormonal effects were not implicated (29348). In vitro, piperine in the capacitation medium inhibited the percentage of eggs fertilized and the degree of polyspermia, without effect on sperm motility (29349).\nImmune effects\nThe effects of white pepper constituents have been investigated on immunological endpoints in laboratory research. In animals and in vitro, piperine improved or normalized various immunological endpoints such as cell viability, oxidative stress, apoptotic markers, cell proliferative response, T and B cell phenotype changes, and cytokine release following treatment with the immunotoxicant cadmium (29219, 29220, 29221, 29222). In vitro, piperine inhibits adhesion of neutrophils to endothelial monolayer; this is potentially due to its ability to block tumor necrosis factor-alpha (TNF-alpha)-induced expression of cell adhesion molecules such as ICAM-1 (intercellular adhesion molecule-1), VCAM-1 (vascular cell adhesion molecule-1) and E-selectin (29223).\nLipid effects\nIn animals, piperine beneficially reduced plasma lipid and lipoproteins levels, increased levels of high-density lipoprotein (HDL) cholesterol, and improved levels of apo A-1 and apo B (29188, 29378). In vitro, piperine inhibited acyl-CoA:cholesterol acyltransferase (ACAT) activity (29271).\nNeurologic effects\nThere is interest in using white pepper as an antidepressant. In animal research, the white pepper constituent piperine had antidepressant effects and a protective effect on neuroblastoma cells (29182, 29183, 29379). In other animal research, piperine protected against chronic unpredictable mild stress (29184, 29185). Suppression of monoamine oxidase activity has also been implicated in the antidepressant effects of piperine (29186, 29187).\n\nThere is also interest in using white pepper for seizures. In animal research, injection of the white pepper constituent piperine blocked convulsions induced by intracerebroventricular injection of threshold doses of kainite, but had no or only slight effects on convulsions induced by L-glutamate, N-methyl-D-aspartate, or guanidinosuccinate (29341, 29342). In another animal study, the effect of piperine on convulsions was associated with higher levels of 5-hydroxytryptamine in the cerebral cortex and lower levels in the hippocampus, midbrain, and cerebellum, as well as higher levels of dopamine in the hypothalamus and decreased norepinephrine throughout the brain (29342).\n\nOther neurologic effects of white pepper have been evaluated. In animal research, the white pepper constituent piperine had cognition-enhancing effects; the mechanism of action is unclear (29379). Although some laboratory studies suggest that the depletion of substance P may play a role in the effects of piperine, not all studies agree (29380, 29287). Also, in vitro, piperine caused a sustained net inward current associated with either an increase or decrease in membrane conductance. It also blocked potassium channels in neurons (29381, 29382). However, piperine has also demonstrated cytotoxicity with neurons, including cerebellar granule neurons and hippocampal neurons, but not astrocytes (29239, 29240, 29241, 29383).\nRespiratory effects\nThere is interest in using white pepper for asthma. In animals, the white pepper constituent piperine exhibits anti-inflammatory effects (29175, 29176, 29177). The anti-inflammatory effect of piperine was suggested to be due to chronic granulative changes and stimulation of the pituitary adrenal axis (29175). In vitro, piperine decreased the production of prostaglandin E2, the expression of interleukin-6 and matrix metalloproteinase13, and decreased inflammatory responses of adipose tissue on macrophages (29176, 51958). The anti-inflammatory effects of piperine may also result from reduced expression and production of pro-inflammatory cytokines (29368). In human research, stimulation of the mucosa of the upper airway with white pepper powder caused dilation of the trachea and bronchi accompanied by a decrease in airway resistance in laryngectomized patients (29391). The effect of this dilation appears to be overpowered by the constriction of the larynx and, as a result, an increase in airway resistance was observed.\nVascular effects\nIn isolated rat hind limb, the white pepper constituent piperine stimulated oxygen uptake and increased vascular resistance (29384)."
        }
    },
    "White Sandalwood": {
        "sections": {
            "Overview": "White sandalwood is an evergreen tree native to India. The oil is prized for perfumes, and is expensive and often counterfeited (108737). The wood and wood oil have also been used in traditional Ayurvedic medicines (73081, 99289). The related species Santalum spicatum and Santalum ellipticum are grown in Australia and Hawaii, respectively, for their oil, but the content of pharmacologically active compounds in these oils is lower (108737).",
            "Safety": "LIKELY SAFE when used orally in amounts commonly found in foods. White sandalwood oil has Generally Recognized As Safe (GRAS) status for use in foods in the US (4912).\nPOSSIBLY UNSAFE when used orally for longer than 6 weeks. Use for more than 6 weeks is associated with kidney damage (12, 19).\nThere is insufficient reliable information available about the safety of white sandalwood when inhaled or when used topically in amounts greater than those found in cosmetics.\nPREGNANCY: LIKELY UNSAFE when used orally in medicinal amounts; sandalwood is reported to have abortifacient effects (19); avoid using.\nLACTATION: Insufficient reliable information available; avoid using amounts greater than those found in foods.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, white sandalwood appears to be well tolerated when taken in food amounts. There is currently a limited amount of information on the adverse effects of white sandalwood when taken in medicinal amounts. Topically and by inhalation, adverse effects to white sandalwood seem to be rare; however, a thorough safety evaluation has not been conducted.\nMost Common Adverse Effects\nOrally: Itching, nausea.\n\nTopically: Contact dermatitis.\nSerious Adverse Effects (Rare)\nOrally: Acute kidney injury.\nDermatologic\nOrally, white sandalwood may cause itching (18).\nless\nGastrointestinal\nOrally, white sandalwood may cause nausea and gastrointestinal complaints (18).\nless\nImmunologic\nTopically or when inhaled, there are case reports of white sandalwood paste or oil causing contact and photoallergic contact dermatitis (73081, 73082, 99292).\nless\nRenal\nOrally, use of large doses of white sandalwood or for more than 6 weeks is associated with kidney damage, with blood in the urine (12, 18, 19).\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nAngina. Sublingual white sandalwood has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nA large clinical trial in adults in China with chest pain presenting to the emergency department shows that taking white sandalwood (dose not specified), in combination with alpinia, indian long pepper, and other herbal ingredients, sublingually for 3 doses relieves chest pain faster and reduces chest pain severity after first-time treatment when compared with nitroglycerin aerosol. However, over 12 weeks of follow-up, no differences in frequency or severity of chest pain are observed between groups (115491). It is unclear if these effects are due to white sandalwood, other ingredients, or the combination. This study is limited by the inclusion of patients with noncardiogenic chest pain, who comprised over half of the patient population.\nless\nAnxiety. Although there has been interest in using inhaled white sandalwood for anxiety, there is insufficient reliable information about the clinical effects of white sandalwood for this purpose.\nBronchitis. Although there has been interest in using oral white sandalwood for bronchitis, there is insufficient reliable information about the clinical effects of white sandalwood for this purpose.\nCommon cold. Although there has been interest in using oral white sandalwood for common cold, there is insufficient reliable information about the clinical effects of white sandalwood for this purpose.\nCough. Although there has been interest in using oral white sandalwood for cough, there is insufficient reliable information about the clinical effects of white sandalwood for this purpose.\nGonorrhea. Although there has been interest in using oral white sandalwood for gonorrhea, there is insufficient reliable information about the clinical effects of white sandalwood for this purpose.\nHeadache. Although there has been interest in using oral white sandalwood for headache, there is insufficient reliable information about the clinical effects of white sandalwood for this purpose.\nMemory. It is unclear if inhaled white sandalwood is beneficial for memory.\nPreliminary clinical research in healthy males shows that inhaling white sandalwood 10% essential oil for 2 minutes does not improve memory recall when compared with sham inhalation (112729).\nless\nMental alertness. It is unclear if inhaled white sandalwood is beneficial for mental alertness.\nPreliminary clinical research shows that inhaling fragrance from white sandalwood oil for 20 minutes or applying white sandalwood oil to the skin does not increase alertness or attentiveness when compared with placebo in healthy individuals (73076, 73080).\nless\nStress. Although there has been interest in using inhaled white sandalwood for stress, there is insufficient reliable information about the clinical effects of white sandalwood for this purpose.\nStroke. Although there has been interest in using oral white sandalwood for stroke, there is insufficient reliable information about the clinical effects of white sandalwood for this purpose.\nUrinary tract infections (UTIs). Although there has been interest in using oral sandalwood for UTIs, there is insufficient reliable information about the clinical effects of white sandalwood for this purpose.\nVaginitis. Oral white sandalwood has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nPreliminary clinical research shows that taking 10 grams of a combination of white sandalwood, tamarind, and neem orally twice daily for 21 days improves some symptoms of discharge, lower abdominal pain, and back pain when compared with baseline in females with bacterial or yeast vaginitis (99290). It is unclear if this effect is due to white sandalwood, other ingredients, or the combination.\nless\nMore evidence is needed to rate white sandalwood for these uses.",
            "Dosing & Administration": "Adult\nOral:\nResearch is limited; typical dosing is unavailable.\nInhalation:Research is limited; typical dosing is unavailable.\nStandardization & Formulation\nThere is concern that many available products claiming to contain white sandalwood oil are adulterated or counterfeited. White sandalwood oil is the subject of International Standard (ISO) 3518-2002, which states that it should contain not less than 41% to 54% alpha-santalol, and not less than 16% to 24% beta-santalol. Testing of samples from six products marketed as white sandalwood oil found that none met the ISO, and only one contained both alpha- and beta-santalol. The constituents found in three of the other oils indicated that they were derived from Amyris balsamifera (also known as balsam torchwood, or West Indian sandalwood). The other two oils were synthetic mixtures, with primarily benzyl benzoate in one, and a mixture of synthetic alcohols in the other (108737).",
            "Interactions with Drugs": "LITHIUM\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPROBABLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, taking white sandalwood might reduce lithium excretion and increase serum levels of lithium.\nWhite sandalwood is thought to have diuretic properties, which may reduce lithium excretion. The dose of lithium might need to be decreased.\nless",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "KIDNEY DISEASE\nWhite sandalwood is contraindicated in kidney disease, particularly in individuals with diseases of the kidney parenchyma. White sandalwood can cause kidney injury when taken in large oral doses (2, 19).\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with white sandalwood.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of white sandalwood.",
            "Mechanism of Action": "General\nThe applicable parts of white sandalwood are the oil and wood (73081, 99289). White sandalwood contains monoterpenoids, saponins, proanthocyanidins, flavonoids, and tannins (99289). Alpha- and beta-santalol are believed to be the main active constituents (11, 73080).\nAnti-inflammatory effects\nWhite sandalwood oil has anti-inflammatory effects, thought to be due to inhibition of cyclooxygenase 1 and 2, and 12-lipoxygenase pathways (108737).\nAntimicrobial effects\nIn vitro, white sandalwood oil has shown activity against fungi, and also Gram positive bacteria, including both methicillin-resistant and vancomycin-resistant Staphylococcus aureus (2, 11, 99289, 108737).\nAnxiolytic effects\nWhite sandalwood is used in aromatherapy to reduce stress and anxiety. In humans, inhalation of white sandalwood oil moderates blood pressure during stressful situations but has no effect on salivary cortisol (99291). Animal research suggests that white sandalwood oil has relaxing effects. Both alpha- and beta-santalol are thought to play a role. Alpha-santalol has been shown to act as a dopamine D2 and serotonin 5-HT2A receptor antagonist in vitro (99291). When applied topically, alpha-santalol moderates blood pressure and pulse, indicative of a relaxing effect (73076).\nCancer-preventive effects\nIn vitro, white sandalwood oil and its constituent alpha-santalol prevent development of skin cancer, stopping the cell cycle at the G2/M phase, and inducing cell death by apoptosis (108737).\nSpasmolytic effects\nWhite sandalwood is traditionally used for coughs and bronchitis. Laboratory research suggests white sandalwood has spasmolytic activity (2, 11)."
        }
    },
    "Wild Carrot": {
        "sections": {
            "Overview": "Wild carrot is a plant. The fruit and seed are used in medicine (4). Carrot seed oil is steam-distilled from the dried root of both the familiar vegetable known as carrot (Daucus carota subsp. sativus), and the wild carrot (4).",
            "Safety": "LIKELY SAFE when the seed oil is used orally in amounts commonly found in foods. Wild carrot seed oil has a Generally Recognized as Safe (GRAS) status in the US (4912).\nPOSSIBLY SAFE when wild carrot seed oil is used orally and appropriately in medicinal amounts (4, 11).\nPOSSIBLY UNSAFE when the seed oil is used orally. Wild carrot seed oil has mild estrogenic activity and irritant effects (4). There is insufficient reliable information available about the safety of the oral use of the seeds or above ground parts during lactation.\nThere is insufficient reliable information available about the safety of the oral use of the above ground parts of wild carrot.\nBREAST-FEEDING:\nPREGNANCY: LIKELY UNSAFE when used orally. The seeds, oil, and above ground parts can cause uterine stimulant, abortifacient, and menstrual stimulant effects (19).",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, excessive doses of wild carrot seed oil might cause renal irritation or neurological effects. Hypersensitivity reactions and increased sensitivity to UV light and sunburn might also occur (4, 19).\n\nTopically, contact with the plant can cause dermatitis (4).\nDermatologic\nOrally, wild carrot seed oil might cause hypersensitivity reactions and increased sensitivity to UV light and sunburn (4, 19).\nless\nImmunologic\nTopically, contact with the plant can cause dermatitis (4).\nless\nNeurologic/CNS\nWild carrot seed contains myristicin. Thus, ingesting excessive doses of wild carrot seed oil might cause neurological effects (4, 19).\nless\nRenal\nWild carrot seed contains terpinen-4-ol. Thus, ingesting excessive doses of wild carrot seed oil might cause renal irritation (4, 19).\nless",
            "Effectiveness": "INSUFFICIENT RELIABLE EVIDENCE TO RATE\nPolycystic ovary syndrome (PCOS). Oral wild carrot has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nA clinical study in 150 females with oligomenorrhea due to PCOS shows that taking a combination product (Aslagh) containing essential oils of wild carrot seed, fennel, and Vitex agnus-castus fruit, 1 gram twice daily for 3 months, either alone or in combination with metformin, improves rates of menstrual bleeding and menstrual cyclicity similarly to metformin alone. All three groups experienced a significant improvement from baseline (108974).\nless\nMore evidence is needed to rate Wild carrot for this use.",
            "Dosing & Administration": "Adult\nOral:\nResearch is limited; typical dosing is unavailable.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of wild carrot.",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nANTIHYPERTENSIVE DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPROBABLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, excessive doses of wild carrot seed oil might interfere with antihypertensive therapy due to cardiotonic effects (4).\nESTROGENS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPROBABLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, excessive use of the above ground parts of wild carrot might interfere with hormonal therapy due to estrogenic effects of wild carrot (4).\nLITHIUM\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPROBABLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nWild carrot is thought to have diuretic properties. Theoretically, due to these potential diuretic effects, wild carrot might reduce excretion and increase levels of lithium. The dose of lithium might need to be decreased.\nPHOTOSENSITIZING DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPROBABLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, concomitant use might result in increased photosensitivity (19). Some drugs that cause photosensitivity include amitriptyline (Elavil), quinolones (Ciprofloxacin, others), sulfa drugs (Septra, Bactrim, others), and tetracycline.",
            "Interactions with Supplements": "HERBS AND SUPPLEMENTS WITH SEDATIVE PROPERTIES\nTheoretically, concomitant use with herbs that have sedative properties might enhance therapeutic and adverse effects. These include California poppy, catnip, German chamomile, hops, Jamaican dogwood, kava, lemon balm, skullcap, valerian, and others.",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with wild carrot.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of wild carrot.",
            "Mechanism of Action": "General\nThe applicable parts of wild carrot are the fruit and seed. They contain flavones including apigenin, chrysin, luteolin, flavonols including kaempferol and quercetin, various glycosides, and the furanocoumarins, 8-methoxypsoralen and 5-methoxypsoralen (4). The essential oil contains about 47% hydrocarbon monoterpenes and 30% oxygenated monoterpenes, including high amounts of geranyl acetate and alpha-pinene. It also contains sesquiterpenes, including 11-alpha-H-himachal-4-en-1-beta-ol (109533).\nAntimicrobial effects\nLaboratory research shows that wild carrot essential oil has activity against Gram positive bacteria. It also has activity against yeasts, including Candida strains and Cryptococcus neoformans, Aspergillus strains, and dermatophyte fungi, including Tricophyton, Epidermophyton, and Microsporum species. It also decreases the biofilm mass associated with Candida albicans (109533).\nCardiovascular effects\nWild carrot seed oil is traditionally used for heart disease. Laboratory research shows some evidence of vasodilation, cardiac depressant, and smooth muscle relaxation effects (11)."
        }
    },
    "Wild Cherry": {
        "sections": {
            "Overview": "Wild cherry is a fast-growing tree native to North and South America. It is also grown in some European countries such as Belgium, the Netherlands, and Germany. The leaves of the wild cherry tree are dark green and shiny, and the fruits are edible (94062, 94063).",
            "Safety": "LIKELY SAFE when used orally in amounts commonly found in foods and beverages. Wild cherry has Generally Recognized as Safe (GRAS) status in the US (4912).\nPOSSIBLY SAFE when used orally and appropriately short-term, in limited amounts (12).\nPOSSIBLY UNSAFE when used orally and long-term or in excessive amounts (12, 19). The constituent prunasin hydrolyzes to hydrocyanic acid (HCN) (11, 12, 13, 18).\nPREGNANCY: LIKELY UNSAFE when used orally because prunasin is potentially teratogenic (19).\nLACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "General\nOrally, large amounts of wild cherry can lead to cyanide toxicity, which can be fatal (18, 41565).\nNeurologic/CNS\nOrally, large amounts of wild cherry can lead to cyanide toxicity, which can be fatal (18, 41565). A case of accidental poisoning has been reported for a 56-year old women who consumed approximately 300 grams of wild cherries that had been steeped in alcohol the evening before symptom onset. The patient presented to the hospital the following day with symptoms including headache, nausea, vomiting, confusion, and severe dyspnea. Eventually the patient became comatose and hypotonic. After regaining consciousness the following day, the patient continued to experience severe sinus bradycardia, as well as disorientation, hallucinations, delusions, and agitation. After about 3 weeks, the patient began to experience blurred vision and tingling sensation of the lower limbs. The symptoms were eventually attributed to cyanide intoxication; the wild cherries the patient had consumed contained 4.7-15 mg/kg cyanide (41565).\nless",
            "Effectiveness": "There is insufficient reliable information available about the effectiveness of wild cherry.",
            "Dosing & Administration": "Standardization & Formulation\nThere is insufficient reliable information available about the standardization and formulation of wild cherry.",
            "Interactions with Drugs": "CYTOCHROME P450 3A4 (CYP3A4) SUBSTRATES\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nIn vitro research suggests that wild cherry can inhibit cytochrome P450 3A4 (CYP3A4) enzymes (6450). Theoretically, wild cherry might increase levels of drugs metabolized by CYP3A4. However, so far, this interaction has not been reported in humans.\nSome drugs metabolized by CYP3A4 include lovastatin (Mevacor), ketoconazole (Nizoral), itraconazole (Sporanox), fexofenadine (Allegra), triazolam (Halcion), and others.\nless",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "None known.",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "Wild cherries are known to contain cyanide. The constituent prunasin hydrolyzes to hydrocyanic acid (HCN) (11, 12, 13, 18). Wild cherry bark collected in the fall has a higher HCN yield (approximately 0.15%) than bark collected in the spring (approximately 0.05%). Leaves collected in the spring have the highest HCN yield (approximately 0.25%) (11).",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of wild cherry.",
            "Mechanism of Action": "General\nThe applicable part of wild cherry is the stem bark and fruit (18). The fruit contains phenolic constituents (94063).\nAntioxidant effects\nWild cherry fruit may have antioxidant effects due to its phenolic constituents, including hyperoside, anthocyanins, and chlorogenic acids (94063).\nCardiovascular effects\nAnimal research shows that wild cherry fruit can lower blood pressure. This effect is attributed to the antioxidant effects of wild cherry. It is speculated that wild cherry may reduce nitric oxide production and oxidative stress, which may improve endothelial dysfunction (94063).\nNeurologic/CNS effects\nWild cherry bark has sedative effects (18).\nRespiratory effects\nWild cherry bark has astringent and antitussive effects (18)."
        }
    },
    "Wild Daisy": {
        "sections": {
            "Overview": "Wild daisy is the common species of daisy. It is native to Europe, northern Africa, and parts of Asia (98489).",
            "Safety": "There is insufficient reliable information available about the safety of wild daisy.\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "General\nThere is currently a limited amount of information on the adverse effects of wild daisy. A thorough evaluation of safety outcomes has not been conducted.",
            "Effectiveness": "INSUFFICIENT RELIABLE EVIDENCE TO RATE\nBleeding. Although there has been interest in using oral wild daisy for bleeding, there is insufficient reliable information about the clinical effects of wild daisy for this purpose.\nBronchitis. Although there has been interest in using oral wild daisy for bronchitis, there is insufficient reliable information about the clinical effects of wild daisy for this purpose.\nCough. Although there has been interest in using oral wild daisy for cough, there is insufficient reliable information about the clinical effects of wild daisy for this purpose.\nWounds. Although there has been interest in using topical wild daisy for wounds, there is insufficient reliable information about the clinical effects of wild daisy for this purpose.\nMore evidence is needed to rate wild daisy for these uses.",
            "Dosing & Administration": "Adult\nOral:\nResearch is limited; typical dosing is unavailable. Traditionally, wild daisy tea, prepared by steeping 2 teaspoons of dried wild daisy in 300 mL of boiling water for 20 minutes, has been taken orally 2-4 times daily (18).\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of wild daisy.",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with wild daisy.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of wild daisy.",
            "Mechanism of Action": "General\nThe applicable parts of wild daisy are the aerial parts, especially the flower. Constituents of wild daisy include saponins, including triterpene saponins such as perennisosides and bellissaponins, as well as flavonoids and alcohol glycosides (34183, 34185, 34195, 98489).\nAntifungal\nIn vitro and animal research suggests that wild daisy extract has antifungal activity (34189).\nDermatological effects\nTopically, wild daisy is used for wounds and skin diseases. In vitro research shows that wild daisy extract and isolated triterpene saponins promote collagen synthesis in human dermal fibroblasts (98489).\nPhotoprotective effects\nIn vitro research in keratinocytes shows that incubation with wild daisy extract 1% reduces interleukin-6 expression and cytotoxicity after exposure to ultraviolet A radiation when compared with control (111443)."
        }
    },
    "Wild Indigo": {
        "sections": {
            "Overview": "Wild indigo is a plant with yellow flowers. When the plant's sap is exposed to air, it turns purple. Wild indigo sap is sometimes used as a dye. The root is traditionally used as medicine. Do not confuse wild indigo dye with indigo carmine, a synthetic dye derived from coal tar (86404, 86407, 86414, 86422).",
            "Safety": "LIKELY UNSAFE when used orally in large doses. Wild indigo is considered poisonous when consumed in doses of about 30 grams (12, 19).\nThere is insufficient reliable information available about the safety of wild indigo when used orally in lower doses or when used topically.\nPREGNANCY AND LACTATION: LIKELY UNSAFE when used orally or topically due to its toxic potential (12, 19).",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, large doses of wild indigo are considered poisonous and can cause vomiting, diarrhea, gastrointestinal complaints, and spasms (12). Wild indigo has also been studied in combination with other herbal extracts.\nGastrointestinal\nOrally, large doses of wild indigo can cause vomiting, diarrhea, and gastrointestinal complaints (12).\nless\nMusculoskeletal\nOrally, large doses of wild indigo are considered poisonous and can cause spasms (12).\nless",
            "Effectiveness": "INSUFFICIENT RELIABLE EVIDENCE TO RATE\nCommon cold. Clinical research shows that taking three tablets of a specific combination product (Esberitox, Schaper & Brmmer GmbH & Co. KG) containing dry extracts of echinacea root, thuja leaf, and wild indigo root three times daily for 7-9 days improves the severity of cold symptoms, general well-being, and overall response rate when compared with placebo in patients experiencing moderate cold symptoms (6392). It is not clear if these effects are due to wild indigo, the other ingredients, or the combination.\nMore evidence is needed to rate wild indigo for this use.",
            "Dosing & Administration": "Adult\nOral:General: Traditionally, one cup of wild indigo tea is taken three times daily. The tea is prepared by simmering 0.5-1 gram of dried wild indigo root in 150 mL of boiling water for 10-15 minutes and then straining (18).\n\nCommon cold: Three tablets of a specific product (Esberitox, Schaper & Brmmer GmbH & Co. KG) containing 3.2 mg per tablet of dry extract of wild indigo root, echinacea root, and thuja leaf, taken three times daily for 7-9 days, has been used (6392).Topical:General: Traditionally, an ointment, prepared using one part of wild indigo liquid extract to eight parts of ointment base, is applied to the affected area (18).\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of wild indigo.",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "GASTROINTESTINAL DISORDERS\nUse of wild indigo is contraindicated in patients with inflammatory gastrointestinal conditions, particularly with accompanying capillary congestion (19).\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the toxicology of wild indigo.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of wild indigo.",
            "Mechanism of Action": "General\nThe applicable part of wild indigo is the root (393). Constituents of wild indigo include baptin, baptisin, baptisinine, baptisol, genistein, resins, alkaloids, flavonoids, and fixed oils. The roots also contain an acidic arabinogalactan protein (31786, 31794, 48557, 48577, 86420).\nImmunologic effects\nIn vitro, wild indigo extracts have demonstrated immunostimulating properties (393, 36792, 48531, 74992, 86415, 86416). Researchers have described this activity as either immunomodulating (48526) or immunostimulating, which may be due to an increase in macrophage activity (48531, 36792). However, most in vitro research conducted on wild indigo has evaluated herbal combinations (48528, 48535, 48554, 48648, 48653, 48655, 48657, 48658). The effect of wild indigo alone is unclear at this time.\n\nAnimal research has shown that a specific arabinogalactan protein from the roots of wild indigo increases the production of immunoglobulin M (IgM) from mouse lymphocytes and the production of interleukin (IL)-6 and nitrite from alveolar mouse macrophages (48577)."
        }
    },
    "Wild Lettuce": {
        "sections": {
            "Overview": "The Latin name of wild lettuce, Lactuca virosa, translates to \"toxic milky extract.\" Its light green stem can grow up to 6 feet in height and produces a milky juice when scratched (93563).",
            "Safety": "POSSIBLY SAFE when mature, properly harvested wild lettuce is used orally and appropriately (12, 4).\nLIKELY UNSAFE when used orally in large doses or when harvested prematurely. Large doses of wild lettuce, or prematurely harvested wild lettuce, have been reported to cause anticholinergic side effects, stupor, depressed respiration, and death (4, 93563).\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nThere is currently a limited amount of information on the adverse effects of wild lettuce. Orally, large amounts of wild lettuce, as well as eating prematurely harvested wild lettuce, can cause sweating, increased respiration, tachycardia, pupil dilation, dizziness, ringing in the ears, vision disorders, pressure in the head, somnolence, excitatory states (18, 93563), respiratory depression, coma, and death (4).\n\nTopically, wild lettuce can cause contact dermatitis (4).\n\nIntravenously, boiled wild lettuce has been reported to cause fever, severe headache, tachycardia, nausea, and abdominal pain in three intravenous drug users (93566).\nCardiovascular\nOrally, large amounts of wild lettuce or prematurely harvested wild lettuce has been reported to cause sweating, flushing, and tachycardia (18, 93563).\nless\nDermatologic\nTopically, wild lettuce can cause contact dermatitis (4). It can cause an allergic reaction in individuals sensitive to the Asteraceae/Compositae family. Members of this family include ragweed, chrysanthemums, marigolds, daisies, and many other herbs.\nless\nGastrointestinal\nOrally, wild lettuce has been reported to cause nausea, vomiting, and abdominal cramps (93563).\n\nIntravenously, boiled wild lettuce, prepared by hand in combination with valerian root, has been reported to cause nausea and abdominal pain in three intravenous drug users (93566).\nless\nGenitourinary\nOrally, wild lettuce can cause urinary retention (93563).\nless\nImmunologic\nIntravenously, boiled wild lettuce, prepared by hand in combination with valerian root, has been reported to cause fever, severe headache, and tachycardia in three intravenous drug users. This reaction was hypothesized to be due to an immunologic response (93566).\nless\nNeurologic/CNS\nOrally, large amounts of wild lettuce or prematurely harvested wild lettuce has been reported to cause dizziness, pressure in the head, somnolence, anxiety, headache, excitatory states (18, 93563), and coma (4).\nless\nOcular/Otic\nOrally, large amounts of wild lettuce or prematurely harvested wild lettuce has been reported to cause mydriasis, pupil dilation, dizziness, ringing in the ears, and vision disorders (18, 93563).\nless\nPulmonary/Respiratory\nOrally, large amounts of wild lettuce or prematurely harvested wild lettuce has been reported to cause increased respiration (18) or respiratory depression (4).\nless",
            "Effectiveness": "There is insufficient reliable information available about the effectiveness of wild lettuce.",
            "Dosing & Administration": "Adult\nOral:\nORAL: A typical dose of the dried leaves is 0.5-3 grams as tea three times daily. The leaves are typically steeped in 150 mL of boiling water and then strained (4). A typical dose of the liquid extract (1:1 in 25% alcohol) is 0.5-3 mL three times daily (4). For the dried latex extract, lactucarium, a typical dose is 0.3-1 grams three times daily (4). A typical dose of the soft extract is 0.3-1 grams three times daily (4).",
            "Interactions with Drugs": "CNS DEPRESSANTS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, concomitant use with drugs with sedative effects might cause additive therapeutic effects and adverse effects (19).",
            "Interactions with Supplements": "HERBS AND SUPPLEMENTS WITH SEDATIVE PROPERTIES\nTheoretically, concomitant use with herbs that have sedative properties might enhance therapeutic and adverse effects. These include calamus, California poppy plant, catnip leaves, hops, Jamaican dogwood bark, kava root, passionflower, sage, St. John's wort, sassafras bark, skullcap, valerian, and others.",
            "Interactions with Conditions": "EXPAND ALL\n|\nCOLLAPSE ALL\nBENIGN PROSTATIC HYPERPLASIA (BPH)\nContraindicated in prostate enlargement (12). Wild lettuce might contain hyoscyamine (4) which is contraindicated in conditions involving urinary retention, including BPH (15).\nless\nCROSS-ALLERGENICITY\nWild lettuce can cause an allergic reaction in individuals sensitive to members of the Asteraceae/Compositae plant family. Members of this family include ragweed, chrysanthemums, marigolds, daisies, and many other herbs.\nless\nNARROW-ANGLE GLAUCOMA\nContraindicated (12). Wild lettuce might contain hyoscyamine (4) which can exacerbate narrow-angle (closed-angle) glaucoma (15).\nless\nSURGERY\nWild lettuce has CNS depressant effects. Theoretically, wild lettuce might cause additive CNS depression when combined with anesthesia and other medications during and after surgical procedures. Tell patients to discontinue wild lettuce at least 2 weeks before elective surgical procedures.\nless",
            "Interactions with Lab Tests": "None known.",
            "Mechanism of Action": "General\nThe applicable parts of wild lettuce are the latex and leaf. Wild lettuce contains lactucin and lactupicrin (4). The milky latex, known as lactucarium, can cause mydriasis and diuresis, which is attributed to the presence of trace amounts of hyoscyamine (4, 93563). However, the dried latex contains no hyoscyamine (4). Low concentrations (nanogram amounts) of morphine have been found in Lactuca species and are considered too low to have a pharmacological effect (4).\nGastrointestinal effects\nThe milky latex of wild lettuce, lactucarium, has antispasmodic and laxative effects and seems to decrease gastrointestinal inflammation (4, 93563).\nGenitourinary effects\nTraditionally, wild lettuce has been used for kidney disorders and for alleviating painful uterine contractions. The milky latex of wild lettuce, lactucarium, has diuretic and antispasmodic activity (93563).\nSedative effects\nWild lettuce is thought to have mild sedative, analgesic, and hypnotic or tranquilizing effects (4, 18, 93563, 93565). Lactucin, lactupicrin, and hyoscyamine have all been proposed responsible for the sedative activity, but the active constituent(s) has not been identified (4). Low concentrations (nanogram amounts) of morphine have been found in Lactuca species and are considered too low to have a pharmacological effect (4)."
        }
    },
    "Wild Mint": {
        "sections": {
            "Overview": "Wild mint is a perennial herb that grows in marshes, around ponds, and on the banks of rivers. It is native to Europe, northern Africa, and western Asia, and has been introduced to America and Australia (18, 98217).",
            "Safety": "There is insufficient reliable information available about the safety of wild mint.\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "General\nNo adverse effects have been reported; however, a thorough evaluation of safety outcomes has not been conducted.",
            "Effectiveness": "There is insufficient reliable information available about the effectiveness of wild mint.",
            "Dosing & Administration": "Adult\nOral:\nGeneral: One small cup of tea is consumed throughout the day.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of wild mint.",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "None known.",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the toxicology of wild mint.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of wild mint.",
            "Mechanism of Action": "General\nThe applicable parts of wild mint are the above-ground parts. Compounds isolated from wild mint essential oil include the monoterpene menthofuran, and several p-menthane lactones (mintlactone, isomintlactone, hydroxymintlactone, menthfurolactone, and epimenthofurolactone). Also present are cineole, menthone, naringenin, piperitenone oxide, beta-caryophyllene, limonene, borneol, terpinen-4-ol, germacrene D, beta-elemol, and viridiflorol (98216, 98217). The constituents and their relative quantities vary with the geographical location of the plants (98217).\nAntibacterial effects\nThe essential oil from wild mint has shown antibacterial activity, especially against Escherichia coli, in vitro (98218). It also has some activity against Salmonella typhi, Staphylococcus aureus, and Bacillus subtilis (98218).\nAntifungal effects\nThe essential oil from wild mint has shown fungicidal activity against Candida albicans and Trichophyton species in vitro (98218).\nAntioxidant effects\nThe essential oil from wild mint has antioxidant and free radical scavenging activity, possibly due to its cineole content (98217, 98218).\nAnxiolytic effects\nWild mint might have anxiolytic effects due to binding of viridiflorol to benzodiazepine binding sites associated with the neurotransmitter gamma-aminobutyric acid (GABA) (98217). The constituent naringenin is also suggested to have an anxiolytic effect, but this is not antagonized by the benzodiazepine antagonist, flumazenil (98219). Naringenin does reduce motor movements in a rat model of anxiety, similarly to midazolam (98219).\nMonoamine oxidase (MAO) inhibitory effects\nIn a rat liver mitochondrial cell preparation, naringenin isolated from an ethanol extract of the above-ground parts of wild mint has inhibitory activity against monoamine oxidase enzymes A and B (MAO-A and MAO-B) (98216)."
        }
    },
    "Wild Thyme": {
        "sections": {
            "Overview": "Wild thyme is a perennial shrub native to northern and central Europe. It has long, trailing stems and grows best on dry, stony ground, open sandy heaths, and grasslands. It has traditionally been used for a variety of conditions based on its purported anthelmintic, anti-inflammatory, anticholesterolemic, antiseptic, antispasmodic, expectorant, gastrointestinal, immunostimulant, and sedative effects (95929).",
            "Safety": "LIKELY SAFE when used in amounts commonly found in foods. Wild thyme has Generally Recognized as Safe (GRAS) status in the US (4912).\nPOSSIBLY SAFE when preparations of the above ground flowering parts are used orally and appropriately (12).\nPREGNANCY AND LACTATION: Insufficient reliable information; avoid using in medicinal amounts.",
            "Adverse Effects": "General\nNo adverse effects have been reported. However, a thorough evaluation of safety outcomes has not been conducted.",
            "Effectiveness": "INSUFFICIENT RELIABLE EVIDENCE TO RATE\nIrritable bowel syndrome (IBS). Although there has been interest in using oral wild thyme for IBS, there is insufficient reliable information about the clinical effects of wild thyme for this purpose.\nMore evidence is needed to rate wild thyme for this use.",
            "Dosing & Administration": "Adult\nOral:\nResearch is limited; typical dosing is unavailable.\nStandardization & Formulation\nThe European Pharmacopoeia specifies that wild thyme used for medicinal purposes should contain at least 1.2% essential oil, in which the total content of carvacrol and thymol is at least 40% (95929).",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "THYROID DISORDERS\nTheoretically, wild thyme might suppress thyroid function by decreasing hormone production and/or release (19). Until more is known, use with caution in patients with thyroid disorders.\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with wild thyme.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of wild thyme.",
            "Mechanism of Action": "General\nThe applicable parts of wild thyme are the above ground, flowering parts. Wild thyme contains an essential oil in varying amounts, depending on the geographic region, habitat, climatic conditions, age of the plant, and time of harvest. Constituents of the essential oil include carvacrol, borneol, isobutyl acetate, caryophyllene, 1,8-cineole, citral, citronellal, citronellol, p-cymene, geraniol, linalool, alpha-pinene, gamma-terpinene, alpha-terpineol, terpinyl acetate, and thymol (95929). In addition to the essential oil, wild thyme also contains flavonoids, phenol carboxylic acids, triterpenes and tannins (95929).\nAntimicrobial effects\nIn vitro research suggests that wild thyme essential oil has activity against Staphylococcus aureus, Bacillus subtilis, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Salmonella typhi, Lactobacillus acidophilus, Vibrio cholerae, and Candida albicans. The antimicrobial activity of wild thyme essential oil is thought to be due to carvacrol and/or thymol (95929, 112035). In vitro research also suggests that wild thyme essential oil can enhance the antimicrobial effects of amphotericin B, fluconazole, tetracycline, and vancomycin (112035). Phenolic compounds in the oil also inhibit growth and mycotoxin production of Aspergillus species (95929).\nAntioxidant effects\nWild thyme essential oil has antioxidant activity, including inhibiting linoleic acid peroxidation, and scavenging free radicals (95929).\nCytotoxic effects\nWild thyme essential oil and its constituents, carvacrol and thymol, have in vitro cytotoxic activity against mouse leukemia P388 cells (95929).\nGastrointestinal effects\nAnimal research shows that wild thyme extract improves pain, restores the gut barrier, and reduces the expression of inflammatory mediators in a rat model of irritable bowel syndrome. Researchers theorize these effects may be due to inhibition of mast cell degranulation and inhibition of serotonin receptors, specifically 5-HT3 and 5-HT4 (112036).\nGlycemic effects\nAnimal research suggests that wild thyme extract has hypoglycemic effects, possibly through upregulation of AMP-activated protein kinase (AMPK) and insulin receptor substrate 1 (IRS1), genes involved in insulin signaling (112034)."
        }
    },
    "Wild Yam": {
        "sections": {
            "Overview": "Wild yams, of which there are over 600 species, are perennial woody vines found in tropical and temperate climates worldwide (92715). About 12 species are edible, but many wild yam species are bitter tasting and are only grown as a source of diosgenin. Diosgenin, which was first isolated in 1940, is used to synthesize corticosteroids and sex hormones (515, 13167, 92724). Some wild yam products are promoted as \"natural DHEA\", but dehydroepiandrosterone (DHEA) can only be synthesized from diosgenin in the laboratory, not in the body (515, 2112).",
            "Safety": "POSSIBLY SAFE when used orally. A dose of 50 mg (containing 8 mg diosgenin) has been used with apparent safety for 12 weeks (12, 96724). ...when used topically. A wild yam cream has been used with apparent safety for 3 months (10989).\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, wild yam is generally well tolerated.\nMost Common Adverse Effects\nOrally: Fever, headache, upset stomach, and vomiting.\nSerious Adverse Effects (Rare)\nOrally: Anaphylaxis.\nGastrointestinal\nOrally, wild yam can cause upset stomach and vomiting, especially at higher doses (12, 86450).\nless\nHematologic\nIn one case report, a 55-year-old female with protein S deficiency and systemic lupus erythematosus (SLE) had temporary vision loss in the left eye from hemiretinal vein thrombosis 3 days after taking a combination phytoestrogen product containing wild yam 276 mg, dong quai 100 mg, red clover 250 mg, and black cohosh 250 mg (13155). It is unclear if wild yam contributed to this event.\nless\nImmunologic\nThere are three case reports of anaphylaxis after ingestion of cooked wild yam (96722).\nless\nNeurologic/CNS\nOrally, wild yam can cause headache and fever, especially at higher doses (86450).\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nPOSSIBLY INEFFECTIVE\nMenopausal symptoms. Topical wild yam does not seem to improve menopausal symptoms.\nWild yam applied topically as a cream in menopausal patients for 3 months appears to be no better than placebo for relieving vasomotor symptoms, such as hot flashes and night sweats. It also does not appear to change serum follicle stimulating hormone (FSH), estradiol, or progesterone levels (10989).\nless\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nCognitive function. It is unclear if oral wild yam is beneficial for improving cognitive function in healthy adults.\nPreliminary clinical research in healthy adults shows that taking a specific wild yam extract (Diopower 15, Anti-Aging Pro Corporation) orally, 50 mg (containing diosgenin 8 mg) daily for 12 weeks, modestly improves overall measures of cognitive function and semantic fluency when compared with placebo (96724).\nless\nDysmenorrhea. Although there is interest in using oral or topical wild yam for dysmenorrhea, there is insufficient reliable information about the clinical effects of wild yam for this condition.\nGallbladder disease. Although there is interest in using oral wild yam for gallbladder disease, there is insufficient reliable information about the clinical effects of wild yam for this condition.\nInfertility. Although there is interest in using oral or topical wild yam for infertility, there is insufficient reliable information about the clinical effects of wild yam for this condition.\nOsteoporosis. Although there is interest in using oral wild yam for osteoporosis, there is insufficient reliable information about the clinical effects of wild yam for this condition.\nPostmenopausal conditions. Although there is interest in using oral wild yam for postmenopausal conditions, there is insufficient reliable information about the clinical effects of wild yam for these conditions.\nPremenstrual syndrome (PMS). Although there is interest in using oral wild yam for PMS, there is insufficient reliable information about the clinical effects of wild yam for this condition.\nRheumatoid arthritis (RA). Although there is interest in using oral wild yam for RA, there is insufficient reliable information about the clinical effects of wild yam for this condition.\nSexual dysfunction. Although there is interest in using oral wild yam for sexual dysfunction, there is insufficient reliable information about the clinical effects of wild yam for this condition.\nMore evidence is needed to rate wild yam for these uses.",
            "Dosing & Administration": "Adult\nOral:\nResearch is limited; typical dosing is unavailable.\nTopical:\nWild yam has been used in a cream formulation. See Effectiveness section for condition-specific information.\nStandardization & Formulation\nWild yam is often used as a source of the glycoside, diosgenin (515). The diosgenin content of different wild yam species can vary significantly (86451, 86439). For example, edible species of wild yam such as Dioscorea alata, Dioscorea batatas, and Dioscorea japonica have relatively low amounts of diosgenin. Wild yam species such as Dioscorea villosa have higher amounts of diosgenin, but these species are not usually eaten (13167). A specific wild yam extract (Diopower 15, Anti-Aging Pro Corporation) used in clinical research has been standardized to contain diosgenin 8 mg per 50 mg of extract (96724).",
            "Interactions with Drugs": "ESTROGENS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, wild yam might increase or decrease the effects of estrogen.\nWild yam root shows estrogenic and anti-estrogenic effects in vitro (6180, 70411, 96723, 96725). Theoretically, wild yam might interfere with hormone therapy.\nless",
            "Interactions with Supplements": "None known.",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with wild yam.",
            "Pharmacokinetics": "Metabolism\nAfter oral administration, the diosgenin constituent of wild yam is metabolized in the liver and eliminated via the bile (86436).",
            "Mechanism of Action": "General\nThe applicable parts of wild yam are the root and rhizome. The tubers of Dioscorea species contain the glycoside diosgenin, a steroid precursor that can be used for commercial production of oral contraceptives, topical hormones, systemic corticosteroids, androgens, estrogens, progestogens, and other sex hormones (515). Dioscorea is also used as the precursor for manufacturing progesterone contained in some \"natural progesterone\" cosmetic products. Another constituent in wild yam is allantoin (102611).\n\nThere are over 600 different species of Dioscorea. The diosgenin content and pharmacological effects of species can vary significantly. For example, edible species of wild yam such as Dioscorea alata, Dioscorea batatas, and Dioscorea japonica have relatively low amounts of diosgenin. Species such as Dioscorea villosa have higher amounts of diosgenin and this species is not usually eaten (13167). Dioscorea opposite, or Chinese yam, also contains 0.15% adenosine and 0.08% arbutin (96723).\nAnti-osteoporotic effects\nA study in spayed female, osteoporotic rats shows that giving diosgenin daily for 12 weeks improves markers for bone architecture and structure when compared with control (112221).\nAntidiabetic effects\nA study in type 2 diabetic male mice shows that giving diosgenin daily for 24 weeks improves markers of retinopathy (i.e. retinal thickness and number of retinal ganglion cells) when compared with control (112222).\nGastrointestinal effects\nIn an animal model of antibiotic-associated diarrhea, wild yam reduced diarrhea. Although the mechanism of action is not known, possibilities include enriching levels of probiotic bacteria and overall bacterial diversity in the large intestine. Also, the constituent allantoin seems to help with cecal healing (102611). In addition, the wild yam constituent diosgenin prevents estrogen-induced bile flow suppression (5129) and attenuates indomethacin-induced intestinal inflammation (5131).\nHormonal effects\nThe chemical transformation of the wild yam constituent diosgenin to estrogen, progesterone, or other steroidal compounds is not thought to occur in the human body (515). However, wild yam does seem to have some estrogenic properties, although these properties vary between species. One wild yam extract enhances estradiol binding to estrogen receptors and induces transcription activity in estrogen-responsive cells (6180). In laboratory research, evaluation of four Dioscorea species, including D. oppositifolia (Chinese yam), D. alata, D. collettii var. hypoglaucau, and D. zingiberensis, found that only Dioscorea oppositifolia exhibits estrogenic effects on ovarian cells (96725). In animal research, the extract from Dioscorea oppositifolia increases levels of estradiol and follicle stimulating hormone (FSH), upregulates the expression of estrogen receptors in the uterus, and induces the proliferation of breast cancer cells via stimulation of estrogen receptors. Adenosine and arbutin are thought to be the constituents responsible for these estrogenic effects (96723). Postmenopausal adults who substitute 390 grams daily of wild yam (Dioscorea alata) for another staple food such as rice for 30 days have significant increases in serum estrone, sex hormone binding globulin, and possibly serum estradiol levels (13167). There is some evidence that the diosgenin constituent of wild yam might stimulate growth of mammary tissue (5130).\n\nTopically applied wild yam doesn't appear to cause changes in serum follicle stimulating hormone (FSH), estradiol, or progesterone (10989).\nNeurological effects\nIn animal studies, the wild yam constituent diosgenin improves memory deficits and enhances object recognition memory (96724)."
        }
    },
    "Willard Water": {
        "sections": {
            "Overview": "Willard water was developed in the early twentieth century at the South Dakota School of Mines by a chemistry professor named John Wesley Willard, Ph.D. It was developed and patented as an industrial cleanser to clean and degrease train parts. However, it became legendary among townsfolk who used Williard water to treat almost every disease known to humans and animals, and as a plant fertilizer. It is not recognized as safe or effective by the FDA (6).",
            "Safety": "There is insufficient reliable information available about the safety of Willard water.\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Effectiveness": "There is insufficient reliable information available about the effectiveness of Willard water.",
            "Dosing & Administration": "Adult\nNo typical dosage.",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "None known.",
            "Interactions with Lab Tests": "None known.",
            "Mechanism of Action": "The formula for Willard water has changed over time. Some of the ingredients found in products analyzed by the FDA included rock salt in various combinations, lignite, sodium metasilicate, sulfated castor oil, calcium chloride, and magnesium sulfate (18)."
        }
    },
    "Willow Bark": {
        "sections": {
            "Overview": "Willow bark is the bark of several species of willow tree including Salix alba (white willow or European willow), Salix nigra (black willow or pussy willow), Salix fragilis (crack willow), Salix purpurea (purple willow), and others. Willow bark is traditionally used to reduce pain and fever and was the original source of salicin, the prodrug for salicylic acid (86473, 91407).",
            "Warnings": "Coronavirus disease 2019 (COVID-19): Some experts have warned that willow bark might interfere with the body's immune and inflammatory response against COVID-19. There is no strong evidence to support these warnings, but there's also no evidence that willow bark has benefit against COVID-19 infection.",
            "Safety": "POSSIBLY SAFE when used orally and appropriately, short-term. Willow bark has been used safely for up to 12 weeks (6456, 12474, 12475, 12804, 12811, 86473, 91406).\nCHILDREN: POSSIBLY UNSAFE when used orally for viral infections. Salicylic acid and aspirin are contraindicated in children with viral infections (12801). Although Reye's syndrome has not been reported, the salicin constituent in willow bark is similar to aspirin and might pose the same risk.\nPREGNANCY: Insufficient reliable information available; avoid using.\nLACTATION: POSSIBLY UNSAFE when used orally. Willow bark contains salicylates which are excreted in breast milk and have been linked to adverse effects in breast-fed infants (12802, 12803).",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, willow bark seems to be well tolerated.\nMost Common Adverse Effects\nOrally: Diarrhea, dyspepsia, heartburn, and vomiting. May cause itching and rash in sensitive individuals.\nSerious Adverse Effects (Rare)\nOrally: Gastrointestinal bleeding and renal impairment. May cause serious allergic reactions, including anaphylaxis, in people who are allergic to aspirin.\nCardiovascular\nIn one clinical trial, a single patient withdrew from the study investigating oral willow bark due to blood pressure instability that the authors determined was 'possibly' related to treatment (12804).\nless\nDermatologic\nOrally, willow bark may cause itching and rash in some people due to allergy (6456, 12474, 12475, 12804, 86459).\nless\nGastrointestinal\nOrally, willow bark extract can cause gastrointestinal adverse effects, but these appear to be less frequent than those caused by NSAIDs. Examples include diarrhea, heartburn, vomiting, and dyspepsia (12474, 12475, 12804, 86459). In a case report of a child, severe gastrointestinal bleeding occurred following use of a specific syrup (FreddoBaby), which contained ribwort plantain, licorice, willow bark, black elder, meadowsweet, and propolis. The adverse effect was attributed to salicylate content of the syrup. This product has since been withdrawn from the market (86477).\nless\nImmunologic\nOrally, willow bark may cause serious allergic reactions, including anaphylaxis, in people who are allergic to aspirin (10392)\nless\nNeurologic/CNS\nOrally, willow bark may cause headache and dizziness (12804). In a clinical trial evaluating a combination product containing willow bark, black cohosh, sarsaparilla, poplar bark, and guaiac wood (Reumalex), severe headaches occurred (35946).\nless\nOcular/Otic\nOrally, symptoms of allergy to willow bark have included swollen eyes (6456).\nless\nRenal\nSalicylates can inhibit prostaglandins, which can reduce renal blood flow (12805). Salicin can cause renal papillary necrosis (12806). The risk for toxicity is greater with high acute doses or chronic use (12805).\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nPOSSIBLY EFFECTIVE\nBack pain. Oral willow bark extract has been evaluated for the treatment of back pain, with promising results.\nClinical research in patients with chronic low back pain shows that taking a standardized willow bark extract providing salicin 120 mg or 240 mg daily for 4 weeks reduces lower back pain and decreases the need for rescue analgesia when compared with placebo. Salicin 240 mg appears to be more effective than salicin 120 mg, and significant pain relief may be observed after 1 week of high-dose use (6456). Additional research suggests that taking willow bark extract providing salicin 240 mg daily for 4 weeks is as effective as rofecoxib (Vioxx) for lower back pain (12804).\nless\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nAnkylosing spondylitis. Although there has been interest in using oral willow bark for pain associated with ankylosing spondylitis, there is insufficient reliable information about the clinical effects of willow bark for this purpose.\nCommon cold. Although there has been interest in using oral willow bark for common cold symptoms, there is insufficient reliable information about the clinical effects of willow bark for this purpose.\nDysmenorrhea. Although there has been interest in using oral willow bark for dysmenorrhea, there is insufficient reliable information about the clinical effects of willow bark for this purpose.\nGout. Although there has been interest in using oral willow bark for gout, there is insufficient reliable information about the clinical effects of willow bark for this purpose.\nHeadache. Although there has been interest in using oral willow bark for headache, there is insufficient reliable information about the clinical effects of willow bark for this purpose.\nInfluenza. Although there has been interest in using oral willow bark for pain and fever associated with influenza, including swine flu, there is insufficient reliable information about the clinical effects of willow bark for this purpose.\nJoint pain. Oral willow bark has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nClinical research in patients with joint pain shows that taking capsules of a specific combination product (Instaflex Joint Support, Direct Digital) containing glucosamine sulfate 500 mg, methylsufonlylmethane 167 mg, white willow bark extract 83 mg, ginger root concentrate 17 mg, boswellia extract 42 mg, turmeric root extract 17 mg, cayenne 40 m H.U. 17 mg, and hyaluronic acid 1.3 mg three times daily for 8 weeks reduces joint pain severity by 37% compared to only 16% with placebo. However, the specific combination product does not appear to significantly improve joint stiffness or function when compared with placebo (89560). It is unclear if these findings are due to willow bark, other ingredients, or the combination.\nless\nMyalgia. Although there has been interest in using oral willow bark for myalgia, there is insufficient reliable information about the clinical effects of willow bark for this purpose.\nObesity. Oral willow bark has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nPreliminary clinical research suggests that willow bark in combination with ephedra and cola nut might cause modest weight loss in overweight and obese people. Willow bark 600 mg daily (containing 90 mg salicin) in divided doses given for 3 months in combination with these central nervous system stimulants might cause a 2 kg reduction in weight (12811). However, this combination may not be appropriate due to safety concerns associated with ephedra. Ephedra is banned in the US due to severe adverse effects (10055).\nless\nOsteoarthritis. Small clinical studies suggest that oral willow bark extract may improve symptoms of osteoarthritis, although some conflicting evidence exists.\nSome preliminary clinical research in patients with osteoarthritis shows that taking willow bark extract standardized to contain 240 mg of salicin daily for 2 weeks produces moderate analgesic activity when compared with placebo (12474, 86490). Additional research shows that taking a specific willow bark extract (Optovit actiFLEX, Hermes Arzneimittel GmbH) standardized to contain salicin 120-240 mg daily for 6 weeks improves swelling, tenderness, and physical function similarly to conventional non-steroidal anti-inflammatory drugs (NSAIDs) (91406). However, other research shows that taking willow bark extract standardized to 240 mg of salicin daily for 6 weeks does not improve pain, stiffness, or physical function when compared with placebo (12475).\nless\nRheumatoid arthritis (RA). It is unclear if oral willow bark is beneficial in patients with RA.\nClinical research in a small number of patients with RA shows that willow bark extract standardized to 240 mg of salicin daily for 6 weeks does not improve pain when compared with placebo (12475). However, it is possible this study was underpowered to detect a significant difference in pain in these patients.\nless\nMore evidence is needed to rate willow bark for these uses.",
            "Dosing & Administration": "Adult\nOral:\nWillow bark extract has most often been used in doses providing 120-240 mg of salicin daily for up to 6 weeks. See Effectiveness section for condition-specific information.\n\nWillow bark extracts are typically standardized to salicin content, with concentrations ranging from 6.7% to 30.7% (94105). Most products used in clinical research have been administered to provide salicin 120-240 mg daily (6456, 12474, 12475, 12804, 86490).\nStandardization & Formulation\nSpecific willow bark products used in clinical trials have included Optovit actiFLEX (Hermes Arzneimittel GmbH) and Assalix (Bionorica SE) (12804, 91406). Optovit actiFLEX is a standardized 70% ethanol extract of willow bark. Each tablet contains willow bark extract 393.24 mg standardized to salicin 60 mg (91406). Assalix is willow bark extract standardized to 15% salicin. Each capsule contains salicin 60 mg (12804).\n\nA combination product containing willow bark that has been used in clinical research includes Instaflex Joint Support (Direct Digital), which contains glucosamine sulfate 1500 mg, methylsufonlylmethane 500 mg, white willow bark extract 250 mg, ginger root concentrate 50 mg, Indian frankincense extract 125 mg, turmeric root extract 50 mg, cayenne 40 m H.U. 50 mg, and hyaluronic acid 4 mg per three capsules (89560).",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nACETAZOLAMIDE\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Anecdotal evidence)\nTheoretically, willow bark might result in additive adverse effects associated with acetazolamide.\nWillow bark contains salicin, a plant salicylate. Human case reports suggests that a combination of acetazolamide and salicylate increases unbound plasma levels of acetazolamide, as well as adverse effects related to acetazolamide (86481).\nless\nANTICOAGULANT/ANTIPLATELET DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPROBABLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, willow bark might increase the risk of bleeding when taken with anticoagulant/antiplatelet drugs.\nWillow bark has antiplatelet effects, but less so than aspirin (12810).\nless\nASPIRIN\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPROBABLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, willow bark might increase the effects and adverse effects of aspirin.\nWillow bark contains salicin, a plant salicylate. It might have an additive effect when taken with other salicylate-containing drugs such as aspirin (12808).\nless\nCHOLINE MAGNESIUM TRISALICYLATE (Trilisate)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPROBABLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, willow bark might increase the effects and adverse effects of choline magnesium trisalicylate.\nWillow bark contains salicin, a plant salicylate. It might have an additive effect when taken with other salicylate-containing drugs such as choline magnesium trisalicylate (12808).\nless\nSALSALATE (Disalcid)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPROBABLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, willow bark might increase the effects and adverse effects of salsalate.\nWillow bark contains salicin, a plant salicylate. It might have an additive effect when taken with other salicylate-containing drugs such as salsalate (12808).\nless",
            "Interactions with Supplements": "EXPAND ALL\n|\nCOLLAPSE ALL\nANTICOAGULANT/ANTIPLATELET HERBS AND SUPPLEMENTS\nWillow bark has antiplatelet effects.\nTaking willow bark with other herbs and supplements that have antiplatelet or anticoagulant effects could theoretically increase the risk of bleeding (12810). See products with anticoagulant activity here. See products with antiplatelet activity here.\nless\nSALICYLATE-CONTAINING HERBS\nWillow bark contains salicin, a plant salicylate.\nTaking willow bark with other salicylate-containing herbs could theoretically potentiate salicylate-related effects and adverse effects (12808). See products containing salicylate here.\nless",
            "Interactions with Conditions": "EXPAND ALL\n|\nCOLLAPSE ALL\nBLEEDING DISORDERS\nWillow bark has antiplatelet effects and could theoretically increase the risk of bleeding in individuals with bleeding disorders (12810).\nless\nKIDNEY DYSFUNCTION\nTheoretically, willow bark might worsen kidney function in patients with compromised kidney function. There is some concern that salicin might reduce renal blood flow (12805). Chronic use of high doses might contribute to renal failure in predisposed people (12806). Avoid use in people with compromised renal function.\nless\nPERIOPERATIVE\nWillow bark has antiplatelet effects, which might cause excessive bleeding if used perioperatively. Tell patients to discontinue willow bark at least 2 weeks before elective surgical procedures.\nless\nSALICYLATE PRECAUTIONS\nWillow bark contains salicin, a plant salicylate, and should be avoided or used cautiously in individuals with aspirin hypersensitivity, asthma, active peptic ulcer disease, diabetes, gout, hemophilia, hypoprothrombinemia, kidney or liver disease, or children with flu-like symptoms or Reye's syndrome (86464). Willow bark may cause serious allergic reactions, including anaphylaxis, in people who are allergic to aspirin (10392).\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with willow bark.",
            "Pharmacokinetics": "Absorption\nIntake of willow bark extract or salicin itself results in increased plasma levels of salicylic acid (12808, 86460). More than 80% of the salicin in willow bark is absorbed after oral administration (86482). Bioavailability of willow bark may be lower than synthetic salicylates due to manufacturing processes. A dose of 240 mg of salicin is equivalent to 87 mg of aspirin (12808).\nMetabolism\nPeak levels of salicylic acid, as well as its metabolites, salicyluric acid and gentisic acid, are reached within 2 hours after oral administration of willow bark extract. Approximately 86% of the total of these three metabolites is salicylic acid itself (12808).\nExcretion\nSalicyluric acid as the predominant metabolite in the urine after oral use of willow bark extract. The plasma half-life of salicylic acid appears to be 2.5 hours (12808).",
            "Mechanism of Action": "General\nWillow bark is the bark of Salix tree species such as the white willow. Willow bark constituents include flavonoids, tannins, and salicylates. The most active constituent of willow bark is thought to be salicin. Salicin is metabolized to salicyl alcohol and then to salicylic acid. From there, metabolism is the same as aspirin (12808). Other salicylates may include salicortin and tremulacin (86466). Salicin content of various willow species ranged from 0.04-12.6%; levels were dependent on the season, year of growth, and actual Salix species (86474, 86486). Although willow bark extracts are usually standardized to salicin content, some authors believe that polyphenols, such as flavonoids, may also play a role in the benefits of willow bark (86471, 91406).\nAnalgesic and anti-inflammatory effects\nPreliminary research suggests that willow bark extracts have analgesic and anti-inflammatory effects (12476, 86492). An ethanolic extract of willow bark seems to inhibit cyclooxygenase (COX)-2 mediated prostaglandin release, but it doesn't seem to directly affect COX-1 or COX-2 activity. Constituents of willow bark other than salicin may have lipoxygenase-inhibiting and antioxidant effects that could contribute to its analgesic effect (6456, 12476, 86467). They also might prevent prostaglandin and cytokine release (12476, 86492). Some research suggests that extended treatment with willow bark may be necessary for a therapeutic effect (12809, 12812).\nAntiplatelet effects\nWillow bark inhibits platelet aggregation, but to a lesser degree than aspirin (12810).\nAntipyretic effects\nPreliminary research suggests that willow bark extracts have antipyretic effects (12476).\nWeight loss effects\nWillow bark is sometimes included in weight loss supplements. Some evidence suggests that willow bark or aspirin and caffeine might act synergistically with ephedrine for weight loss by inhibiting prostaglandin, which increases norepinephrine release. However aspirin, and theoretically willow bark, have no thermogenic effect when given alone (314, 729, 10003, 12811)."
        }
    },
    "Wine": {
        "sections": {
            "Overview": "Wine is a beverage created through fermentation of grape juice. During fermentation, sugars in grape juice are converted to alcohol (506).",
            "Safety": "LIKELY SAFE when used orally, responsibly, and in moderation (11880, 97061).\nPOSSIBLY UNSAFE when used orally in excess of 1 or 2 5-oz glasses of wine daily. Larger amounts can cause significant adverse effects (11880). A 2025 Scientific Statement by the American Heart Association states that binge drinking or regular consumption of 3 or more alcoholic drinks per day, or 15 ounces of regular wine with 12% alcohol by volume, increases blood pressure and is associated with worse cardiovascular outcomes (116671).\nThere is insufficient reliable information available about the safety of wine when used topically.\nPREGNANCY: LIKELY UNSAFE when used orally; alcohol is a teratogen. Use during pregnancy is associated with significant risk of spontaneous abortion, fetal alcohol syndrome, and developmental and behavioral dysfunction in infants and children exposed to alcohol in utero (8100); avoid using.\nLACTATION: LIKELY UNSAFE when used orally. Alcohol is secreted in breast milk. Chronic use can cause abnormal psychomotor development and disrupt the infant's sleep-wake pattern. Alcohol also seems to reduce milk production (11878); avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, the side effects of wine depend on the amount of alcohol ingested and can vary among individuals.\nMost Common Adverse Effects\nOrally: Most adverse effects are associated with alcohol content and include abdominal pain, aggression, blackouts, central nervous system (CNS) depression, confusion, diarrhea, drowsiness, emotional lability, flushing, hypoglycemia, hypothermia, indigestion, lack of coordination and trouble walking, migraines, nausea, neuropathies, perceptual and sensational disturbances, and vomiting.\nSerious Adverse Effects (Rare)\nOrally: Chronic heavy alcohol ingestion (three or more drinks daily) can lead to amnesia, cardiac myopathy, cirrhosis, dementia, hepatotoxicity, malnutrition, myocardial infarction (MI), physical dependence, and somnolence. Other effects of chronic use are chronic cerebellar syndrome, hypomagnesemia, Korsakoff's psychosis, pancreatitis, skeletal myopathies, various types of cancer, and Wernicke's encephalopathy.\n\nChronic ingestion of 3 or more alcoholic beverages daily is associated with an increased risk of all-cause mortality, ischemic stroke, and hypertension. Consumption of any amount of alcohol can increase the risk of hemorrhagic stroke.\nCardiovascular\nOrally, chronic heavy alcohol ingestion of 3 or more drinks daily is associated with an increased risk of all-cause mortality, atrial fibrillation, cardiac myopathy, hypertension, ischemic stroke, and myocardial infarction (MI) (2261, 6843, 6892, 8102, 9004, 33984, 34028, 34054, 34058, 34059)(116671). A 2025 Scientific Statement by the American Heart Association states that binge drinking or regular consumption of 3 or more alcoholic drinks per day, or 15 ounces of regular wine with 12% alcohol by volume, increases blood pressure and is associated with worse cardiovascular outcomes (116671). Consumption of any amount of alcohol can increase the risk of hemorrhagic stroke (841, 2271).\nless\nGastrointestinal\nOrally, wine can cause a variety of side effects which depend on the amount of alcohol ingested and can vary among individuals. Some common side effects include abdominal pain, diarrhea, indigestion, nausea, and vomiting. (6843, 8972, 9004, 34013, 34031). Chronic alcohol use is also associated with pancreatitis (6843, 9004).\nless\nHepatic\nOrally, chronic heavy alcohol ingestion (3 or more drinks daily) can lead to cirrhosis and hepatotoxicity (6843, 9004).\nless\nImmunologic\nPeople who are allergic to sulfites and/or yeast might react to wine. Wine is associated with triggering asthmatic reactions in people with a history of asthma, possibly due to salicylates and/or added sulfites contained in wines (6174). A case report describes a 33-year-old female who developed allergic reactions ranging from mild symptoms to anaphylaxis after consumption of beer or wine. The allergy was attributed to the yeast Saccharomyces cerevisiae, which is used in the fermentation of both beverages (107819).\nless\nMusculoskeletal\nOrally, wine can cause a variety of side effects which depend on the amount of alcohol ingested and can vary among individuals. Some common side effects include lack of coordination and trouble walking. Other effects of chronic use include skeletal myopathies (6843, 8972, 9004).\nless\nNeurologic/CNS\nOrally, wine can cause a variety of side effects which depend on the amount of alcohol ingested and can vary among individuals. Some common side effects include blackouts, central nervous system (CNS) depression, drowsiness, lack of coordination and trouble walking, migraines, neuropathies, and perceptual and sensational disturbances. Chronic heavy alcohol ingestion (three or more drinks daily) can lead to amnesia, dementia, physical dependence, and somnolence. Other effects of chronic use are chronic cerebellar syndrome, Korsakoff's psychosis, and Wernicke's encephalopathy (6843, 8972, 9004, 34055, 34068).\n\nHeavy alcohol consumption (15 or more drinks weekly) is also associated with a higher percentage of white matter changes and larger ventricular and sulcal size on magnetic resonance imaging (MRI) of the brain. This suggests that heavy alcohol consumption decreases cerebral blood flow and may contribute to brain atrophy (8651). Consumption of any amount of alcohol can increase the risk of hemorrhagic stroke (841, 2271).\nless\nOncologic\nThere is evidence that heavy alcohol consumption is associated with the mutation of the p53 gene in individuals with esophageal carcinoma (9005). There is also some evidence that heavy consumption of wine is associated with the highest risk of esophageal cancer when compared with heavy consumption of beer and spirits (8972, 9004). Chronic heavy alcohol ingestion (three or more drinks daily) can lead to mouth cancer, esophageal cancer, pharyngeal cancer, laryngeal cancer, and liver cancer (6843, 8972, 9004, 31557, 33977, 34010, 34037, 34045, 34061, 34065)(34069, 34085). Some research suggests an association between alcohol consumption and an increased risk of pancreatic cancer, but other studies do not support this association (8038). Daily consumption of one or more alcoholic drinks in females might increase the risk of breast cancer by 2% to 15% and increase mortality from breast cancer by as much as 30% (6843, 8100, 8974, 9006, 96686). There is also evidence suggesting that females who consume alcohol daily have an increased risk of developing breast cancer when the daily intake of folate is 300 mcg or less (8974, 9006). However, the association of wine intake and breast cancer risk in females may vary depending on the type of wine. Red wine results in higher levels of free testosterone and luteinizing hormone (LH) and lower hormone binding globulin (SHBG) levels when compared with white wine. This suggests that red wine has similar activity to aromatase inhibitors and may not increase the risk of breast cancer unlike white wine (97992).\n\nObservational research suggests that wine consumption is associated with a higher risk of developing skin cancer in females and a higher risk of invasive melanoma in both males and females (97055, 97991).\nless\nPsychiatric\nOrally, wine can cause a variety of side effects which depend on the amount of alcohol ingested and can vary among individuals. Some common side effects include aggression, confusion, and emotional lability (6843, 9004, 34040). Chronic heavy alcohol ingestion (3 or more drinks daily) can lead to dementia, physical amnesia, and somnolence (6843, 8972, 9004).\nless\nPulmonary/Respiratory\nOrally, wine can cause a variety of side effects due to the alcohol content. The side effects depend on the amount ingested and can vary among individuals. A common side effect includes respiratory depression (6843, 8972, 9004). Wine is also associated with triggering asthmatic reactions in people with a history of asthma, possibly due to salicylates and/or added sulfites contained in wines (6174).\nless\nOther\nOrally, chronic heavy alcohol ingestion (3 or more drinks daily) can lead to malnutrition and poor glycemic control (6843, 8972, 9004).\n\nThere is some evidence consumption of more than 6 beers per week is associated with a larger waist-to-hip ratio than those consuming an equivalent amount of hard liquor or wine. However, an association between moderate alcohol intake equivalent to approximately 3 beers per week or less and waist-to-hip ratio does not seem to exist (10164, 10165). It is also unclear whether waist-to-hip ratios associated with the intake of wine, beer, or other alcoholic beverages have any clinical significance (9007).\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nPOSSIBLY EFFECTIVE\nCognitive function. Consumption of up to one alcoholic drink daily is associated with better cognitive function in older males.\nObservational research in elderly males suggests that a history of consuming up to 1 alcoholic drink daily is associated with better general cognitive function during their late 70s and 80s when compared with non-drinkers (6824, 6829). However, consumption of more than 4 drinks daily during middle age seems to be associated with significantly poorer cognitive function in later life (6824).\nless\nDiabetes. Light to moderate consumption of alcohol, including wine, is associated with a reduced risk of developing type 2 diabetes and a reduced risk of coronary heart disease (CHD) in those with existing type 2 diabetes. However, the benefits of wine in the management of type 2 diabetes are unclear.\nObservational research in healthy males suggests that light to moderate alcohol consumption from wine and other sources is associated with a reduced risk of developing type 2 diabetes (6172, 6891). A meta-analysis of 13 population studies suggests that drinking about 1.5-2 five-oz glasses of wine daily is associated with the greatest reduction in the risk of developing diabetes in both males and females, with a 20% lower risk when compared with never drinking wine (96699). Additionally, in patients with a history of gestational diabetes, consuming approximately 3 servings of wine weekly is associated with a 44% to 54% lower risk of developing type 2 diabetes when compared with no consumption in age-adjusted and multivariate analyses, although this result was no longer significant when adjusted for BMI. Consumption of 1-2 servings of wine weekly was associated with a 42% lower risk of developing type 2 diabetes in age-adjusted analyses only (105948).\n\nLight to moderate alcohol consumption, including wine, is also associated with a reduced risk of coronary heart disease (CHD) in males and females with type 2 diabetes when compared with non-drinkers with type 2 diabetes. The risk reduction for CHD associated with light to moderate alcohol consumption in patients with type 2 diabetes is similar to that found in people without diabetes who consume light to moderate amounts of alcohol (8653, 8654). Additionally, a cross-sectional study in patients with type 2 diabetes suggests an inverse association between moderate alcohol consumption and carotid intima media thickness (107816).\n\nHowever, despite these promising results in observational research, clinical studies specifically addressing wine consumption in patients with type 2 diabetes show mixed results. A meta-analysis of 9 small clinical studies, most of which had a short follow-up period, shows that moderate wine consumption does not improve glycemic control, blood pressure, or lipid levels when compared with control beverages or alcohol abstinence in patients with type 2 diabetes (103187). However, another study not included in the above analysis that evaluated people with diabetes who abstained from alcohol prior to the study shows that drinking 5 oz of white wine, but not red wine, daily for 2 years reduces fasting blood glucose by 17 mg/dL and reduces homeostatic model assessment of insulin resistance (HOMA-IR) score by 1.2 when compared with drinking mineral water. In a subgroup analysis of slow ethanol metabolizers (homozygous carriers of the wild-type C alcohol dehydrogenase alleles, ADH1B*1), drinking red or white wine improves glycemic control when compared with patients that are fast ethanol metabolizers (homozygous for ADH1B*2) (96697). Another clinical study in patients with type 2 diabetes who are consuming a Mediterranean diet shows that drinking 150 mL of red or white wine daily with dinner for 2 years prevents progression of carotid atherosclerosis, though no progression occurred in a control group consuming 150 mL of mineral water daily with dinner (99641).\nless\nHelicobacter pylori. Moderate to high alcohol consumption seems to reduce the risk of Helicobacter pylori infection.\nObservational research suggests that moderate to high consumption of alcohol, more than 75 grams weekly, from beverages such as beer and wine, is associated with a reduced risk of infection (8034).\nless\nOsteopenia. Observational research suggests that moderate alcohol consumption may improve bone mineral density (BMD) in postmenopausal patients.\nObservational research suggests that moderate alcohol consumption in postmenopausal patients is associated with increased BMD in the trochanter, femoral neck, mid-radius, and lumbar spine (6825, 6836, 8655). Alcohol intake of one-half to 1 drink daily seems to have the greatest effect on BMD when compared with non-drinkers and heavy drinkers of alcohol (8655).\nless\nOverall mortality. Light to moderate alcohol consumption seems to reduce the risk of all-cause mortality in middle-aged or older adults.\nObservational research suggests that light to moderate consumption of alcohol is associated with a reduced risk of all-cause mortality in people who are middle-aged or older (2058, 6823, 6837, 6843).\nless\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nAlzheimer disease. It is unclear if wine consumption is beneficial for preventing Alzheimer disease.\nA meta-analysis of observational research suggests that light to moderate consumption of alcohol (less than 7.5 drinks weekly or 12.5 grams daily), preferably wine, is associated with a reduced risk of developing dementia, including Alzheimer disease, when compared with non-drinkers. The lowest risk of dementia was observed with consumption of 4 drinks weekly or 6 grams daily (97063).\nless\nAnxiety. It is unclear if alcohol consumption is beneficial for anxiety.\nThe effect of alcohol on anxiety is complex and may be affected by the psychological state of the user. It sometimes reduces anxiety, sometimes increases it, and sometimes has no effect (2266).\nless\nAtherosclerosis. It is unclear if moderate alcohol consumption is beneficial for atherosclerosis.\nA cross-sectional study in patients with type 2 diabetes suggests an inverse association between moderate alcohol consumption and carotid intima media thickness (107816).\nless\nCancer. It is unclear if wine consumption is beneficial for preventing cancer or cancer-related mortality. The available evidence suggests variable effects depending on cancer type.\nObservational research suggests that intake of up to 21 alcoholic drinks weekly, including wine, is associated with a slightly reduced risk of cancer-related mortality (6823). However, a meta-analysis of 42 population studies suggests that wine intake is not associated with the overall risk of developing cancer, when comparing the highest intake and lowest intakes (116675). The association between wine consumption and risk of specific types of cancer has also been investigated. Moderate consumption of wine has been associated with a DECREASED risk of developing bladder cancer (97989), brain cancer (96695), renal cell cancer (97060, 97064), and multiple myeloma (97990). However, wine intake is not associated with changes in the risk of colorectal cancer (103189), endometrial cancer (97065), gastric cancer (96694), or lung cancer (116674). Furthermore, white wine consumption has been associated with an INCREASED risk of breast cancer, and skin cancer (96686, 97991, 116675). Results of a meta-analysis suggest that moderate to heavy consumption of alcohol, including wine, in males is associated with an 11% reduction in the risk of developing non-Hodgkin lymphoma (99638).\nless\nCardiovascular disease (CVD). Most observational research suggests that light to moderate consumption of alcoholic beverages is associated with a reduced risk of developing cardiovascular disease, and a reduced risk of cardiovascular-related death. However, clinical research is limited. Also, binge drinking or regular consumption of 3 or more alcoholic drinks per day is associated with worse cardiovascular outcomes.\nSome population research suggests that consumption of alcoholic drinks, including wine, by otherwise healthy adults is associated with a reduced risk of developing CVD. Moderate alcohol use (1-2 drinks daily) is associated with a 30%-50% reduced risk of coronary heart disease, atherosclerosis, and myocardial infarction (MI) when compared with nondrinkers (2267, 2268, 2271, 6888, 6892, 8648, 8649, 10128, 11879, 96690)(116672). Other observational research suggests that drinking one or fewer glasses of wine weekly over 10 years is associated with a 60% lower risk of cardiovascular events. Light to moderate alcohol consumption is also associated with a reduced risk of ischemic stroke (2271, 2279, 6834, 6842, 6893). There is some evidence that light to moderate consumption of alcoholic drinks (1-2 drinks daily), including wine, is also associated with a reduced risk of all-cause mortality in people who are middle-aged or older (2058, 6823, 6837, 6843). The relationship between alcohol consumption and cardiovascular mortality has also been investigated. Population research suggests that light to moderate consumption of alcohol is associated with a reduced risk of cardiovascular mortality in otherwise healthy adults (2058, 2270, 6835, 6837, 116672). Also, light to moderate alcohol consumption in the year prior to a first acute MI is associated with reduced cardiovascular and all-cause mortality risk when compared with non-drinkers (8650).\n\nHowever, more than 2 drinks daily can increase the risk of cardiovascular and overall mortality (841, 2060, 2261, 6173, 6890, 8648, 11879). A 2025 Scientific Statement from the American Heart Association concludes that while the available evidence shows that consuming 1-2 alcoholic drinks per day does not INCREASE the risk for coronary artery disease, heart failure, sudden cardiac death, and stroke, it only POSSIBLY supports a risk reduction (116671). This statement is based on the overall lack of evidence from randomized clinical trials investigating the effect of light to moderate alcohol consumption on cardiovascular outcomes. A large meta-analysis suggests that individuals who report light to moderate consumption of alcohol have overall healthier lifestyles than those who abstain from alcohol and adjusting for these lifestyle factors attenuates any of the cardioprotective epidemiological effects that have been associated with light to moderate alcohol intake (107884). Also, population research suggests that drinking more than 1 glass of wine weekly is not associated with lower cardiovascular risk when compared with abstaining from alcohol (102886). Consuming any amount of alcohol is associated with an increased risk of hemorrhagic stroke (841, 2271, 6842).\n\nAlcohol consumption has also been evaluated in patients with existing CVD. A meta-analysis of cohort data as well as published observational and randomized controlled studies in patients with existing CVD suggests that consumption of 6-8 grams of alcohol daily is associated with a 21%, 27%, and 50% reduction in all-cause mortality, cardiovascular mortality, and cardiovascular events, respectively, when compared with non-drinkers (107817). However, in males with established coronary heart disease (CHD), consumption of 1-14 alcoholic drinks weekly, including wine, does not seem to have any effect on CVD or all-cause mortality when compared with males who drink less than 1 drink weekly. Further, in males with a history of MI, consuming 3 or more drinks daily is associated with increased mortality (6173).\nless\nCongestive heart failure (CHF). While light to moderate consumption of alcohol is associated with a reduced risk of developing CHF in older adults and a reduction in all-cause mortality in those with ischemic left ventricular (LV) dysfunction, it is unclear if moderate wine consumption is associated with these benefits.\nObservational research in adults 65 years or older suggests that consuming 1-4 alcoholic drinks daily is associated with a reduced risk of CHF (8104). There is conflicting evidence about whether moderate alcohol consumption improves outcomes in patients that already have CHF, although no exacerbation of CHF was found. Consumption of 1-14 alcoholic drinks per week is associated with reduced all-cause mortality in people with ischemic LV dysfunction when compared with non-drinkers with ischemic LV dysfunction. This benefit does not seem to occur for those patients with non-ischemic LV dysfunction (6827). However, other observational research has not found an inverse association between moderate wine consumption and rates of all-cause mortality, sudden death, or hospitalization in chronic heart failure patients (96689).\nless\nDementia. It is unclear if wine consumption is beneficial for dementia.\nA meta-analysis of observational research suggests that light to moderate consumption of alcohol (less than 7.5 drinks weekly or 12.5 grams daily), preferably wine, is associated with a reduced risk of all-cause dementia when compared with non-drinkers. The lowest risk of dementia was observed with consumption of 4 drinks weekly or 6 grams daily. However, consumption of 23 or more alcoholic drinks weekly is associated with an increased risk of all-cause dementia (97063).\nless\nDepression. It is not clear if wine consumption is beneficial for depression.\nObservational research suggests that low to moderate consumption of wine (2-7 drinks weekly) is associated with a 32% lower rate of depression when compared with not consuming wine (96696).\nless\nMetabolic syndrome. There is limited evidence on the consumption of red wine for metabolic syndrome.\nObservational research suggests that moderate red wine consumption (at least one 5-ounce glass daily) is associated with a 44% lower odds of developing metabolic syndrome when compared with not drinking any red wine. The association appears to be strongest for females less than 70 years-old and for people who currently smoke or have a history of smoking. Drinking white wine does not seem to affect the risk of metabolic syndrome (97062).\nless\nObesity. It is unclear if wine consumption is beneficial in patients with obesity.\nSome observational research in non-smokers suggests that higher wine consumption in adolescence is linked to lower mid-life body mass index (BMI) when compared with lower wine consumption. No association between wine consumption and mid-life BMI was reported in adolescent smokers over a 20-year follow-up (103188). It is unknown if wine consumption reduces the risk of developing obesity or improves weight loss in obese patients.\nless\nSystemic lupus erythematosus (SLE). It is unclear if wine consumption is beneficial in preventing SLE in females.\nObservational research suggests that modest daily alcohol consumption is associated with a reduced risk of developing SLE in females. When the data were stratified by alcohol type, 2 or more servings of wine weekly was associated with a 35% reduced risk of developing SLE when compared with not drinking alcohol (96684).\nless\nWound healing. Although there has been interest in topical wine for wound healing, there is insufficient reliable information about the clinical effects of alcohol for this purpose.\nMore evidence is needed to rate wine for these uses.",
            "Dosing & Administration": "Adult\nOral:\nGeneral: Alcohol intake is often measured in number of \"drinks\". One drink is equivalent to a 4 oz or 120 mL glass of wine, 12 oz of beer, or 1 oz of spirits.\n\nMost of the beneficial effects of alcohol have been demonstrated with light to moderate consumption, though definitions on what constitutes such consumption vary.\nStandardization & Formulation\nThere is insufficient available information about the standardization of wine.",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nACITRETIN (Soriatane)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPROBABLE\nLevel of Evidence\nB (Nonrandomized clinical trial)\nConcomitant use increases the risk of long-term teratogenic effects.\nAlcohol increases the transesterification of acitretin to etretinate, which is a teratogen that can remain in the body for years after discontinuation of acitretin. Patients of reproductive potential should avoid alcohol completely while taking acitretin and at least 2 months after discontinuation (108003).\nless\nANTIDIABETES DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPROBABLE\nLevel of Evidence\nC (Consensus)\nConcomitant use may interfere with blood glucose control.\nAlcohol can impair gluconeogenesis and may increase the risk of acute hypoglycemia when used concomitantly with antidiabetes drugs (2262). However, the carbohydrates in wine may also worsen glycemic control in patients with diabetes.\nless\nANTIHYPERTENSIVE DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPROBABLE\nLevel of Evidence\nB (Lower quality RCT)\nTheoretically, concomitant use may interfere with blood pressure control.\nClinical research suggests that consumption of alcohol can increase both systolic and diastolic blood pressure (34015, 34050, 34052, 34053). However, acute alcohol intoxication can also increase the risk of hypotension and additive effects with antihypertensive drugs (2262).\nless\nASPIRIN\nInteraction Rating\nMAJOR Do not take this combination.\nSeverity\nHIGH\nOccurrence\nPROBABLE\nLevel of Evidence\nC (Consensus)\nConcomitant use may increase the risk of gastrointestinal (GI) bleeding.\nConcomitant use of aspirin with alcohol may increase the risk of GI bleeding (2262).\nless\nBUPROPION (Wellbutrin)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Anecdotal evidence)\nTheoretically, concomitant use may increase the risk of adverse effects from alcohol.\nIn patients taking bupropion, there have been rare reports of adverse psychiatric events or reduced alcohol tolerance. Additionally, in chronic alcohol users, abrupt discontinuation of alcohol while taking bupropion may increase the risk of seizure (108023).\nless\nCEFAMANDOLE (Mandol)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nC (Consensus)\nConcomitant use may cause a disulfiram-like reaction.\nCefamandole can cause a disulfiram-like reaction when taken with alcohol (2262).\nless\nCEFOPERAZONE (Cefobid)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nC (Consensus)\nConcomitant use may cause a disulfiram-like reaction.\nCefoperazone can cause a disulfiram-like reaction when taken with alcohol (2262).\nless\nCETIRIZINE (Zyrtec)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, concomitant use might increase the risk of CNS impairment.\nCetirizine may cause somnolence in some patients. There is some concern that taking cetirizine in conjunction with alcohol might reduce alertness and impair CNS performance (108022).\nless\nCHLORPROPAMIDE (Diabinese)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPROBABLE\nLevel of Evidence\nC (Consensus)\nConcomitant use may cause a disulfiram-like reaction.\nChlorpropamide can cause a disulfiram-like reaction when taken with alcohol (506).\nless\nCISAPRIDE (Propulsid)\nInteraction Rating\nMAJOR Do not take this combination.\nSeverity\nHIGH\nOccurrence\nPROBABLE\nLevel of Evidence\nB (Lower quality RCT)\nConcomitant use may increase blood alcohol levels and adverse effects.\nConcomitant use of alcohol can increase blood alcohol levels and adverse effects (2262). Also, red wine increases plasma cisapride concentrations, possibly by reducing metabolism (1383).\nless\nCITALOPRAM (Celexa)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Anecdotal evidence)\nTheoretically, concomitant use might increase the risk of adverse effects from alcohol.\nSome case reports suggest that citalopram may reduce alcohol tolerance and increase the risk of adverse effects from alcohol (108024).\nless\nCNS DEPRESSANTS\nInteraction Rating\nMAJOR Do not take this combination.\nSeverity\nHIGH\nOccurrence\nLIKELY\nLevel of Evidence\nC (Consensus)\nConcomitant use may increase sedative and other adverse effects.\nConcomitant use of alcohol with CNS depressants can increase sedative and other adverse effects, potentially through inhibition of the metabolism of certain CNS depressants (2262).\nless\nCYCLOSPORINE (Neoral, Sandimmune)\nInteraction Rating\nMAJOR Do not take this combination.\nSeverity\nHIGH\nOccurrence\nPROBABLE\nLevel of Evidence\nB (Lower quality RCT)\nRed wine can reduce the levels and clinical effects of cyclosporine.\nRed wine reduces plasma cyclosporine concentrations, possibly by reducing cyclosporine absorption. There is evidence the reduction in cyclosporine AUC by red wine is less in Asians (8% to 14%) than Caucasians (35% to 36%) (1384, 1387, 8977).\nless\nDISULFIRAM (Antabuse)\nInteraction Rating\nMAJOR Do not take this combination.\nSeverity\nMODERATE\nOccurrence\nLIKELY\nLevel of Evidence\nC (Consensus)\nConcomitant use may cause a disulfiram reaction.\nDisulfiram can cause a disulfiram reaction when taken with alcohol (2262). Patients taking disulfiram should not consume any alcohol.\nless\nDOXYCYCLINE (Vibramycin)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nB (Nonrandomized clinical trial)\nChronic alcohol use might reduce the levels and clinical effects of doxycycline.\nAlthough acute alcohol ingestion does not seem to significantly impact the pharmacokinetics of doxycycline, chronic alcohol ingestion has been shown to significantly reduce the half-life and serum concentration of doxycycline (107998).\nless\nELUXADOLINE (Viberzi)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nA (High-quality randomized controlled trial (RCT))\nChronic or excessive alcohol use might increase the risk of pancreatitis from eluxadoline.\nIn clinical studies, the risk of pancreatitis with eluxadoline was increased in chronic alcohol users and in those with acute intake of 3 or more alcoholic beverages daily (108004).\nless\nERYTHROMYCIN\nInteraction Rating\nMAJOR Do not take this combination.\nSeverity\nHIGH\nOccurrence\nPROBABLE\nLevel of Evidence\nC (Consensus)\nConcomitant use may increase blood alcohol levels and adverse effects.\nConcomitant use of erythromycin with alcohol can increase blood alcohol levels and adverse effects (2262).\nless\nFELODIPINE (Plendil)\nInteraction Rating\nMAJOR Do not take this combination.\nSeverity\nHIGH\nOccurrence\nPROBABLE\nLevel of Evidence\nB (Lower quality RCT)\nConsumption of red wine can rapidly increase felodipine levels and adverse effects.\nRed wine taken on an empty stomach can cause \"dose dumping\" of extended-release felodipine, possibly by changing absorption or metabolism. Red wine can delay the appearance of felodipine in plasma until 4 hours after dosing and can rapidly increase its plasma concentration, producing peak serum levels 3 to 4 times higher than when felodipine is given with water. This can cause an increase in adverse effects 5 hours after dosing (11976).\nless\nFLIBANSERIN (Addyi)\nInteraction Rating\nMAJOR Do not take this combination.\nSeverity\nHIGH\nOccurrence\nPROBABLE\nLevel of Evidence\nA (High-quality randomized controlled trial (RCT))\nConcomitant use increases the risk of severe hypotension and syncope.\nAlcohol use is contraindicated in patients taking flibanserin due to the risk of severe hypotension and syncope (108002).\nless\nGRISEOFULVIN (Fulvicin)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nC (Consensus)\nConcomitant use may cause a disulfiram-like reaction.\nGriseofulvin can cause a disulfiram-like reaction, including tachycardia and facial flushing, when taken with alcohol (2262).\nless\nH2-BLOCKERS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nC (Consensus)\nConcomitant use might increase blood alcohol levels and adverse effects.\nConcomitant use of the H2-blockers cimetidine and ranitidine with low doses of alcohol (0.15 grams/kg) might increase blood alcohol levels and adverse effects. Effects with higher doses of alcohol (0.3-1.5 grams/kg) are variable (2262).\nless\nHEPATOTOXIC DRUGS\nInteraction Rating\nMAJOR Do not take this combination.\nSeverity\nHIGH\nOccurrence\nPROBABLE\nLevel of Evidence\nC (Consensus)\nConcomitant use of alcohol with hepatotoxic drugs may increase the risk of hepatotoxicity.\nConcomitant use of excessive amounts of alcohol with potentially hepatotoxic drugs can increase the risk of liver damage (2262).\nless\nLEVOCETIRIZINE (Xyzal)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, concomitant use might increase the risk of CNS impairment.\nLevocetirizine may cause somnolence in some patients. There is some concern that taking levocetirizine in conjunction with alcohol might reduce alertness and impair CNS performance (108026).\nless\nLEVOMILNACIPRAN (Fetzima)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, concomitant use may increase the absorption and elimination of levomilnacipran.\nIn vitro research shows that alcohol increases the release of levomilnacipran from extended-release capsules, resulting in complete drug release in 4 hours (108024). This effect has not been evaluated in humans.\nless\nMETFORMIN (Glucophage)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nC (Consensus)\nConcomitant use may increase the risk of lactic acidosis.\nConcomitant consumption of large amounts of alcohol can increase the risk of lactic acidosis with metformin (107995).\nless\nMETRONIDAZOLE (Flagyl)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nC (Consensus)\nConcomitant use may cause a disulfiram-like reaction.\nAlthough there is some disagreement over the likelihood of a disulfiram-like reaction with concomitant use of alcohol and metronidazole (108000), prescribing materials recommend discontinuing alcohol intake during the use of metronidazole. In the US, it is recommended to discontinue alcohol during and for at least three days after therapy with metronidazole (107999); in Canada, it is recommended to discontinue alcohol during and for at least 1 day after therapy with metronidazole (108001).\nless\nMONOAMINE OXIDASE INHIBITORS (MAOIs)\nInteraction Rating\nMAJOR Do not take this combination.\nSeverity\nHIGH\nOccurrence\nPROBABLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nConcomitant use may cause hypertensive crisis.\nWine contains tyramine (105702), which is metabolized by monoamine oxidase. Concurrent use of MAOIs with tyramine-containing beverages can lead to elevated levels of tyramine in the body. This can increase the effects of tyramine, which has been reported to cause hypertension, headache, and hypertensive crisis in numerous cases (100189, 100192, 101010). Sensitivity to tyramine can increase up to 10-fold to 100-fold in people using an MAOI (100189, 101010).\nless\nNARCOTIC DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nC (Consensus)\nConcomitant use of large amounts of alcohol may decrease the metabolism of narcotic drugs.\nConcomitant consumption of large amounts of alcohol can decrease the metabolism of narcotic drugs (2262).\nless\nNONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs)\nInteraction Rating\nMAJOR Do not take this combination.\nSeverity\nHIGH\nOccurrence\nPROBABLE\nLevel of Evidence\nC (Consensus)\nConcomitant use may increase the risk of gastrointestinal (GI) bleeding.\nConcomitant use of NSAIDs with alcohol may increase the risk of GI bleeding (2262).\nless\nPHENYTOIN (Dilantin)\nInteraction Rating\nMAJOR Do not take this combination.\nSeverity\nHIGH\nOccurrence\nPROBABLE\nLevel of Evidence\nC (Consensus)\nConcomitant use may decrease the effectiveness of phenytoin.\nChronic, heavy alcohol use can induce the metabolism, reducing therapeutic effectiveness of phenytoin (2262).\nless\nSECNIDAZOLE (Solosec)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Anecdotal evidence)\nConcomitant use may cause a disulfiram-like reaction.\nAlthough high quality evidence is lacking, there is concern that secnidazole can cause a disulfiram-like reaction when taken with alcohol. Prescribing materials in the US recommend discontinuation of alcohol during and for at least two days after therapy with secnidazole (107996).\nless\nSULFONAMIDE ANTIBIOTICS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nC (Consensus)\nConcomitant use may cause a disulfiram-like reaction.\nSulfonamide antibiotics can cause a disulfiram-like reaction when taken with alcohol (2262).\nless\nTINIDAZOLE (Tindamax)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Anecdotal evidence)\nConcomitant use may cause a disulfiram-like reaction.\nAlthough high quality evidence is lacking, there is concern that tinidazole can cause a disulfiram-like reaction when taken with alcohol. Prescribing materials in the US recommend discontinuation of alcohol during and for at least three days after therapy with tinidazole (107997).\nless\nTOLBUTAMIDE (Orinase)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nC (Consensus)\nTheoretically, concomitant use may cause a disulfiram-like reaction.\nTolbutamide can cause a disulfiram-like reaction when taken with alcohol (2262).\nless\nVARENICLINE (Chantix)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Anecdotal evidence)\nTheoretically, concomitant use may increase the risk of adverse effects from alcohol.\nThere have been reports of patients experiencing increased effects from alcohol while taking varenicline. Some cases involved unusual and sometimes aggressive behavior and were accompanied by amnesia (108021). Caution patients to use alcohol with caution when taking varenicline, as it may alter alcohol tolerance.\nless\nVASODILATORS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPROBABLE\nLevel of Evidence\nC (Consensus)\nConcomitant use may increase the risk of acute hypotension.\nAcute alcohol intoxication can increase the risk of hypotension and additive effects with vasodilators (2262).\nless\nWARFARIN (Coumadin)\nInteraction Rating\nMAJOR Do not take this combination.\nSeverity\nHIGH\nOccurrence\nPROBABLE\nLevel of Evidence\nC (Consensus)\nAlcohol can alter the effects of warfarin, although the exact effect depends on the nature of alcohol consumption.\nAcute alcohol intoxication can decrease metabolism and increase the effects of warfarin. In contrast, chronic, heavy alcohol use can induce metabolism of warfarin, reducing therapeutic effectiveness (2262).\nless",
            "Interactions with Supplements": "EXPAND ALL\n|\nCOLLAPSE ALL\nBETA-CAROTENE\nConsuming alcohol can lower levels of beta-carotene in the body.\nDrinking about three 5-ounce glasses of wine daily for 3 weeks decreases plasma beta-carotene levels by 15% when compared with drinking water (33986). Chronic alcohol intake is typically associated with low serum beta-carotene levels (97528). In addition, high consumption of alcohol can increase serum concentrations of retinol, a form of vitamin A for which beta-carotene is a precursor. Researchers are concerned that increased retinol concentrations might promote carcinogenesis (10134).\nless\nHERBS AND SUPPLEMENTS WITH SEDATIVE PROPERTIES\nAlcohol has sedative effects and can cause central nervous system depression.\nConsumption of alcohol with herbs that have sedative properties might enhance adverse effects (2262). See other products with sedative-hypnotic activity here.\nless\nTHIAMINE\nConsuming alcohol can lower levels of thiamine.\nConcomitant chronic use of alcohol might interfere with the absorption of thiamine, leading to thiamine deficiency and serious sequelae such as Wernicke-Korsakoff syndrome (2263, 11075). Concomitant use might also interfere with the absorption of other B vitamins and other nutrients (2263).\nless\nTYRAMINE\nTaking tyramine along with fermented beverages, such as wine, can increase the risk for serious adverse effects.\nFermented beverages, such as wine, contain tyramine (15702). These beverages might increase the risk of hypertensive crisis when taken with tyramine supplements.\nless\nVITAMIN B12\nConsuming alcohol can modestly lower levels of vitamin B12.\nClinical research shows that moderate alcohol consumption (30 grams daily) for 8 weeks, reduces serum vitamin B12 concentrations by 5% when compared with not drinking alcohol (97517). Concomitant chronic use of alcohol might interfere with absorption of vitamin B12, other B vitamins, and other nutrients (2263).\nless\nVITAMIN C\nConsuming alcohol can lower levels of ascorbic acid or vitamin C.\nAlcohol intake can increase urinary excretion of vitamin C by 47% (90941). While reductions in vitamin C levels do not always occur in healthy patients (33986, 90939), patients with chronic alcohol use or patients that are acutely unwell or critically ill might experience vitamin C deficiency and possibly scurvy (90940, 97527).\nless",
            "Interactions with Conditions": "EXPAND ALL\n|\nCOLLAPSE ALL\nASTHMA\nWine is associated with triggering asthmatic reactions, possibly due to salicylates and/or added sulfites contained in wines (6174).\nless\nGASTROESOPHAGEAL REFLUX DISEASE (GERD)\nAlcohol use can exacerbate GERD (2261, 2263).\nless\nGOUT\nAlcohol use may exacerbate gout (2263) and increase plasma levels of uric acid (19691, 33986, 33993).\nless\nHEART CONDITIONS\nAlcohol use can exacerbate variant angina, congestive heart failure (CHF) (2261, 2263, 6889) and idiopathic cardiomyopathy (6889).\nless\nHYPERTENSION\nConsuming three or more alcoholic drinks daily can increase blood pressure and exacerbate hypertension (2261, 34015, 34050, 34052, 34053).\nless\nINSOMNIA\nAlcohol use can exacerbate insomnia (2263).\nless\nLIVER DISEASE\nAlcohol use can exacerbate liver disease (2261).\nless\nNEUROLOGICAL CONDITIONS\nAlcohol use can exacerbate degenerative neurological conditions (6889).\nless\nPANCREATITIS\nAlcohol use can exacerbate pancreatitis (2261).\nless\nPEPTIC ULCERS\nAlcohol use can exacerbate peptic ulcers (2261, 2263).\nless\nPORPHYRIA\nAlcohol use can exacerbate porphyria (2261).\nless\nPSYCHIATRIC DISORDERS\nConsuming three or more alcoholic drinks daily can exacerbate psychiatric disorders and increase cognitive impairment (2261). Additionally, patients with psychiatric disorders are more likely to be taking one or more medications with central nervous system (CNS) activity, which may increase the risk of adverse effects. Alcohol should be used with caution and in moderation in these patients.\nless\nPERIOPERATIVE\nTheoretically, consuming alcohol might cause additive CNS depression when combined with anesthesia and other medications during and after surgical procedures. Alcohol has CNS depressant effects. Tell patients to discontinue alcohol use at least 2 weeks before elective surgical procedures.\nless",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with wine.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of wine.",
            "Mechanism of Action": "General\nWine is the natural yeast fermentation product of the juice of sun-ripened grapes, the fruit of Vitis vinifera. Wine normally contains 10% to 14% alcohol, predominantly as ethanol, which is a central nervous system (CNS) depressant (2263).\nAnti-inflammatory effects\nIn an ex vivo study, light to moderate daily wine consumption in patients with cardiovascular disease attenuated the effects of inflammatory cytokine secretion from peripheral blood mononuclear cells at basal conditions when compared with alcohol not containing wine microconstituents (107820).\nAnticancer effects\nRed wine results in higher levels of free testosterone, lower sex hormone binding globulin (SHBG) levels, and higher luteinizing hormone (LH) levels compared to white wine in females. This suggests that red wine has similar activity to aromatase inhibitors and may not increase the risk of breast cancer unlike white wine (97992).\nAntidiabetes effects\nModerate alcohol intake may be protective against the development of type 2 diabetes due to an increase in insulin sensitivity as shown by a decrease in the homeostatic model assessment of insulin resistance (HOMA-IR) score and decreased plasma insulin (6891, 96697). There is some research that suggests that light to moderate alcohol consumption is associated with a reduction in the low-grade systemic inflammation associated with type 2 diabetes. However, plasma levels of specialized pro-resolving mediators of inflammation (SPMs), which drive resolution of this inflammation and are elevated in people with type 2 diabetes, were not affected by daily consumption for 4 weeks of 300 mL of red wine in men or 230 mL of red wine in women (99642).\nAntiplatelet effects\nSeveral red wine components, including trans-resveratrol, quercetin, and catechins, have in vitro antiplatelet effects (2057). Red wine and white wine seem to have similar effects on platelets (2057, 2949). Human data also suggest rebound hypercoagulability can occur when acute or chronic alcohol consumption stops, but that red wine attenuates this effect (2060, 2061).\nBone effects\nModerate alcohol consumption may be protective against postmenopausal bone loss due to an increase in estrogen levels, increased calcitonin secretion, and reduced parathyroid hormone secretion (6825, 6836, 8655). However, heavy and chronic alcohol consumption reduces bone mineral density, possibly due to increased calcium and magnesium excretion, increased cortisol secretion, and reduced osteoblast activity (6836, 8656). Chronic alcoholics also have other risk factors for osteoporosis, including poor nutrition, smoking, sedentary lifestyle, and lower body weight (6825, 6836).\nCardiovascular effects\nSeveral mechanisms have been proposed for the protective effects of alcohol against coronary heart disease (CHD) (2060, 2268, 2270, 6839, 6840). One to two alcoholic drinks per day increases high-density lipoprotein (HDL) cholesterol by about 12% (6892) and apolipoprotein A-I by about 2.2% (8649). This increase in HDL cholesterol levels may account for about 50% of the cardioprotective effect of moderate alcohol consumption (2261, 6838, 6841).\n\nModerate alcohol consumption also decreases low-density lipoprotein (LDL) cholesterol by 5% to 17% (6841, 8649), triglycerides by 5% to 10%, and apolipoprotein B levels by 3.7% (8649).\n\nSome research has suggested that ceramides are a better predictor of CVD than traditional risk biomarkers. A small clinical study of older adults at high CVD risk shows that drinking white wine in combination with the antioxidant tyrosol modulates the blood lipid profile, including reductions in the ratios of certain ceramides and attenuation of changes in plasma diacylglycerol levels, when compared with white wine alone (107821).\n\nThere is concern that moderate alcohol consumption can increase systolic blood pressure (6841). However, there is evidence that light to moderate alcohol consumption does not increase the risk of hypertension and may actually decrease the risk (8102). Furthermore, clinical studies assessing wine polyphenols alone found no significant effects on blood pressure. Clinical research shows that drinking a dairy drink containing specific red wine polyphenols (Provinols, Seppic S.A.) 280 mg or 560 mg daily for 4 weeks does not reduce blood pressure compared to placebo in hypertensive patients that are not at risk for cardiovascular disease. Normally 2-3 glasses of wine contain about 560 mg of polyphenols (96685). Further clinical research shows that taking grape extract (MegaNatural) 250 mg with wine extract (Provinols, Seppic S.A) 550 mg daily for 4 weeks is no different than placebo for lowering blood pressure in patients with hypertension (96693).\n\nIt is possible that wine polyphenols are more effective when administered together with other natural wine constituents. For example, another small clinical study shows that drinking dealcoholized red wine daily for 4 weeks reduces blood pressure and increases serum nitric oxide levels compared to drinking red wine containing 30 grams of alcohol or gin containing 30 grams of alcohol in older men at high cardiovascular risk (96687, 96688).\n\nEffects of alcohol on blood clotting include a reduction in clotting potential and enhancement of clot breakdown (2261). Alcohol consumption decreases platelet aggregation, possibly via inhibition of prostaglandin synthesis (6892). Moderate alcohol consumption is also associated with an increase in plasma levels of tissue-type plasminogen activator, an indicator of fibrinolytic capacity (6894). Alcohol also seems to lower fibrinogen and interleukin-1 alpha concentrations (11943). Light to moderate alcohol consumption also seems to produce a reduction in coronary narrowing due to atherosclerosis (2261, 6840, 8652).\n\nRed wine may also have anti-inflammatory effects. It reduces plasma levels of inflammatory factors including high sensitivity C-reactive protein (hs-CRP), interleukin (IL)-6, IL-10, and tumor necrosis factor-alpha. This follows a reduction in expression of various intercellular cell adhesion molecules, such as intercellular cell adhesion molecule-1 and vascular cell adhesion molecule-1 (VCAM-1. These markers of inflammation lead to endothelial injury and atherosclerosis (11943, 116673).\n\nAnother theory is that drinking wine can increase omega-3 fatty acid levels in the blood. Omega-3 fatty acid levels have been associated with reduced mortality from heart disease. A retrospective study found increased eicosapentaenoic acid (EPA) associated with increased wine ethanol intake (96692).\n\nThere is also evidence that an increased intake of dietary folate or the use of supplemental folate (400 mcg/day) in moderate alcohol users can lower homocysteine levels compared with nonusers of alcohol (8101). High levels of homocysteine are a risk factor for cardiovascular disease. Homocysteine breakdown and removal requires folate, and alcohol is an antagonist of folate metabolism (8101). The protective effect of alcohol against cardiovascular disease is lost at higher intakes of alcohol (greater than one to two drinks per day). High alcohol consumption can cause increased homocysteine levels, hypertension, hemorrhagic stroke, fatal arrhythmias, and direct damage to heart muscle (alcoholic cardiomyopathy) (2060, 2261, 2267, 2270, 8101, 8102, 8103).\n\nSome alcoholic beverages, in particular red wine, have constituents that may be more protective than others against coronary heart disease, but there is no conclusive evidence of this from clinical studies (2267, 2268, 6892).\n\nRed wine has higher concentrations of polyphenolic compounds than other alcoholic drinks. The antioxidant properties of these polyphenols may contribute to protection against coronary heart disease by reducing oxidation of LDL cholesterol (2268). The polyphenolic compounds in red wine include trans-resveratrol; proanthocyanidins; anthocyanins; and flavonoids such as quercetin, kaempferol, and catechins (1262, 2057, 8976). However, the polyphenol content of wine is highly dependent on grape type, climate, and wine-making methods (2057). Unlike red wines, white wines have very low polyphenol concentrations (2030).\n\nThe antioxidant potential of plasma and erythrocytes is increased for up to 4.5 hours after red wine consumption (6828). However, there is some evidence that the increase of polyphenols in plasma after red wine consumption is not sufficient to acutely influence lipoprotein oxidation (1262, 6826, 8976). There is evidence that other foods such as onions and black tea may be better sources of polyphenols than red wine (8976). Additionally, a difference in lifestyle among wine, beer, and other alcohol beverage drinkers, including diet and social class, might also explain why some alcoholic beverages appear to offer more protection than others against CHD (10129).\n\nRed wine might also reduce mutagenic DNA damage and improve endothelial function when added to a high fat diet. Red wine also might have additive vaso-relaxing benefits with a low-fat, high plant material diet (2059).\n\nPossible mechanisms by which alcohol could have a protective effect against ischemic stroke include increasing HDL and prostacyclin, decreasing fibrinogen, and inhibiting platelet aggregation (6842). There is evidence that moderate alcohol intake increases cerebral blood flow (8651). Moderate alcohol consumption is associated with a lower prevalence of white matter changes and brain infarcts on magnetic resonance imaging in adults 65 years of age or older compared to non-drinkers and heavy drinkers (8651).\nCognitive effects\nAn observational study in Chinese adults 65 years or older with baseline cognitive function ranging from healthy to severe dementia suggests that alcohol consumption is associated with negative and long-term effects on cognitive function, even after adjusting for numerous covariates (107818).\nGastrointestinal effects\nWine stimulates gastric acid secretion and gastrin release. This may explain why moderate to high alcohol consumption from beverages such as wine seems to prevent Helicobacter pylori infection (8034)"
        }
    },
    "Winter Cherry": {
        "sections": {
            "Overview": "Winter cherry is a perennial plant growing to between 30 cm and 60 cm tall. It is native to central and southern Europe, Iran, China, and Southeast Asia (18, 95930).",
            "Safety": "There is insufficient reliable information available about the safety of winter cherry.\nPREGNANCY: POSSIBLY UNSAFE when used orally. Preliminary data from an animal study suggest that winter cherry extracts can block embryo implantation (95931). Avoid using.\nLACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "General\nNo adverse effects have been reported. However, a thorough evaluation of safety outcomes has not been conducted.",
            "Effectiveness": "INSUFFICIENT RELIABLE EVIDENCE TO RATE\nBenign prostatic hyperplasia (BPH). Preliminary clinical research in men aged 40-75 years with untreated, symptomatic BPH shows that taking a mixture of alcoholic extracts of winter cherry fruit, sweet violet flowers, and Echium amoenum flowers orally, 1 mL twice daily for 2 weeks, reduces prostate volume and symptoms of BPH when compared with placebo. Prostate volume decreased by about 17% in the extract group while it increased by about 3% in the placebo group. The overall IPSS improved by about 51% in the extract group and by only about 25% in the placebo group (95930). It is not clear if these benefits are due to winter cherry, other ingredients, or the combination.\nMore evidence is needed to rate winter cherry for this use.",
            "Dosing & Administration": "Adult\nBenign prostatic hyperplasia (BPH): a mixture of alcoholic extracts of winter cherry fruit, sweet violet flowers, and Echium amoenum flowers orally, 1 mL twice daily for 2 weeks, has been used (95930).\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of winter cherry.",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nANTIDIABETES DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nIn animal diabetic models, winter cherry extract decreases blood glucose (100179, 100180). This effect has not been shown in humans. Theoretically, winter cherry might have additive effects with antidiabetes drugs and increase the risk of hypoglycemia.\nSome antidiabetes drugs include glimepiride (Amaryl), glyburide (Diabeta, Glynase PresTab, Micronase), insulin, pioglitazone (Actos), rosiglitazone (Avandia), and others.\nless\nCYTOCHROME P450 2E1 (CYP2E1) SUBSTRATES\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nIn vitro, winter cherry extract inhibited levels of cytochrome P450 2E1 (CYP2E1) (100179). Theoretically, winter cherry might inhibit the metabolism and increase the effects and side effects of CYP2E1 substrates.\nSome drugs metabolized by CYP2E1 include acetaminophen, chlorzoxazone (Parafon Forte), ethanol, theophylline, and anesthetics such as enflurane (Ethrane), halothane (Fluothane), isoflurane (Forane), methoxyflurane (Penthrane).\nless",
            "Interactions with Supplements": "HERBS AND SUPPLEMENTS WITH HYPOGLYCEMIC POTENTIAL\nIn animal diabetic models, winter cherry extract decreases blood glucose (100179, 100180). This has not been shown in humans. However, theoretically, winter cherry might have additive effects when used with other herbs and supplements that also lower glucose levels. This might increase the risk of hypoglycemia.\nSome herbs and supplements with hypoglycemic effects include alpha-lipoic acid, bitter melon, chromium, devil's claw, fenugreek, garlic, guar gum, horse chestnut, Panax ginseng, psyllium, Siberian ginseng, and others.\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the toxicology of winter cherry.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of winter cherry.",
            "Mechanism of Action": "General\nThe applicable parts of winter cherry are the ripe fruit and leaves (18). Constituents isolated from winter cherry extracts include physalins, alkaloids, flavonoids, phenolic acids, megastigmane glycosides, citric acid, and vitamin C (95930, 95931, 100179, 100180).\nAntidiabetic effects\nWinter cherry is traditionally used for diabetes. In an animal model, winter cherry extract reduced levels of fasting blood glucose and improved lipid levels, insulin sensitivity, and glucose uptake into cells (100179, 100180). In vitro, winter cherry extract inhibited the enzyme alpha-glucosidase (100179).\nAntifertility effects\nIn female rats, winter cherry extract given on days 1-5 of pregnancy reduces the number of embryos implanted, and the number and weight of neonates (95931). A winter cherry extract has also been reported to have anti-estrogenic effects (95931).\nHormonal effects\nPreliminary evidence from animal studies suggests that winter cherry might have estrogen antagonist effects, and also decrease testosterone levels (95930, 95931)."
        }
    },
    "Winter Savory": {
        "sections": {
            "Overview": "Winter savory is a plant that is native to Southern Europe, the Mediterranean region, and the Balkans. It is used traditionally in medicine (97016, 98681, 112314).",
            "Safety": "LIKELY SAFE when used orally in amounts commonly found in foods. Winter savory has Generally Recognized as Safe (GRAS) status in the US (4912).\nThere is insufficient reliable information available about the safety of winter savory when used in medicinal amounts.\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "General\nOrally, winter savory is well tolerated when used in amounts commonly found in foods (4912). There is currently insufficient reliable information available about the safety of winter savory when used in medicinal amounts.",
            "Effectiveness": "INSUFFICIENT RELIABLE EVIDENCE TO RATE\nPremature ejaculation. Preliminary clinical research in males with premature ejaculation shows that taking a combination product (Eiacumev, Farmaceutica MEV) containing winter savory, chanca piedra, tribulus, cardamom, tryptophan, niacin, thiamine, and vitamins C and B6 for 3 months lengthens the intravaginal time to ejaculation by about 30 seconds when compared to a control group receiving counseling (97016). Although winter savory is traditionally used for premature ejaculation, it is not clear if this effect is due to winter savory, the other ingredients, or the combination. Also, it is not clear whether an increase of 30 seconds to ejaculation is beneficial in terms of quality of life.\nMore evidence is needed to rate winter savory for this use.",
            "Dosing & Administration": "Adult\nOral:\nResearch is limited; typical dosing is unavailable.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of winter savory.",
            "Interactions with Drugs": "LITHIUM\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPROBABLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nWinter savory is thought to have diuretic properties (6, 11). Theoretically, winter savory might reduce the excretion of lithium and increase plasma levels of lithium. The dose of lithium might need to be decreased.",
            "Interactions with Supplements": "None known.",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with winter savory.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of winter savory.",
            "Mechanism of Action": "General\nThe applicable parts of winter savory are the leaf and stem. Winter savory contains flavonoids, ursolic, ellagic, and oleanolic acids, isoscutellarein, glycosides of luteolin and quercetin, and volatile oil (11, 98681, 112316). The main constituents of the volatile oil are carvacrol, p-cymene, borneol, and gamma-terpinol, with lesser amounts of thymol, p-thymol, timol, linalool, lauolene, rosmarinic acid, caryophyllene, terpinen-4-ol, 1-octan-3-ol, and 1.8-cineole (6, 11, 98681, 106553, 112313, 112314, 112315). The total phenolic and flavonoid content of tinctures prepared from winter savory is influenced by particle size and extraction mode, with those prepared by maceration or remaceration having a high content of polyphenols. Rosmarinic, caffeic, and chlorogenic acids, as well rutin and (-)-catechin, were identified in such tinctures (106553).\nAnti-anxiety effects\nResearch using an animal model shows that giving an extract of dried winter savory leaves orally daily for 14 days reduces acute anxiety. The constituents rosmarinic acid and carvacrol also have anxiolytic effects when used alone in the same model (112314).\nAnti-inflammatory effects\nIn vitro, an alcoholic extract of the aerial parts of winter savory has anti-inflammatory activity, measured by inhibition of cyclo-oxygenases 1 and 2, 5-lipoxygenase, and myeloperoxidase (112316).\nAntimicrobial effects\nIn vitro, the water-soluble fraction of winter savory volatile oil has strong antimicrobial activity at 25% concentration against Pasteurella aerogenes, Streptococcus agalactiae and Acinetobacter baumannii. At 50%, it is bactericidal against Salmonella typhimurium, Klebsiella pneumoniae, Bacillus subtilis, Enterococcus faecalis, and Staphylococcus aureus, and can inhibit the growth of Serratia marcescens, Streptococcus dysgalactiae, Pseudomonas aeruginosa and Proteus mirabilis. At this concentration, it is also fungicidal for Candida albicans (106554, 112315). The antimicrobial effects involve disruption of cell membrane integrity (106554). The carvacrol constituent of the volatile oil damages cell walls, releasing lipopolysaccharides, and also disrupts ion transport across the cytoplasmic membrane (112313).\nAntioxidant effects\nIn vitro, winter savory volatile oil, and an alcoholic extract of the aerial parts prevent lipid oxygenation, and increase total antioxidant capacity, superoxide radical scavenging activity and catalase activity, and reduce malondialdehyde generation (112313, 112316). The antioxidant activity may be due to the phenolic constituent, carvacrol (112313).\nDiuretic effects\nCarvacrol, a constituent of winter savory, might have diuretic effects (6, 11).\nSexual function effects\nWinter savory is used as a traditional remedy for male sexual dysfunction, especially premature ejaculation. In an animal model, winter savory increased acute testosterone levels, as well as the time to ejaculation (98681).\nVasodilator effects\nSome evidence suggests that eriodictyol, a flavonoid found in winter savory, might have a vasodilator effect (4124)."
        }
    },
    "Wintergreen": {
        "sections": {
            "Overview": "Wintergreen is an evergreen shrub native to the northern United States and Canada (18). It has creeping stems from which erect branches grow up to 15 cm in height (11). Wintergreen has been used traditionally for a variety of conditions due to its potential analgesic, anti-inflammatory, and antipyretic effects (104534).",
            "Safety": "LIKELY SAFE when used orally in very small amounts commonly found in foods. Wintergreen oil has Generally Recognized As Safe status (GRAS) in the US (4912) The highest concentration recommended for use as a food flavoring is 0.04% (6).\nPOSSIBLY SAFE when wintergreen leaf is used orally and appropriately in medicinal amounts (12). ...when wintergreen oil is used topically and appropriately (272).\nPOSSIBLY UNSAFE when wintergreen oil is used orally. Wintergreen oil contains large amounts of methyl salicylate, which is toxic (272). Ingesting as little as 6 mL can be lethal for an adult (6). One teaspoon (5 mL) of wintergreen oil is equivalent to approximately 7 grams of salicylate, or more than 20 adult aspirin tablets (6).\nCHILDREN: LIKELY UNSAFE when wintergreen oil is used orally. Ingesting as little as 4 mL can be lethal to children (159). ...when wintergreen oil is used topically in children less than 2 years old (272).\nPREGNANCY: Insufficient reliable information is available; avoid using in amounts greater than those found in foods.\nLACTATION: LIKELY UNSAFE when used orally or topically. Wintergreen products are likely toxic to nursing infants (19).",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, wintergreen leaf seems to be well tolerated, while wintergreen oil may be unsafe. Topically, wintergreen oil seems to be well tolerated.\nSerious Adverse Effects (Rare)\nOrally: Salicylate poisoning due to methyl salicylate in wintergreen oil.\nDermatologic\nWintergreen oil can cause contact dermatitis, which can be irritant or allergic in nature (18, 3811, 112157). When the oil is applied topically it should not be covered with an occlusive dressing because this could result in absorption of toxic amounts of methyl salicylate (272).\nless\nGastrointestinal\nOrally, wintergreen oil can result in symptoms of salicylate poisoning, including nausea, vomiting, diarrhea, and stomach pain (272). Wintergreen causes gastrointestinal irritation (19).\nless\nNeurologic/CNS\nOrally, wintergreen oil can result in symptoms of salicylate poisoning, including headache, tinnitus, and confusion (272).\nless",
            "Effectiveness": "INSUFFICIENT RELIABLE EVIDENCE TO RATE\nBack pain. Although there has been interest in using topical wintergreen oil for back pain, there is insufficient reliable information about the clinical effects of wintergreen for this purpose.\nJoint pain. Although there has been interest in using topical wintergreen oil for joint pain, including in those with osteoarthritis or rheumatoid arthritis, there is insufficient reliable information about the clinical effects of wintergreen for this purpose.\nMuscle soreness. Although there has been interest in using topical wintergreen oil for muscle soreness, there is insufficient reliable information about the clinical effects of wintergreen for this purpose.\nMore evidence is needed to rate wintergreen for these uses.",
            "Dosing & Administration": "Adult\nOral:\nResearch is limited; typical dosing is unavailable.\n\nTraditionally, wintergreen leaf has been used as a tea prepared with 1 teaspoon of the dried leaves in 1 cup boiling water. The tea is taken cold, 1 cup per day (5253, 5254).\nTopical:\nResearch is limited; typical dosing is unavailable.\n\nTraditionally, wintergreen is used as a gel, lotion, ointment, or liniment (containing 10% to 60% methyl salicylate) 3-4 times daily (3). Heat can increase skin absorption which may lead to toxicity; do not apply after strenuous exercise, and do not use a heating pad after application (3).\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of wintergreen.",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nASPIRIN\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPROBABLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nUsing wintergreen oil topically in large amounts, with occlusive dressings, or for prolonged periods of time might increase the risk of additive salicylate toxicity when used with aspirin.\nWintergreen oil contains methyl salicylate (159, 272). Topical analgesic gels, lotions, creams, ointments, liniments, and sprays can contain up to 55% methyl salicylate (6181).\nless\nWARFARIN (Coumadin)\nInteraction Rating\nMAJOR Do not take this combination.\nSeverity\nHIGH\nOccurrence\nPROBABLE\nLevel of Evidence\nD (Anecdotal evidence)\nUsing wintergreen oil topically might increase the effects and adverse effects of warfarin.\nSeveral case reports show that concomitant use of topical wintergreen oil-containing products and warfarin can increase INR and bleeding risk due to systemic absorption of the methyl salicylate contained in wintergreen oil (3811, 6181). Topical analgesic gels, lotions, creams, ointments, liniments, and sprays can contain up to 55% methyl salicylate (6181).\nless",
            "Interactions with Supplements": "None known.",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "Presentation\nPatients presenting after overdose with wintergreen oil may experience symptoms consistent with salicylate poisoning due to the methyl salicylate content in wintergreen oil. These symptoms include nausea, vomiting, diarrhea, headache, tinnitus, and confusion (272).\nTreatment\nThere is insufficient reliable information available about the treatment of overdose with wintergreen oil.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of wintergreen.",
            "Mechanism of Action": "General\nThe applicable parts of wintergreen are the leaf, oil, and fruit. The oil is obtained by steam distillation of water-macerated leaves. During this process, gaultherin (also called monotropitoside) is enzymatically hydrolyzed to methyl salicylate (6, 11, 18). The leaves contain 0.5% to 0.8% wintergreen oil (6). Wintergreen oil contains 96% to 98% methyl salicylate (6, 18). Wintergreen fruit extracts contain at least 45 phenolic constituents including salicylates, flavan-3-ols, procyanidins, flavonoids, and phenolic acid. The primary phenolic constituents of wintergreen berry extract include gaultherin, methyl salicylate triglycoside, physanguloside A, and procyanidin B2 (104534). Wintergreen leaf extracts contain over 40 phenolic constituents, including salicylates, catechins, procyanidins, phenolic acids, and flavonoids (112156).\nAnalgesic effects\nWintergreen oil contains a high concentration of methyl salicylate, which is structurally similar to aspirin (6).\nAnti-inflammatory effects\nIn vitro studies show that wintergreen fruit, leaf, and stem extracts inhibit pro-inflammatory enzymes, including cyclooxygenase-2 and hyaluronidase, and reduce neutrophil release of pro-inflammatory interleukins, tumor necrosis-factor-alpha, and tissue remodeling enzymes (104534, 112156, 115302).\nAntioxidant effects\nIn vitro studies show that wintergreen fruit, leaf, and stem extracts scavenge free radicals, reduce reactive oxygen species production, and restore antioxidant activity. (104534, 112156, 115302).\nDermatologic effects\nAn in vitro study in UVA irradiated cells shows that wintergreen fruit, leaf, and stem extracts reduce the production and release of reactive oxygen species, proinflammatory interleukins, and tumor necrosis-factor-alpha. This suggests that wintergreen may prevent UVA induced photodamage, which contributes to skin barrier disruption, chronic skin damage and photoaging (115302)."
        }
    },
    "Witch Hazel": {
        "sections": {
            "Overview": "Witch hazel is a deciduous, flowering shrub or small tree. It is native to Eastern North America (86503, 93896). Witch hazel water (Hamamelis water, distilled witch hazel extract) is distilled from dried leaves, bark, and partially dormant twigs of witch hazel (11). Witch hazel has been used traditionally by Native Americans for skin wounds and inflammatory skin conditions (86532, 93895).",
            "Safety": "LIKELY SAFE when witch hazel water is used topically and appropriately (272).\nPOSSIBLY SAFE when used orally and appropriately (12). In high doses, tannins in witch hazel bark may cause liver or kidney damage (8, 12). The volatile oil contains safrole, a known carcinogen, but in amounts too small for concern (4).\nCHILDREN: POSSIBLY SAFE when applied topically and appropriately (67795).\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nTopically, witch hazel is generally well tolerated. Orally, witch hazel seems to be well tolerated at appropriate doses, but high doses may be associated with more adverse effects due to the tannin content in witch hazel.\nMost Common Adverse Effects\nTopically: Contact dermatitis.\nSerious Adverse Effects (Rare)\nOrally: Kidney and liver damage when preparations containing at least 10% tannins are used in high doses.\nDermatologic\nTopically, witch hazel can cause contact dermatitis (6, 86505). A small number of people develop redness or burning (67795).\nless\nGastrointestinal\nWitch hazel contains tannins, with the leaf containing 8% to 10% tannins and the bark containing up to 12% tannins (512, 10377, 93894). Orally, plants with at least 10% tannins can cause gastrointestinal disturbances (12).\nless\nHepatic\nWitch hazel contains tannins, with the leaf containing 8% to 10% tannins and the bark containing up to 12% tannins (512, 10377, 93894). Orally, plants with at least 10% tannins can cause necrotic conditions of the liver (12).\nless\nOncologic\nWitch hazel contains tannins, with the leaf containing 8% to 10% tannins and the bark containing up to 12% tannins (512, 10377, 93894). Some evidence suggests that tannins might cause cancer; other evidence shows tannins may prevent it (12). Regular consumption of herbs with high tannin concentrations correlates with increased incidence of esophageal or nasal cancer (12).\nless\nRenal\nWitch hazel contains tannins, with the leaf containing 8% to 10% tannins and the bark containing up to 12% tannins (512, 10377, 93894). Orally, plants with at least 10% tannins can cause kidney damage (12).\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nPOSSIBLY EFFECTIVE\nHemorrhoids. Topical witch hazel seems to relieve hemorrhoid symptoms.\nApplying witch hazel water topically may help to temporarily relieve itching, discomfort, irritation, and burning associated with anorectal disorders (272).\nless\nPOSSIBLY INEFFECTIVE\nAtopic dermatitis (eczema). Topical witch hazel does not appear to improve symptoms in patients with atopic dermatitis.\nA moderate sized clinical study in patients with moderately severe atopic dermatitis shows that applying a cream containing witch hazel daily for 14 days does not improve itching, erythema, or scaling when compared with placebo. Witch hazel cream also appears to be less effective when compared with a cream containing hydrocortisone (86527).\nless\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nAcne. Although there has been interest in using topical witch hazel for acne, there is insufficient reliable information about the clinical effects of witch hazel for this purpose.\nBruises. Although there has been interest in using topical witch hazel for bruises, there is insufficient reliable information about the clinical effects of witch hazel for this purpose.\nBurns. Although there has been interest in using topical witch hazel for minor burns, there is insufficient reliable information about the clinical effects of witch hazel for this purpose.\nCancer. Although there has been interest in using oral and topical witch hazel for cancer, there is insufficient reliable information about the clinical effects of witch hazel for this purpose.\nInsect bite. Although there has been interest in using topical witch hazel for insect bites, there is insufficient reliable information about the clinical effects of witch hazel for this purpose.\nMinor bleeding. Although there has been interest in using topical witch hazel for minor bleeding, there is insufficient reliable information about the clinical effects of witch hazel for this purpose.\nPostmenopausal conditions. It is unclear if topical witch hazel is beneficial for improving vaginal dryness in postmenopausal individuals.\nA small clinical study in postmenopausal individuals shows that applying a moisturizing cream containing witch hazel distillate (Remifemin FeuchtCreme, Schaper-Brummer) 2.5 grams into the vagina daily for 7 days eliminates subjective feelings of vaginal dryness in 55% of patients after the first application and 80% of patients after 7 days of use, with all patients experiencing an improvement in feelings of dryness compared to baseline (96721). The validity of these findings is limited by the lack of a control group.\nless\nSkin irritation. It is unclear if topical witch hazel is beneficial for children with skin irritation.\nA small observational study in children with minor skin injuries, diaper rash, or dermatitis suggests that topical application of witch hazel ointment (Hametum, Spitzner Arzneimittel) appears to improve symptoms of skin irritation as effectively as a dexpanthenol ointment (67795).\nless\nSunburn. Small clinical studies suggest that topical witch hazel might reduce erythema after a sunburn.\nTwo small clinical studies in healthy individuals show that applying witch hazel lotion or cream to the skin after ultraviolet exposure reduces erythema when compared with control formulations; however, witch hazel may be less effective when compared with hydrocortisone cream (11151, 86531).\nless\nVaricose veins. Although there has been interest in using topical witch hazel for varicose veins, there is insufficient reliable information about the clinical effects of witch hazel for this purpose.\nMore evidence is needed to rate witch hazel for these uses.",
            "Dosing & Administration": "Adult\nTopical:\nWitch hazel has been used in various topical formulations, including as a cream, lotion, ointment, and aqueous solution. See Effectiveness section for condition-specific information.\nChildren\nTopical:\nResearch is limited; typical dosing is unavailable.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of witch hazel.",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "None known.",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with witch hazel.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of witch hazel.",
            "Mechanism of Action": "General\nThe applicable parts of witch hazel are the leaf and bark. The active constituents include gallotannins such as hamamelitannin, gallic acid, myricetin, quercetin, kaempferol, and catechol derivatives (10377, 93895). The bark and leaves are both a source of volatile essential oils (86512, 93895). The leaf contains 8-10% tannins (512). The bark contains up to 12% tannins (10377, 93894).\n\nSteam distillation used for producing witch hazel water removes the tannins (13). Thus, the astringent properties of witch hazel water result from its 14-15% alcohol content (13).\nAnti-inflammatory effects\nWitch hazel leaf and bark possess anti-inflammatory properties in animal models (10377, 86525, 86528). Constituents, such as hamamelitannin and galloyated proanthocyanidins have been shown to inhibit 5-lipooxygenase activity in laboratory research (86530). Also, tannins, applied topically to broken skin or mucous membranes induce protein precipitation. They tighten up superficial cell layers and shrink colloidal structures thereby causing capillaries to constrict. The decrease in vascular permeability approximates an anti-inflammatory effect (7). The anti-inflammatory effects of witch hazel might explain its anti-hemorrhoidal and skin-protective benefits.\nAnti-viral effects\nIn laboratory research, witch hazel bark extract had antiviral activity against influenza A virus and human papillomavirus (HPV) type 16. The bark extract inhibits various steps in the influenza A virus lifecycle, as well as the attachment of HPV. Tannins play a large role in these processes (93894).\nAntimicrobial effects\nWitch hazel leaf and bark possess astringent properties (10377). Antibacterial effects of witch hazel extract have been shown in laboratory research (59335, 86516). The astringent activity of tannins causes an indirect antibacterial effect (7).\nStyptic effects\nWitch hazel leaf and bark possess styptic properties (10377). Tannins, applied topically to broken skin or mucous membranes induce protein precipitation. They tighten up superficial cell layers and shrink colloidal structures thereby causing capillaries to constrict (7)."
        }
    },
    "Wood Anemone": {
        "sections": {
            "Overview": "Wood anemone is a flowering plant traditionally used in folk medicine (103591). Traditional uses include headache, stomach pain, gout, leprosy, lethargy, eye inflammation, delayed menstruation, whooping cough, asthma, and for its potential antimicrobial, diuretic, and abortive properties (103591).",
            "Safety": "LIKELY UNSAFE when the fresh plant is used orally. Freshly harvested wood anemone can cause severe irritation to the gastrointestinal tract (18).\nThere is insufficient reliable information available about the safety of the dried, cut above ground parts.\nPREGNANCY AND LACTATION: LIKELY UNSAFE when the fresh plant is used orally or topically (18). There is insufficient reliable information available about the safety of the oral or topical use of the dried, cut plant during pregnancy and lactation; avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, fresh wood anemone is likely unsafe (18). No adverse effects related to the dried parts of wood anemone have been reported. However, a thorough evaluation of safety outcomes has not been conducted.\nMost Common Adverse Effects\nOrally: Colic, diarrhea, gastrointestinal tract irritation, urinary tract irritation.\n\nTopically: Blisters, burns.\nDermatologic\nTopically, fresh wood anemone can cause slow-healing blisters and burns after prolonged skin contact (18).\nless\nGastrointestinal\nOrally, the ingestion of freshly harvested wood anemone can cause colic, diarrhea, and severe irritation to the gastrointestinal tract and the urinary drainage passages (18).\nless",
            "Effectiveness": "There is insufficient reliable information available about the effectiveness of wood anemone.",
            "Dosing & Administration": "Adult\nOral:\nResearch is limited; typical dosing is unavailable.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of wood anemone.",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with wood anemone.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of wood anemone.",
            "Mechanism of Action": "General\nThe applicable parts of wood anemone are the above ground parts (18). Both protoanemonin and ranunculin are destroyed to an unknown extent during the drying process (2).\nAntioxidant effects\nIn vitro, wood anemone has antioxidant effects (103591). These effects may play a role in the potential clinical effects of wood anemone.\nIrritating effects\nThe fresh plant is irritating to the skin, gastrointestinal lining, and urinary tract lining. When the fresh plant is crushed or cut into small pieces, the glycoside ranunculin is enzymatically changed into a severely irritating protoanemonin (18). Protoanemonin rapidly degrades into the less toxic anemonin (18)."
        }
    },
    "Wood Sage": {
        "sections": {
            "Overview": "Wood sage is an herb that smells faintly of leeks when being dried. It is native to western and central Europe, including the Mediterranean region. It has traditionally been used for gastrointestinal disorders, respiratory tract infections, wound healing, and for its purported expectorant and spasmolytic effects (18).",
            "Safety": "There is insufficient reliable information available about the safety of wood sage.\nPREGNANCY AND LACTATION: Insufficient reliable information is available; avoid using.",
            "Adverse Effects": "General\nNone reported; however, a thorough evaluation of safety outcomes has not been conducted.",
            "Effectiveness": "There is insufficient reliable information available about the effectiveness of wood sage.",
            "Dosing & Administration": "Adult\nResearch is limited; typical dosing unavailable.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of wood sage.",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "None known.",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with wood sage.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of wood sage.",
            "Mechanism of Action": "General\nThe applicable parts of wood sage are the above ground parts. It contains flavonoids, a volatile oil, diterpenes, and iridoid monoterpenes (18)."
        }
    },
    "Wood Sorrel": {
        "sections": {
            "Overview": "Wood sorrel is a flowering plant. Traditionally, the whole plant is used to make medicine.",
            "Safety": "POSSIBLY UNSAFE when used orally. Wood sorrel contains oxalic acid, which can be toxic when consumed in large amounts (6, 17).\nCHILDREN: POSSIBLY UNSAFE when used orally. Wood sorrel contains oxalic acid, which can be toxic when consumed in large amounts (17).\nPREGNANCY: LIKELY UNSAFE when used orally because it might stimulate menses (19); avoid using.\nLACTATION: POSSIBLY UNSAFE when used orally (6, 17); avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nThere is currently a limited amount of information on the adverse effects of wood sorrel. A thorough evaluation of safety outcomes has not been conducted.\nMost Common Adverse Effects\nOrally: Dermatitis, diarrhea, nausea, and polyuria.\nDermatologic\nOrally, consuming excessive amounts of wood sorrel can cause dermatitis. Wood sorrel contains oxalic acid, which is thought to be responsible for this adverse effect (4, 17).\nless\nGastrointestinal\nOrally, consuming excessive amounts of wood sorrel can cause diarrhea, nausea, and other gastrointestinal symptoms. Wood sorrel contains oxalic acid, which is thought to be responsible for these adverse effects (6, 17).\nless\nRenal\nOrally, consuming excessive amounts of wood sorrel can cause polyuria (6, 17).\nless",
            "Effectiveness": "INSUFFICIENT RELIABLE EVIDENCE TO RATE\nGingivitis. Although there has been interest in using oral wood sorrel for gingivitis, there is insufficient reliable information about the clinical effects of wood sorrel for this purpose.\nScurvy. Although there has been interest in using oral wood sorrel for scurvy, there is insufficient reliable information about the clinical effects of wood sorrel for this purpose.\nWound healing. Although there has been interest in using oral wood sorrel for wound healing, there is insufficient reliable information about the clinical effects of wood sorrel for this purpose.\nMore evidence is needed to rate wood sorrel for these uses.",
            "Dosing & Administration": "Adult\nResearch is limited; typical dosing is unavailable.\n\nWood sorrel administration should be separated from food. Wood sorrel contains oxalate, which can bind to multivalent metal ions in the gastrointestinal tract and decrease mineral absorption (7, 12).\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of wood sorrel.",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "EXPAND ALL\n|\nCOLLAPSE ALL\nCALCIUM\nTheoretically, taking wood sorrel might decrease the absorption of multivalent metal ions, such as calcium.\nWood sorrel contains oxalate. Oxalate can bind to multivalent metal ions in the gastrointestinal tract and decrease mineral absorption (7, 12).\nless\nIRON\nTheoretically, taking wood sorrel might decrease the absorption of multivalent metal ions, such as iron.\nWood sorrel contains oxalate. Oxalate can bind to multivalent metal ions in the gastrointestinal tract and decrease mineral absorption (7, 12).\nless\nZINC\nTheoretically, taking wood sorrel might decrease the absorption of multivalent metal ions, such as zinc.\nWood sorrel contains oxalate. Oxalate can bind to multivalent metal ions in the gastrointestinal tract and decrease mineral absorption (7, 12).\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "Presentation\nWood sorrel contains oxalic acid. Oxalic acid poisoning affects the skin, eyes, respiratory system, and kidneys. Once absorbed, oxalic acid reacts with calcium in plasma, forming insoluble calcium oxalate crystals that may precipitate in the kidneys, blood vessels, heart, lungs, and liver. Oxalate can have a corrosive effect on the digestive tract; symptoms of oxalate irritation include swelling of the mouth, tongue, and throat, leading to difficulty in speaking and breathing (12, 17).\nTreatment\nThere is insufficient reliable information available about the treatment of overdose with wood sorrel.",
            "Pharmacokinetics": "There is insufficient reliable information about the pharmacokinetics of wood sorrel.",
            "Mechanism of Action": "General\nThe applicable part of wood sorrel is the whole flowering plant. It contains 0.3-1.25% oxalic acid (18). Oxalate content is highest in the fresh leaves and roots (17, 19)."
        }
    },
    "Wormseed": {
        "sections": {
            "Overview": "Wormseed is an herb. Historically, the flowers have been used for their anthelmintic activity. More recently the leaves and stems have also been used for this purpose (112383). However, wormseed can be toxic even in the amounts used for traditional purposes, such as the treatment of parasitic infestations (18).",
            "Safety": "UNSAFE when used orally due to its highly toxic adverse effects (18).\nPREGNANCY AND LACTATION: UNSAFE when used orally due to potential for toxicity (18); avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, wormseed is unsafe.\nSerious Adverse Effects (Rare)\nSymptoms of poisoning are possible in the amounts traditionally used as medicine. Symptoms of toxicity include epileptiform spasms, gastroenteritis, kidney irritation, muscle twitching, stupor, visual disorders, and even death.\nGastrointestinal\nOrally, wormseed can cause gastroenteritis (18).\nless\nImmunologic\nOrally, wormseed can cause allergic reactions in individuals sensitive to the Asteraceae/Compositae family, which includes ragweed, chrysanthemums, marigolds, daisies, and many other herbs (18).\nless\nMusculoskeletal\nOrally, wormseed can cause muscle twitching (18).\nless\nNeurologic/CNS\nOrally, wormseed can cause epileptiform spasms (18).\nless\nOcular/Otic\nOrally, wormseed can cause visual disorders (18).\nless\nRenal\nOrally, wormseed can cause kidney irritation (18).\nless\nOther\nOrally, death has been reported with less than 10 grams of wormseed (18).\nless",
            "Effectiveness": "INSUFFICIENT RELIABLE EVIDENCE TO RATE\nInfluenza. Although there has been interest in using oral wormseed for influenza, there is insufficient reliable information about the clinical effects of wormseed for this purpose.\nIntestinal parasite infection. Although there has been interest in using oral wormseed for various intestinal parasite infections, there is insufficient reliable information about the clinical effects of wormseed for this purpose.\nMore evidence is needed to rate wormseed for this use.",
            "Dosing & Administration": "Adult\nResearch is limited; typical dosing is unavailable.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of wormseed.",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "CROSS-ALLERGENICITY\nWormseed can cause an allergic reaction in individuals sensitive to the Asteraceae/Compositae family. Members of this family include ragweed, chrysanthemums, marigolds, daisies, and many other herbs.\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "Presentation\nWormseed can be toxic when taken orally. Symptoms of toxicity include epileptiform spasms, gastroenteritis, kidney irritation, muscle twitching, stupor, and visual disorders. Death has occurred with the use of less than 10 grams of wormseed (18).\nTreatment\nThere is insufficient reliable information available about the treatment of toxicity with wormseed.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of wormseed.",
            "Mechanism of Action": "General\nThe applicable parts of wormseed are the above ground parts, including the flowers, leaves and stems (18, 112383).\nAnthelmintic activity\nThe anthelmintic activity of wormseed is attributed to the sesquiterpene lactone constituent, beta-santonin (18), though other research shows that the constituents artemisinin, isoguaiacin, and norisoguaiacin also exhibit anthelmintic activity (112382, 112383). When wormseed is used with a laxative, it appears to paralyze the muscles of ascarids and facilitate their elimination from the body (18).\n\nIn vitro research shows wormseed extract exhibits anthelmintic activity against Haemonchus contortus, a gastrointestinal nematode that commonly infects ruminant animals (112382, 112383). Additionally, in gerbils artificially infected with Haemonchus contortus, oral treatment with a hexane extract of wormseed effectively resolved the infection as well as ivermectin, while ethyl acetate and methanolic extracts of wormseed slightly improved but did not resolve the infection. (112382).\nAntiviral effects\nIn vitro research shows wormseed extract to exhibit antiviral activity against avian influenza A H5N1 and human influenza A H1N1 viruses. Interference of viral adsorption, viral replication, and direct viricidal activity on the strains was exhibited by both wormseed flower extract and santonin, a primary active constituent in wormseed. Santonin also demonstrated neuraminidase inhibition activity in a dose-dependent manner (112384).\nNeurologic effects\nSome data suggest wormseed lowers body temperature when a fever is present (18)."
        }
    },
    "Wormwood": {
        "sections": {
            "Overview": "Wormwood is a perennial bush with aromatic leaves and a bitter taste (12814). Wormwood is a component of the alcoholic beverages vermouth and absinthe (12814, 15007). Orally, wormwood has traditionally been used as an anthelmintic, antipyretic, antispasmodic, aphrodisiac, appetite stimulant, diaphoretic, and tonic. Topically, wormwood has been used as a counterirritant.",
            "Warnings": "Coronavirus disease 2019 (COVID-19): Despite claims to the contrary, there is no good evidence to support using wormwood for COVID-19. Recommend healthy lifestyle choices and proven prevention methods instead.",
            "Safety": "LIKELY SAFE when used orally in the amounts commonly found in foods. Wormwood extracts are included in bitters, vermouth, absinthe, and other food or drink products (12814, 15007). Wormwood products that are thujone-free have Generally Recognized As Safe (GRAS) status for use in foods in the US (4912); however, products containing thujone might not be safe. Wormwood is described in the pharmacopoeia of various European countries. After being banned for a period of time, it is now allowed in European Union countries; however, beverages must not contain thujone in concentrations greater than 35 mg/kg (12814, 15007, 86551).\nPOSSIBLY SAFE when wormwood products not containing thujone are used orally in medicinal amounts, short-term (93468, 93469). A specific product (SedaCrohn, Noor Herbals, LLC; standardized to <5 ppm thujone/capsule) containing powdered wormwood has been used with apparent safety in doses up to 2250 mg daily for up to 10 weeks (93468). Slightly lower doses of 1800 mg daily have also been used with apparent safety for up to 6 months (93469). ...when a wormwood extract is used topically in a 3% ointment or liniment three times daily for 4 weeks (95925).\nPOSSIBLY UNSAFE when wormwood products containing thujone are used orally. Thujone is a neurotoxin that is present in wormwood oil (12617). Seizures, rhabdomyolysis, and acute kidney failure can occur when as little as 10 mL of wormwood oil is ingested (662, 12817).\nPREGNANCY: LIKELY UNSAFE ..when used orally in amounts greater than those found in foods (662, 12817). Some wormwood products contain thujone, a neurotoxin. Theoretically, thujone also has potential uterine and menstrual stimulant effects (12617). There is insufficient reliable information available about the safety of wormwood when used topically during pregnancy.\nLACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nWormwood contains thujone, a neurotoxin. When products containing thujone are used orally in medicinal amounts, wormwood may be unsafe.\nMost Common Adverse Effects\nOrally: The oil from wormwood leaves can cause diffuse muscle aches, nausea, and vomiting.\nSerious Adverse Effects (Rare)\nOrally: The oil from wormwood leaves can cause acute kidney toxicity, rhabdomyolysis, and seizures.\nDermatologic\nTopically, a single case report describes a sensitivity or first degree chemical burn reaction, with facial pain and erythema, after a 50-year-old adult applied a homemade poultice containing wormwood to the face for an unreported length of time (93466).\nless\nGastrointestinal\nOrally, the oil from wormwood leaves can cause nausea and vomiting (662). Use of a home-prepared wormwood extract has been associated with vomiting and severe diarrhea in an infant (93467).\nless\nHematologic\nOrally, use of a home-prepared wormwood extract has been associated with severe metabolic acidosis in an infant (93467).\nless\nImmunologic\nTheoretically, wormwood might cause an allergic reaction in people sensitive to the Asteraceae/Compositae family (12815). Members of this family include ragweed, chrysanthemums, marigolds, daisies, and many other herbs.\nless\nMusculoskeletal\nOrally, the oil from wormwood leaves can cause diffuse muscle aches and rhabdomyolysis (662).\nless\nNeurologic/CNS\nOrally, the oil from wormwood leaves can cause seizures (662).\nless\nRenal\nOrally, the oil from wormwood leaves can cause acute kidney toxicity and acute kidney failure (662).\nless\nOther\nChronic ingestion of absinthe, an alcoholic beverage that contains wormwood extract, has been linked to absinthism. Absinthism was first described in the 1800s when absinthe was at its peak levels of consumption. It has been characterized by addiction, gastrointestinal adverse effects, insomnia, auditory and visual hallucinations, tremors, paralysis, epilepsy, and brain damage. There is also increased risk of psychiatric disease and suicide (662, 12814, 15008). Increasing thujone concentrations of absinthe increases anxiety and decreases attention in healthy individuals (86541). A case of bradyarrhythmias associated with absinthe intoxication has also been reported (86543). However, there is speculation that some of the symptoms of absinthism originally described might be attributed to adulteration with metals or toxic plants such as calamus and tansy, rather than the ingredients usually used in absinthe drinks (15007). Some researchers also suggest that absinthism is not a unique condition and is indistinguishable from alcohol use disorder. In fact, some evidence suggests that the thujone concentrations in the absinthe formulations from the 1800s were too low to cause significant thujone-related toxicities (15008, 15009).\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nBiliary disorders. Although there has been interest in using oral wormwood for biliary disorders, there is insufficient reliable information about the clinical effects of wormwood for this purpose.\nCrohn disease. Small clinical studies suggest that oral wormwood may modestly improve symptoms in patients with Crohn disease.\nPreliminary clinical research in patients with Crohn disease shows that taking a specific product (SedaCrohn, Noor Herbals, LLC) containing powdered wormwood 750 mg 2-3 times daily for 6-10 weeks improves quality of life and mood, increases symptom remission, and reduces corticosteroid requirements when compared with placebo (86545, 93468). Clinical remission occurred in 8 out of 10 patients taking wormwood, compared with only 2 out of 10 patients taking placebo (93468).\nless\nDepression. Although there has been interest in using oral wormwood for depression, there is insufficient reliable information about the clinical effects of wormwood for this purpose.\nDyspepsia. Although there has been interest in using oral wormwood for dyspepsia, there is insufficient reliable information about the clinical effects of wormwood for this purpose.\nGastritis. Although there has been interest in using oral wormwood for gastritis, there is insufficient reliable information about the clinical effects of wormwood for this purpose.\nIgA nephropathy. It is unclear if oral wormwood is beneficial in patients with IgA nephropathy.\nPreliminary clinical research in patients with IgA nephropathy shows that taking powdered wormwood (Seda-Leukin, Noor Herbals LLC) 600 mg three times daily for 6 months along with standard treatment reduces proteinuria when compared with baseline. The urinary protein:creatinine ratio decreased from 2340 mg/gram to 315 mg/gram over 6 months. Furthermore, systolic and diastolic blood pressures decreased by 10% and 14%, respectively (93469). The validity of these findings is limited by the lack of a comparator group.\nless\nInsect bite. Although there has been interest in using topical wormwood for insect bites, there is insufficient reliable information about the clinical effects of wormwood for this purpose.\nOsteoarthritis. It is unclear if topical wormwood is beneficial in patients with knee osteoarthritis.\nPreliminary clinical research in patients with knee osteoarthritis shows that applying an ointment or liniment containing wormwood extract 3% to the knee three times daily for 4 weeks might improve pain, although any pain improvement was not maintained 2 weeks after discontinuation. Topical wormwood appears to be less effective than topical piroxicam gel, which improves pain, stiffness, and physical function when compared with baseline, with benefits maintained 2 weeks after discontinuation (95925).\nless\nMore evidence is needed to rate wormwood for these uses.",
            "Dosing & Administration": "Adult\nOral:\nResearch is limited; typical dosing is unavailable.\nStandardization & Formulation\nSome wormwood products are prepared with an intent to minimize thujone concentrations. Thujone levels differ with respect to the method of preparation and the solvent. Percolation with water produces no thujone because thujone is not soluble in water. Percolation with 90% ethanol produces approximately 0.18 mg of thujone per gram of wormwood. Using 30% alcohol produces approximately 0.17 mg of thujone per gram of wormwood. Distillation of macerated wormwood in alcohol produces the highest concentration of thujone, approximately 0.24 mg of thujone per gram of wormwood (15007).\n\nClinical trials have investigated the effects of two specific products (SedaCrohn and Seda-Leukin, Noor Herbals, LLC) (86545, 93468, 93469). SedaCrohn contains 0.2% to 0.38% absinthin and less than 5 ppm thujone/capsule (86545, 93468). SedaLeukin contains 0.2% to 0.38% absinthin, 0.25% to 0.52% etheric oils, and is devoid of alpha- and beta-thujone (93469).",
            "Interactions with Drugs": "ANTICONVULSANTS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, taking wormwood might interfere with the effects of anticonvulsant drugs.\nThujone, a constituent of wormwood, has convulsant effects (12816).\nless",
            "Interactions with Supplements": "THUJONE-CONTAINING HERBS\nWormwood contains thujone, a neurotoxin.\nTheoretically, concomitant use with other thujone-containing herbs might increase the risk of thujone toxicity (12815). Avoid use.\nless",
            "Interactions with Conditions": "EXPAND ALL\n|\nCOLLAPSE ALL\nCROSS-ALLERGENICITY\nTheoretically, wormwood oil can cause an allergic reaction in people sensitive to the Asteraceae/Compositae family (12815). Members of this family include ragweed, chrysanthemums, marigolds, daisies, and many other herbs.\nless\nKIDNEY DISEASE\nAnecdotal evidence suggests that ingestion of wormwood oil might lead to kidney failure (662). Use wormwood cautiously in patients with kidney disease.\nless\nPORPHYRIA\nAlpha-thujone, a constituent of wormwood oil, might increase production of porphyrins (12816). Avoid use in patients with underlying defects in hepatic heme synthesis.\nless\nSEIZURE DISORDERS\nWormwood contains thujone, which can cause seizures (662, 12816). Avoid use in patients with seizure disorder.\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "Presentation\nWormwood contains thujone, a neurotoxin, which can be removed during preparation to reduce concerns for toxicity (15007). Oil made from wormwood leaves contains high concentrations of thujone and can be toxic at doses as low as 10 mL (662, 12817). Some reports of toxicity with wormwood involve the use of homemade preparations, including a wormwood poultice for topical application and a wormwood extract for ingestion. It is unclear how much wormwood and/or thujone was present in these products (93466, 93467).\n\nThere are also concerns for toxicity with the chronic ingestion of absinthe, an alcoholic beverage that contains wormwood extract. This has been linked to absinthism, which is characterized by addiction, anxiety, auditory and visual hallucinations, bradyarrhythmias, brain damage, decreased attention, epilepsy, gastrointestinal adverse effects, increased risk of psychiatric disease and suicide, insomnia, paralysis, and tremors (662, 12814, 15008, 86541, 86543). It is unclear if all of these adverse effects are due to wormwood. There is some speculation that some of the effects might be associated with alcohol or contaminants in absinthe, such as metals or toxic plants (15007, 15008, 15009).\nTreatment\nThere is insufficient reliable information available about the treatment of overdose with wormwood.",
            "Pharmacokinetics": "Metabolism\nPreliminary research suggests that thujone is metabolized by the cytochrome P450 enzyme system; however, the specific human isozyme has not been identified (12816).",
            "Mechanism of Action": "General\nThe applicable parts of wormwood are the above ground parts. Wormwood is an aromatic bush. It contains up to 0.2% to 1.7% essential oil (12814, 12815, 15007). Wormwood oil contains 40% to 90% of the monoterpene thujone, which is responsible for wormwood's'toxicity. About 70% to 90% of the thujone content exists as beta-thujone and 10% to 30% as alpha-thujone (15007). Alpha-thujone is more toxic than beta-thujone (12814, 12815). Wormwood also contains absinthin, anabsinthin, artabsin, resins, and various organic acids (12814, 12815, 93469).\nAnti-inflammatory effects\nWormwood extract has been studied for Crohn disease due to its anti-inflammatory effects (86545, 93468). Wormwood extract has been shown to reduce levels of the inflammatory cytokine, tumor necrosis factor (TNF)-1, in laboratory models and human research (93468).\nAntibacterial effects\nIn vitro, a methanolic extract of wormwood aerial parts has demonstrated antibacterial activity against Staphylococcus aureus and Escherichia coli (107484).\nCannabinoid receptor effects\nThujone is structurally similar to detla-9 tetrahydrocannabinol (THC), the active ingredient in marijuana, but it seems to have low affinity for the cannabinoid receptor (12815, 86533).\nConvulsant effects\nThe thujone constituent is a CNS stimulant and can cause seizures. Alpha- and beta- thujone block gamma-aminobutyric acid (GABA) channels, which is likely responsible for their convulsant activity (12816, 15008).\nDermatologic\nIn a small clinical study, a wormwood extract cream applied topically to the periorbital area was found to reduce dark circles faster than placebo, potentially due to its antioxidant properties (115306).\nHepatoprotective effects\nAn aqueous methanolic wormwood extract seems to protect against acetaminophen induced hepatotoxicity, possibly by preventing the breakdown of acetaminophen into reactive metabolites (12818).\nPorphoryn effects\nAlpha-thujone might increase production of porphyrins, making it potentially more toxic to patients with underlying defects in hepatic heme synthesis (12816).\nSleep effects\nIn a mouse model of sleep, a hydroalcoholic extract of wormwood aerial parts increases sleep time and reduces sleep latency (107485).\nWound healing effects\nIn a rat model of wound healing, topical administration of a methanolic extract of wormwood aerial parts improves wound contraction similar to a reference drug (107484)."
        }
    }
}